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Summary
With more and more biological information generated, the most pressing task of bioinformatics
has become to analyse and interpret various types of data, including nucleotide and amino acid
sequences, protein structures, gene expression profilings and so on. In this thesis, we apply
the data mining techniques of feature generation, feature selection, and feature integration with
learning algorithms to tackle the problems of disease phenotype classification and patient survival
prediction from gene expression profiles, and the problems of functional site prediction from
DNA sequences.
When dealing with problems arising from gene expression profiles, we propose a new fea-
ture selection process for identifying genes associated with disease phenotype classification or
patient survival prediction. This method, ERCOF (Entropy-based Rank sum test and COrre-
lation Filtering), aims to select a set of sharply discriminating genes with little redundancy by
combining entropy measure, Wilcoxon rank sum test and Pearson correlation coefficient test.
As for classification algorithms, we focus on methods built on the idea of ensemble of decision
trees, including widely used bagging, boosting and random forests, as well as newly published
CS4. To compare the decision tree methods with other state-of-the-art classifiers, support vector
machines (SVM) and k-nearest neighbour are also used. Various comparisons among different
feature selection methods and different classification algorithms are addressed based on more
than one thousand tests conducted on six gene expression profiles and one proteomic data.
In the study of patient survival prediction, we present a new idea of selecting informative
training samples by defining long-term and short-term survivors. ERCOF is then applied to
identify genes from these samples. A regression function built on the selected samples and genes
by a linear kernel SVM is worked out to assign a risk score to each patient. Kaplan-Meier plots
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for different risk groups formed on the risk scores are then drawn to show the effectiveness of the
model. Two case studies, one on survival prediction for patients after chemotherapy for diffuse
large-B-cell lymphoma and one on lung adenocarcinomas, are conducted.
In order to apply data mining methodology to identify functional sites in biological se-
quences, we first generate candidate features using k-gram nucleotide acid or amino acid pat-
terns and then transform original sequences respect to the new constructed feature space. Feature
selection is then conducted to find signal patterns that can distinguish true functional sites from
those false ones. These selected features are further integrated with learning algorithms to build
classification and prediction models. Our idea is used to recognize translation initiation sites
and polyadenylation signals in DNA and mRNA sequences. For each application, experimental
results across different data sets (including both public ones and our own extracted ones) are




The past few decades witness an explosive growth in biological information generated by the
scientific community. This is caused by major advances in the field of molecular biology, coupled
with advances in genomic technologies. In turn, the huge amount of genomic data generated not
only leads to a demand on the computer science community to help store, organize and index the
data, but also leads to a demand for specialized tools to view and analyze the data.
“Biology in the 21st century is being transformed from a purely lab-based science to an
information science as well” [3].
As a result of this transformation, a new field of science was born, in which biology, com-
puter science, and information technology merge to form a single discipline [3]. This is bioin-
formatics.
“The ultimate goal of bioinformatics is to enable the discovery of new biological insights
as well as to create a global perspective from which unifying principles in biology can be dis-
cerned” [3].
1.1 Motivation
At the beginning, the main role of bioinformatics was to create and maintain databases to store
biological information, such as nucleotide and amino acid sequences. With more and more data
generated, nowadays, the most pressing task of bioinformatics has moved to analyse and interpret
various types of data, including nucleotide and amino acid sequences, protein domains, protein
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structures and so on. To meet the new requirements arising from the new tasks, researchers in the
field of bioinformatics are working on the development of new algorithms (mathematical formu-
las, statistical methods and etc) and software tools which are designed for assessing relationships
among large data sets stored, such as methods to locate a gene within a sequence, predict protein
structure and/or function, understand diseases at gene expression level and etc.
Motivated by the fast development of bioinformatics, this thesis is designed to apply data
mining technologies to some biological data so that the relevant biological problems can be
solved by computer programs. The aim of data mining is to automatically or semi-automatically
discover hidden knowledge, unexpected patterns and new rules from data. There are a variety
of technologies involved in the process of data mining, such as statistical analysis, modeling
techniques and database technology. During the last ten years, data mining is undergoing very
fast development both on techniques and applications. Its typical applications include market
segmentation, customer profiling, fraud detection, (electricity) loading forecasting, credit risk
analysis and so on. In the current post-genome age, understanding floods of data in molecular bi-
ology brings great opportunities and big challenges to data mining researchers. Successful stories
from this new application will greatly benefit both computer science and biology communities.
We would like to call this discovering biological knowledge “in silico” by data mining.
1.2 Work and Contribution
To make use of original biological and clinical data in the data mining process, we follow the
regular process flow in data mining but with emphasis on three steps of feature manipulation,
viz. feature space generation, feature selection and feature integration with learning algorithms.
These steps are important in dealing with biological and clinical data.
(1) Some biological data, such as DNA sequences, have no explicit features that can be easily
used by learning algorithms. Thus, constructing a feature space to describe original data
becomes necessary.
(2) Quite a number of biological and clinical data sets possess many features. Selecting sig-
nal features and removing noisy ones will not only largely reduce the processing time and
greatly improve the learning performance in the later stage, but also help locate good pat-
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terns that are related to the essence of the study. For example, in gene expression data
analysis, feature selection methods have been widely used to find genes that are most as-
sociated with a disease or a subtype of certain cancer.
(3) Many issues arising from biological and clinical data, in the final analysis, can be treated as
or converted into classification problems and then can be solved by data mining algorithms.
In this thesis, we will mainly tackle gene expression profiles and DNA sequence data.
For gene expression profiles, we apply our method to solve two kinds of problems: pheno-
type classification and patient survival prediction. In these two problems, genes serve as features.
Since profile data often contains thousands of genes, we put forward a new feature selection
method ERCOF to identify genes most related to the problem. ERCOF conducts three-phase
of gene filtering. First, it selects genes using an entropy-based discretization algorithm, which
generally keeps only 10% of discriminating genes. Secondly, these remaining genes are further
filtered by Wilcoxon rank sum test, a non-parametric statistic alternative to the t-test. Genes
passing this round of filtering are automatically divided into two groups: one group consists of
genes that are highly expressed in one type of samples (such as cancer) while another group
consists of genes that are highly expressed in another type of samples (such as non-cancer). In
the third phase, correlated genes in each group are determined by Pearson correlation coefficient
test and only some representatives of them are kept to form the final set of selected genes.
When applying learning algorithms to classify phenotypes, we focus on classifiers built on
the idea of an ensemble of decision trees, including the newly published CS4 [63, 62], as well as
state-of-the-art Bagging [19], Boosting [38], and Random forests [20]. More than one thousand
tests are conducted on six published gene expression profiling data sets and one proteomic data
set. To compare the performance of these ensembles of decision tree methods with those widely
used learning algorithms in gene expression studies, experimental results on support vector ma-
chines (SVM) and k-nearest neighbour (k-NN) are also collected. SVM is chosen because it is
a representative of kernel function. k-NN is chosen because it is the most typical instance-based
classifier. To demonstrate the main advantage of the decision tree methods, we present some of
decision trees induced from data sets. These trees are simple, explicit and easy to understand.
For each classifier, besides ERCOF, we also try features selected by several other entropy-based
filtering methods. Therefore, various comparisons of learning algorithms and feature selection
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methods can be addressed.
In the study of using gene expression profiles to predict patient survival status, we present
a new idea of selecting informative training samples by defining “long-term” and “short-term”
survivors. After identifying genes associated with survival via ERCOF, a scoring model built on
SVM is worked out to assign risk score to each patient. Kaplan-Meier plots for different risk
groups formed on the risk scores are then drawn to show the effectiveness of the model.
Another biological domain to which the proposed 3-step feature manipulation method is
applied is the recognition of functional sites in DNA sequences, such as translation initiation
sites (TIS) and polyadenylation (poly(A)) signal. In this study, we put our emphasis on feature
generation — k-gram nucleotide acid or amino acid patterns are used to construct the feature
space and the frequency of each pattern appearing in the sequence is used as value. Under the
description of the new features, original sequence data are then transformed to frequency vector
data to which feature selection and classification can be applied. In TIS recognition, we test
our methods on three independent data sets. Besides the cross validation within each dat set,
we also conduct the tests across different data sets. In the identification of poly(A) signal, we
make use of both public and our own collected data and build different models for DNA and
mRNA sequences. In both studies, we achieve comparable or better prediction accuracy than
those reported in the literature on the same data sets. In addition, we also verify some known
motifs and find some new patterns related to the identification of relevant functional sites.
The main contributions of this thesis are
(1) articulating a 3-step feature manipulation method to solve some biological problems;
(2) putting forward a new feature selection strategy to identify good genes from a large amount
of candidates in gene expression data analysis;
(3) presenting a new method for the study on patient survival prediction, including selecting
informative training samples, choosing related genes and building an SVM-based scoring
model;
(4) applying the proposed techniques to published gene expression profiles and proteomic
data, and addressing various comparisons on classification and feature selection methods
from a large amount of experimental results;
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(5) pointing out significant genes from each analysed data set, comparing them with literature
and relating some of them to the relevant diseases;
(6) recognizing two types of functional sites in DNA sequence data by using k-gram amino
acid or nucleotide acid patterns to construct feature space and validating learning models
across different independent data sets.
1.3 Structure
Chapter 2 first defines terms and introduces some concepts of supervised machine learning. Then
it reviews some learning algorithms and techniques, including support vector machines (SVM),
k-nearest neighbour (k-NN) and decision tree induction. Presenting methods of ensemble deci-
sion trees is the emphasis of this chapter and state-of-the-art algorithms, such as Bagging, Boost-
ing, Random forests, are described in detail. Newly implemented and published CS4 (cascading-
and-sharing for decision trees) is illustrated at the end, which makes use of different top-ranked
features as the root node of a decision tree in an ensemble.
Chapter 3 surveys feature selection techniques for data mining. It begins with introducing
two broad categories of selection algorithms — filter and wrapper, and indicating that filter is
more suitable to solve biological problems. Then it presents a variety of common filter methods,
such as t-statistic measure, Wilcoxon rank sum test, entropy-based measures, principal compo-
nents analysis and so on. Following these methods, there comes ERCOF, our proposed 3-phase
feature filtering strategy for gene expression data analysis. The chapter ends with a discussion
on applying feature selection to bioinformatics.
Chapter 4 is a literature review of microarray gene expression data studies. The idea of mi-
croarray experiments and the problems arising from gene expression data are introduced before
the extensive survey on various technologies that have been involved in this research area. These
technologies are described in terms of data preprocessing, gene selection, supervised learning,
clustering, and patient survival analysis.
Chapter 5 describes in detail my experimental work on phenotype classification from gene
expression data. The chapter starts with illustrating the proposed feature selection and super-
vised learning scenarios, experimental design and evaluation methods. Then, it presents more
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than 1,000 experimental results obtained from six gene expression profiles and one proteomic
data. For each data set, not only the classification and prediction accuracy is given, but also the
selected discriminatory genes are reported and related to the literature and the disease. Some
comparisons among feature selection methods and learning algorithms are also made based on
the large amount of experimental results. ERCOF and CS4 are shown to be the best feature
selection method and ensemble tree algorithm, respectively.
Chapter 6 presents my work on patient survival prediction using gene expression data. A
new method is illustrated in detail according to the order of selecting informative training sam-
ples, identifying related genes and building an SVM-based scoring model. Case studies, on
survival prediction for patients after chemotherapy for diffuse large-B-cell lymphoma and Stage
I and III lung adenocarcinomas, are presented following the description of the method.
Chapter 7 is my work on applying data mining technologies to recognize functional sites
in DNA sequences. The chapter begins with describing our method of feature manipulation for
dealing with sequence data, with the stress on feature generation using k-gram nucleotide acid or
amino acid patterns. Then the method is applied to identify translation initiation site (TIS) and
polyadenylation (poly(A)) signal. The presentation order for each application is: background
knowledge, data sets description, experimental results, and discussion. For both TIS and poly(A)
signal recognitions, results achieved by our method are comparable or superior to previously
reported ones, and several independent data sets are used to test the effectiveness and robustness
of our prediction models.
Chapter 8 makes conclusions and suggests future work.
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Classification — Supervised Learning
Data mining is to extract implicit, previously unknown and potentially useful information from
data [134]. It is a learning process, achieved by building computer programs to seek regularities
or patterns from data automatically. Machine learning provides the technical basis of data mining.
One major type of learning we will address in this thesis is called classification learning, which
is a generalization of concept learning [122]. The task of concept learning is to acquire the
definition of a general category given a set of positive class and negative class training instances
of the category [78]. Thus, it infers a boolean-valued function from training instances. As a more
general format of concept learning, classification learning can deal with more than two class
instances. In practice, the learning process of classification is to find models that can separate
instances in the different classes using the information provided by training instances. Thus,
the models found can be applied to classify a new unknown instance to one of those classes.
Putting it more prosaically, given some instances of the positive class and some instances of
the negative class, can we use them as a basis to decide if a new unknown instance is positive
or negative [78]. This kind of learning is a process from general to specific and is supervised
because the class membership of training instances are clearly known.
In contrast to supervised learning is unsupervised learning, where there is no pre-defined
classes for training instances. The main goal of unsupervised learning is to decide which in-
stances should be grouped together, in other words, to form the classes. Sometimes, these two
kinds of learnings are used sequentially — supervised learning making use of class information
derived from unsupervised learning. This two-step strategy has achieved some success in gene
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Table 2.1: An example of gene expression data. There are two samples, each of which is
described by 5 genes. The class label in the last column indicates the phenotype of the sample.
Gene1 Gene2 Gene3 Gene4 Gene5 Class
298 654 1284 800 163 ALL
2947 1811 198 679 225 AML
expression data analysis field [41, 6], where unsupervised clustering methods were first used
to discover classes (for example, subtypes of leukemia) so that supervised learning algorithms
could be employed to establish classification models and assign a phenotype to a newly coming
instance.
2.1 Data Representation
In a typical classification task, data is represented as a table of samples (also known as instances).
Each sample is described by a fixed number of features (also known as attributes) and a label that
indicated its class [44]. For example, in studies of phenotype classification, gene expression data







denotes the expression level of gene j in mRNA sample i, and y
i
is the class (e.g.
acute lymphoblastic leukemia) to which sample i belongs (i = 1; 2; : : : ; n and j = 1; 2; : : : ;m).
Table 2.1 shows two samples from a leukemia data set.
2.2 Results Evaluation
Evaluation is the key to making real progress in data mining [134]. To evaluate performance
of classification algorithms, one way is to split samples into two sets, training samples and test
samples. Training samples are used to build a learning model while test samples are used to
evaluate the accuracy of the model. During validation, test samples are supplied to the model,
having their class labels “hidden”, and then their predicted class labels assigned by the model
are compared with their corresponding original class labels to calculate prediction accuracy. If
two labels (actual and predicated) of a test sample are same, then the prediction to this sample is
counted as a success; otherwise, it is an error [134]. An often used performance evaluation term
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B true negativefalse positive
actual class
Figure 2.1: Confusion matrix for two-class classification problem.
some cases, we just simply use number of errors to indicate the performance. Note that, although
the error rate on test samples is often more meaningful to evaluate a model, the error rate on the
training samples is nevertheless useful to know as well since the model is derived from them.
Let’s see the confusion matrix illustrated in Figure 2.1 of a two-class problem. The true
positive (TP) and true negative (TN) are correct classifications in samples of each class, respec-
tively. A false positive (FP) is when a class B sample is incorrectly predicted as a class A
sample; a false negative (FN) is when a class A sample is predicted as a class B sample. Then
each element of a confusion matrix shows the number of test samples for which the actual class
is the row and the predicted class is the column. Thus, the error rate is just the number of
false positives and false negatives divided by the total number of test samples (i.e. error rate =
(FP + FN)=(TP + TN + FP + FN)).
Error rate is a measurement of overall performance of a classification algorithm (also known
as a classifier); however, a lower error rate does not necessarily imply better performance on a
target task. For example, there are 10 samples in class A and 90 samples in class B. If TP = 5
and TN = 85, then FP = 5, FN = 5 and error rate is only 10%. However, in class A, there are
only 50% samples are correctly classified. To more impartially evaluate the classification results,
some other evaluation metrics are constructed:
1. True positive rate (TP rate) = TP=(TP + FN), also known as sensitivity or recall, which
measures the proportion of samples in class A that are correctly classified as class A.
2. True negative rate (TN rate) = TN=(FP+TN), also known as specificity, which measures
the proportion of samples in class B that are correctly classified as class B.

















Figure 2.2: A sample ROC curve. The dotted line on the 45 degree diagonal is the expected curve
for a classifier making random predictions.
4. False negative rate (FN rate) = FN=(TP + FN) = 1  sensitivity.
5. Positive predictive value (PPV) = TP=(TP +FP ), also known as precision, which mea-
sures the proportion of the claimed class A samples are indeed class A samples.
In classification, it is a normal situation that along with a higher TP rate, there comes a higher FP
rate, and same to the TN rate and FN rate. Thus, the receiver operating characteristic (ROC) curve
was invented to characterize the tradeoff between TP rate and FP rate. The ROC curve plots TP
rate on the vertical axis against FP rate on the horizontal axis. With an ROC curve of a classifier,
the evaluation metric will be the area under the ROC curve. The larger the area under the curve
(the more closely the curve follows the left-hand border and the top border of the ROC space), the
more accurate the test. Thus, the ROC curve for a perfect classifier has an area of 1. The expected
curve for a classifier making random predictions will be a line on the 45 degree diagonal and its
expected area is 0.5. Please refer to Figure 2.2 for a sample ROC curve. ROC curve is widely used
in bioinformatics domain, for example, it has been adopted to implement the evaluation scoring
system of KDD Cup 2001 (http://www.cs.wisc.edu/˜dpage/kddcup2001/) and
KDD Cup 2002 (http://www.biostat.wisc.edu/˜craven/kddcup/), both of them
were about classifying biological data.
If the number of samples for training and testing is limited, a standard way of predicting
the error rate of a learning technique is to use stratified k-fold cross validation. In k-fold cross
validation, first, a full data set is divided randomly into k disjoint subsets of approximately equal
size, in each of which the class is represented in approximately the sample proportions as in the
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full data set [134]. Then the above process of training and testing will be repeated k times on
the k data subsets. In each iteration, (1) one of the subsets is held out in turn, (2) the classifier is
trained on the remaining k   1 subsets to build classification model, (3) the classification error
of this iteration is calculated by testing the classification model on the holdout set. Finally, the k
number of errors are added up to yield an overall error estimate. Obviously, at the end of cross
validation, every sample has been used exactly once for testing.
A widely used selection for k is 10. Why 10? “Extensive tests on numerous different data
sets, with different learning techniques, have shown that ten is about the right number of folds to
get the best estimate of error, and there is also some theoretical evidence that backs this up” [134].
Although 10-fold cross validation has become the standard method in practical terms, a single
10-fold cross validation might not be enough to get reliable error estimate [134]. The reason is
that, if the seed of the random function that is used to divide data into subsets is changed, the
cross validation with the sample classifier and data set will often produce different results. Thus,
for a more accurate error estimate, it is suggested to repeat the 10-fold cross validation process
ten times and average the error rates. This is called ten 10-fold cross validation and naturally, it
is a computation-intensive undertaking.
Instead of running cross validation ten times, another approach for a reliable results is called
leave-one-out cross validation (LOOCV). LOOCV is simply n-fold cross validation, where n is
the number of samples in the full data set. In LOOCV, each sample in turn is left out and the
classifier is trained on all the remaining n  1 samples. Classification error for each iteration is
judged on the class prediction for the holdout sample, success or failure. Different from k-fold
(k < n) cross validation, LOOCV makes use of the greatest possible amount of samples for
training in each iteration and involves no random shuffling of samples.
2.3 Algorithms
There are various ways to find models that separate two or more data classes, i.e. do classifica-
tion. Models derived from the same sample data can be very different from one classification
algorithm to another. As a result, different models represent the knowledge learned in different
formats as well. For example, decision trees represent the knowledge in a tree structure; instance-
based algorithms, such as nearest neighbour, use the instances themselves to represent what is
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learned; naive Bayes method represents knowledge in the form of probabilistic summaries. In
this section, we will describe a number of classification algorithms that have been used in the
biomedical domain, including k-nearest neighbour, support vector machines and decision tree
induction methods.
2.3.1 K-nearest neighbour
K-nearest neighbour (k-NN) is a typical instance-based classification and prediction algorithm.
Learning in this kind of methods consists of simply storing the training data [78]. When a new
instance comes, a set of similar related instances is retrieved from memory and used to classify
the new instance. By k-NN, the class label of a new testing sample is decided by the majority
class of its k closest training samples. The distance between two samples is measured by a certain
metric. Generally, the standard Euclidean distance is used. If there are m features to describe a
sample x and f
i
(x) denotes the value of ith feature (i = 1; 2;    ;m), then the Euclidean distance
































Note that using above distance metric assumes that the features are numeric, normalized and
are of equal importance. If different features are measured on different scales and Euclidean
distance is still used directly, the effect of some features might be completely dwarfed by others
that have larger scales of measurement. Therefore, in such case, normalization must be conducted
in advance. For nominal features whose values are symbolic rather than numeric, the distance
between two values is often taken to be 1 if the values are not same, to be 0 if the values are same.
No scaling is necessary in this case since only the values 0 and 1 are used. As for the selection
of k, it can be done by running cross validation on training samples. The k for which the cross
validation error rate is smallest is retained for use on further testing and prediction. In practice,
1, 3 and 5 are the generally adopted values for k.
Although the class prediction for a new sample relies on its k closest neighbours, the con-
tribution of these k neighbours could not be treated equally since some of them might be a bit far
from the target sample while some are closer to it. Thus, one refinement to k-NN algorithm is
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to weight the contribution of each of the k nearest neighbours according to their distance to the
testing sample, assigning bigger weight to closer neighbours. For example, use 1=distane as
the weight.
The nearest neighbour idea originated many decades ago, and k-NN started to be analyzed
by statisticians in early 1950s [134]. Fix and Hodges published their pioneering analysis of the
nearest neighbour in 1951 [37], and Johns first reported its usage in classification problem in
1961 [52]. Recently, k-NN has been widely used in classifying biomedical data — for example,
gene expression data [135, 67, 140, 35, 10], and translation initiation site prediction in DNA
sequences [142, 72]. However, there are some disadvantages of instance-based approaches.
(1) Generally, the cost of classifying new instances can be high. This is due to the fact that
almost all computation happens at the classification time rather than when the training
samples are loaded.
(2) Since there is no separate learning phase, all training samples have to be stored in the
memory when class prediction for a new sample is done. This may consume a long-term
unrealistic amounts of storage.
(3) Typically, instance-based algorithms, especially k-NN, consider all features when finding
similar training samples from memory. This makes them very sensitive to feature selection.
(4) Most of the algorithms do not output explicit knowledge that is learned. When dealing
with biomedical data, this drawback is conspicuous since comprehensible knowledge is
expected by biologists and medical doctors.
2.3.2 Support vector machines
Support vector machines (SVM) is a kind of a blend of linear modeling and instance-based
learning [134], which uses linear models to implement nonlinear class boundaries. It originates
from research in statistical learning theory [130]. An SVM selects a small number of critical
boundary samples from each class of training data and builds a linear discriminant function (also
called maximum margin hyperplane) that separates them as widely as possible. The selected
samples that are closest to the maximum margin hyperplane are called support vectors. Then the
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where the vectors X
i
are the support vectors, y
i
are the class labels (which are assumed to have
been mapped to 1 or -1) of X
i
, vector T represents a test sample. (X
i
 T ) is the dot product




and b are numeric parameters (like
weights) to be determined by the learning algorithm. Please see Figure 2.3 for representation of
a linear SVM.
In the case that no linear separation is possible, the training data will be mapped into a
higher-dimensional spaceH and an optimal hyperplane will be constructed there. The mapping is
performed by a kernel function K(; ) which defines an inner product in H. Different mappings
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An SVM is largely characterized by the choice of its kernel function. There are two types of
widely used kernel functions [24]: polynomial kernel and Gaussian radial basis function kernel
(RBF).










, the value of power d is called
degree and generally is set as 1, 2 or 3. Particularly, the kernel becomes a linear function
if d = 1. It is suggested to choose the value of degree starting with 1 and increment it
until the estimated error ceases to improve. However, it has been observed that the degree
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of a polynomial kernel plays a minor role in the final results [106] and sometime, linear
function performs better than quadratic and cubic kernels due to overfitting of the latter
kernels.













), where  is the width of the
Gaussian. The selection of parameter  can be conducted via cross validation or some other
manners. In [23], when using SVM with RBF kernel on gene expression data analysis,
Brown et al set  equal to the median of the Euclidean distances from each positive sample
(sample with class label as 1) to the nearest negative sample (sample with class label as
-1).
Besides polynomial kernel and Gaussian RBF kernel, other kernel functions include sigmoid
kernel [108], B
n
-spline kernel [108], locality-improved kernel [145], and so on. A tutorial of
SVM can be found in [24].
In order to determine parameters  and b in (2.3), the construction of the discriminant
function finally turns out to be a constrained quadratic problem on maximizing the Lagrangian
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where n is the number of samples in training data. However, the quadratic programming (QP)
problem in equation (2.4) can not be solved easily via standard techniques since it involves a
matrix that has a number of elements equals to the square of the number of training samples. To
efficiently find the solution of the above QP program, Platt developed the sequential minimal op-
timization (SMO) algorithm [93] — one of the fastest SVM training methods. Like other SVM
training algorithms, SMO breaks the large QP problem into a series of smaller possible QP prob-
lems. Unlike other algorithms, SMO tackles these small QP problems analytically, which avoids
using a time-consuming numerical QP optimization as an inner loop. The amount of memory
required by SMO is linear with number of training samples [93]. SMO has been implemented
into Weka, a data mining software package [134].
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SVMs have been shown to perform well in multiple areas of biological analysis, such as
detecting remote protein homologies, recognizing translation initiation sites [145, 142, 72], and
prediction of molecular bioactivity in drug design [132]. Recently, more and more bioinfor-
maticians employ SVMs in their research on evaluating and analyzing microarray expression
data [23, 39, 140]. SVMs have many mathematical features that make them attractive for gene
expression analysis, including their flexibility in choosing a similarity function, sparseness of so-
lution when dealing with large data sets, the ability to handle large feature spaces, and the ability
to identify outliers [23]. Among many published works in this area, Brown et al [23] studied
an expression data set from 2467 genes from the budding yeast Saccharomyces cerevisiae mea-
sured in 79 different DNA microarray hybridization experiments. Their results show that SVMs
outperformed Parzen window, Fisher’s linear discriminant and two decision tree classifiers (C4.5
and MOC1). Furey et al [39] analysed three data sets: ovarian cancer [109], colon cancer [84]
and subtype leukaemia [41]. They reported low test errors on these data sets despite the small
number of tissue samples available for investigation.
On the other hand, in [76], Meyer et al did a bench mark study on comparison of SVMs
with 16 classification methods based on their performance on 21 data sets from widely used UCI
machine learning database [15]. These classifiers include k-NN, classification trees (bagging,
random forests and multiple additive regression trees), linear/quadratic discriminant analysis,
neural networks and so on. For SVMs, they used the C++ library LIBSVM at http://www.
csie.ntu.edu.tw/˜cjlin/libsvm. They evaluated the performance of an algorithm by
classification error and mean squared error. They drew their conclusions that: “support vector
machines yielded good performance, but were not top ranked on all data sets. Simple statistical
procedures and ensemble methods proved very competitive, mostly producing good results ‘out
of the box’ without the inconvenience of delicate and computationally expensive hyperparameter
tuning. ...... In short, our results confirm the potential of SVMs to yield good results, but their
overall superiority can not be attested”.
In many practical data mining applications, success is measured more subjectively in terms
of how acceptable the learned description — rules, decision trees, or whatever — are to a hu-
man user [134]. This measurement is especially important to biomedical applications such as




Decision tree induction is among the most popular classification methods. As mentioned above,
decision tree has an important advantage over other machine learning algorithms such as k-NN
and SVM, in a qualitative dimension: rules produced by decision tree induction are easy to
interpret and understand, and hence, can help greatly in appreciating the underlying mechanisms
that separate samples in different classes.
In general, decision trees try to find an optimal partitioning of the space of possible obser-
vations, mainly by the means of subsequent recursive splits. Most of the algorithms implement
this induction process in a top-down manner: (1) determining the root feature that most discrim-
inatory with regard to the entire training data; (2) using the root feature to split the data into
non-overlapping subsets; (3) selecting a significant feature of each of these subsets to recursively
partition them until reaching one of stopping criteria. This idea was first developed by Ross Quin-
lan and his classic paper was published in 1986 [96]. Figure 2.4 is a decision tree example from
a study of gene expression in two subtypes of acute leukemias, acute lymphoblastic leukemia
(ALL) and acute myeloid leukemia (AML). To classify a new sample, a decision tree sorts the
sample down the tree from the root to some leaf node, which provides the classification of the
sample. Established decision trees can also be re-presented as sets of if-then rules to improve
human readability. For example, from the left-most branch of the decision tree illustrated in Fig-
ure 2.4, a decision rule can be derived as “if Attribute223380.34 and Attribute4847506.77,
then the sample is an ALL sample”.
Among many decision tree based classifiers, C4.5 [97] is a well-established and widely used
algorithm. C4.5 uses the information gain ratio criterion to determine the most discriminatory
feature at each step of its decision tree induction process. In each round of selection, the gain ratio
criterion chooses, from those features with an average-or-better information gain, the feature that
maximizes the ratio of its gain divided by its entropy. C4.5 stops recursively building sub-trees
when (1) an obtained data subset contains samples of only one class ( then the leaf node is labeled
by this class); or (2) there is no available feature (then the leaf node is labeled by the majority
class); or (3) when the number of samples in the obtained subset is less than a specified threshold
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Attribute2233
<= 80.34 > 80.34 
Attribute4847 ALL
<= 506.77 > 506.77 
ALL AML
Figure 2.4: A decision tree for two types (ALL v.s. AML) acute leukemias classification.
Branches correspond to the values of attributes (genes); leaves indicate classifications.
(then leaf node is labeled by the majority class). The precise definition and calculation formulae
of information gain and gain ratio are given in Section 3.22 of Chapter 3. After obtaining a
learned decision tree, C4.5 conducts tree post-pruning to make a decision tree simple and reduce
the probability of over-fitting the training data.
This pruning is known as reduced error pruning. For each of the nodes in the tree, the
traditional process of this pruning consists of removing the subtree rooted at a node, making it
a leaf node and assigning it the most common class of the training samples affiliated with that
node. A node is removed only if the resulting pruned tree performs no worse than the original
over the cross validation set [78]. Since the performance is measured on validation set, this
pruning strategy suffers from the disadvantage that the actual tree is based on less data. However,
in practice, C4.5 makes some estimate of error based on training data itself — using the upper
bound of a confidence interval (by default is 25%) on the resubstitution error. The estimated
error of the leaf is within one standard deviation of the estimated error of the node. Besides
reduced error pruning, C4.5 also provides another pruning option known as subtree raising. In
subtree raising, an internal node might be replaced by one of nodes below and samples will
be redistributed. For a detailed illustration on how C4.5 conducts its post-pruning, please refer
to [97, 134].
Other algorithms for decision tree induction include ID3 (predecessor of C4.5) [96], C5.0
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(successor of C4.5), CART (classification and regression trees) [22] (http://www.salford
-systems.com/), LMDT (Linear Machine Decision Trees) [128], OC1 (oblique classifier
1) [81] and so on. This group of algorithms are most successful for analysis of clinical data
and diagnosis from clinical data. Some examples include locating protein coding regions in
Human DNA [104], prediction of post-traumatic acute lung injury [99], identification of acute
cardiac ischemia [110], prediction of neurobehavioral outcome in head-injury survivors [120].
More recently, they have been used to learn from gene expression data to reconstruct molecular
networks [117] or classify tumors [35].
2.3.4 Ensemble of decision trees
Ensemble methods are learning algorithms that construct a set of classifiers and then classify new
samples by taking a vote of their predictions [33]. Generally speaking, an ensemble method can
increase predictive performance over a single classifier. In [33], Dietterich gave three funda-
mental reasons for why ensemble methods are able to outperform any single classifier within the
ensemble — in terms of statistical, computational and representational issues. Besides, plenty
of experimental comparisons have been performed to show significant effectiveness of ensemble
methods in improving the accuracy of single base classifiers [98, 13, 34, 20, 107].
The original ensemble method is Bayesian averaging [33], but bagging (bootstrap aggre-
gation) [19] and boosting [38] are two of most popular techniques for constructing ensembles.
Next, we will introduce how these two ideas and some other ensemble methods are implemented
to generate decision tree committees.
Bagging of decision trees
The technique of bagging was coined by Breiman [19], who investigated the properties of bag-
ging theoretically and empirically for both classification and numeric prediction. Bagging of
trees combines several tree predictors trained on bootstrap samples of the training data and gives
prediction by taking majority vote. In bagging, given a training set S with n samples, a new train-
ing set S0 is obtained by drawing n samples uniformly with replacement from S. When there
is a limited amount of training samples, bagging attempts to neutralize the instability of single
decision tree classifier by randomly deleting some samples and replicating others. The instability
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Generation of trees:
Let n be the number of samples in the training data S.
For each of k iterations:
Obtain a new training set S0 by drawing n samples with replacement from S.
Apply the decision tree algorithm to S0.
Store the resulting tree.
Classification:
Given a new sample.
For each of the k trees:
Predict class of sample according to the tree.
Return class that has been predicted most often.
Figure 2.5: Algorithm for bagging.
inherent in learning algorithms means that small changes to the training set cause large changes
in the learned classifier. Figure 2.5 is the algorithm for bagging.
Boosting of decision trees
Unlike bagging where individual trees are built independently, each new tree generated in boost-
ing is influenced by the performance of those built previously. Boosting encourages new trees to
become “experts” for samples handled incorrectly by earlier ones [134]. When making classifi-
cation, boosting weights a tree’s contribution by its performance, rather than giving equal weight
to all trees which is adopted by bagging.
There are many variants on the idea of boosting. The version introduced below is called
AdaBoostM1 which was developed by Freund and Schapire [38] and designed specifically for
classification. The AdaBoostM1 algorithm maintains a set of weights over the training data set
S and adjusts these weights after each iteration learning of the base classifier. The adjustments
increase the weight of samples that are misclassified and decrease the weight of samples that are
properly classified. By weighting samples, the decision trees are forced to concentrate on those
samples with high weight. There are two ways that AdaBoostM1 manipulates these weights to
construct a new training set S0 to feed to the decision tree classifier [134]. One way is called
boosting by sampling, in which samples are drawn with replacement from S with probability
proportional to their weights. Another way is boosting by weighting, in which the presence of
sample weights changes the error calculation of tree classifier — using the sum of the weights
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Generation of trees:
Let n be the number of samples in the training data S.
Assign equal weight 1=n to each sample in S.
For each of k iterations:
Apply decision tree algorithm to weighted samples.
Compute error e of the obtained tree on weighted samples.
If e is equal to zero:
Store the obtained tree.
Terminate generation of trees.
If e is greater or equal to 0.5:
If the obtained tree is the first tree generated:
Store the obtained tree.
Terminate generation of trees.
For each of samples in S:
If sample is classified correctly by the obtained tree:
Multiply weight of the sample by e=(1   e).
Normalize weight of all samples.
Classification
Given a new sample.
Assign weight of zero to all classes.
For each of the tree stored:
Add  log(e=(1   e)) to the weight of the class predicted by the tree.
Return class with highest weight.
Figure 2.6: Algorithm for AdaBoostM1.
of the misclassified samples divided by the total weight of all samples, instead of the fraction of
samples that are misclassified. Please refer to Figure 2.6 for a detailed algorithm of AdaBoostM1
using boosting by weighting.
Please note that the approach of boosting by weighting can be used only when the learning
algorithm can cope with weighted samples. If this is not the case, an unweighted data set is gen-
erated from the weighted data by resampling. Fortunately, C4.5 decision tree induction algorithm
has been implemented to deal with weighted samples. For more details about this, please refer
to [98].
Besides bagging and boosting, Dietterich put forward an alternative but very simple idea,
randomization trees, to build ensemble trees. With this idea, the split at each internal node
is selected at random from the k (20 by default) best splits. In case of continuous attributes,
each possible threshold is considered to be a distinct split, so the k best splits may all involve
splitting on the same attribute. Experimentally, Dietterich [34] also compared randomization with
23
bagging and boosting of constructing ensembles of C4.5 decision trees using 33 data sets. His
experimental results showed that (1) when there is little or no classification noise, randomization
is competitive with (sometime is slightly superior to) bagging but not as accurate as boosting;
(2) where there is substantial classification noise, bagging is much better than boosting, and
sometimes better than randomization.
Random forests
Random forests is based on bagged trees, but in addition uses random feature selection at each
node for the set of splitting variables [20].
A more precise definition of random forests given in [20] is: “a random forest is a classifier
consisting of a collection of tree-structured classifiers h(X;V
k
) (k = 1;   ), where the V
k
are
independent identically distributed random vectors and each tree casts a unit vote for the most
popular class at input X”. Using random forests, in the kth iteration, a random vector V
k
is
generated, independent of the past random vectors but with the same distribution. For instance,
V
k
is generated by drawing samples with replacement from original training data. Based on
the bootstrapped data, in [20], the forests using randomly selected attribute or combinations of
attributes at each node were studied. In the former case, at each node, m
try
number of candidate
features are selected from all m features and the best split on these m
try
is used to split the
node. m
try
is defined by the user, and has the same value for each tree grown in the ensemble.
It can take any value in the range of 1 to m. In [20], two values of m
try
were tried — 1 and
int(log
2
m+1). The experimental results illustrated that the algorithm is not very sensitive to the
value of m
try
. In the latter case, more features are defined by taking random linear combinations
of a number of the original input attributes. This approach is used when there are only a few
attributes available so that higher correlations between individual classifiers are expected. After
a splitting feature is determined, random forests grow the tree using CART [22] methodology to
maximum size and do not prune. Different from C4.5, CART selects splitting feature using GINI
impurity criterion. Please refer to Figure 2.7 for the general algorithm of random forests.
In [21], Breiman claimed that “in random forests, there is no need for cross-validation or a
separate test set to get an unbiased estimate of the test set error.” The reason was as follows. In
each of k iterations, about one-third of the samples are left out of the new bootstrap training set
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Generation of trees:
Let n be the number of samples in the training data S,
k be the number of trees to grow,
m
try
be an integer and m
try
<< m, (m is the number of features).
For each of k iterations:
Obtain a new training set S0 by drawing n samples with replacement from S.




Given a new sample.
For each of the k trees:
Predict class of sample according to the tree.
Return class that has been predicted most often.
Figure 2.7: Algorithm for random forests.
and not used in the construction of the tree [20]. These samples are called “out-of-bag” (OOB)
samples to which the tree built in this iteration will be applied to get classification. In this way, a
test set classification is obtained for each sample in about one-third of the constructed trees. The
final classification for a sample is the class having the most votes from the trees in the forest.
Then the final classifications are compared with the real class labels of the OOB samples to
achieve an OOB error estimation.
Although in random forests, the feature selection at each node is random, an upper bound
for its generalization error still can be derived in terms of strength of the individual decision
tree classifiers and their correlations [20]. This not only measures how accurate the individual
classifiers are and the dependence between them, but also gives insight into the ability of the
random forest to predict. The estimation for strength and correlation is conducted by the above
out-of-bag idea. Please see Appendix II of [20] for more information about this issue. Random
forests was claimed to achieve comparable or better accuracy than AdaboostM1 did. Besides, it
is [20] (a) relatively robust to outliers and noise, (b) faster than bagging and boosting, (c) simple
and easily parallelized. In addition, (d) useful internal estimates of error, strength, correlation
and variable importance are possible to obtain.
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CS4 — a new method of ensemble of decision trees
CS4 stands for cascading-and-sharing for decision trees. It is a newly developed classification
algorithm based on an ensemble of decision trees. The main idea of this method is to use dif-
ferent top-ranked features as the root node of a decision tree in an ensemble (also named as a
committee) [62, 63]. Different from bagging or boosting which uses bootstrapped data, CS4 al-
ways builds decision trees using exactly the same set of training samples. The difference between
this algorithm and Dietterich’s randomization trees is also very clear — the root node features
of CS4 induced trees are different from each other while every member of a committee of ran-
domized trees always shares the same root node feature (the random selection of the splitting
feature is only applied to internal nodes). On the other hand, compared with the random forests
method which selects splitting features randomly, CS4 picks up root node features according to
their rank order of certain measurement (such as entropy, gain ratio). Thus, CS4 is claimed as a
novel ensemble tree method.
In detail, to construct k number of decision trees (k  m, m is the number of features
describe the data), we have following steps:
(1) Ranking all the m features according to a certain criterion, with the best feature at the first
position.
(2) i = 1.
(3) Using the ith feature as root node to construct ith decision tree using base classifier.
(4) If i < k, increasing i by 1 and goto (3); otherwise, stop.
In this thesis, we use C4.5 as the base classifier of CS4 and information gain ratio (Sec-
tion 3.22 of Chapter 3) as the measure to rank features.
In the classification phase, CS4 defines the coverage of a rule in a tree as the percentage of
the samples in its class satisfying the rule. Suppose we have discovered k decision trees from
our training set containing class A and class B samples. Then, all the rules derived from the k
trees can be categorized into two groups: one group only containing rules for A samples, another
containing rules for B samples. In each group, we rank the rules in descending order according
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Given a test sample T , each of the k trees will have a rule to fit this sample and therefore, give
a prediction for this sample. Suppose that T satisfies the following k
1
rules of class A samples
and k
2
































= k. The order of these rules is also based on their coverage.

































If Sore(T )A  Sore(T )B , then T will be predicted as a class A sample; Otherwise, T pre-
dicted as a class B sample. In practice, the tie-score case occurs rarely [62].
The algorithm of CS4 can be easily applied to solve multi-class problems. If the given data
set contains p classes samples (p  2), similarly, we can sort p groups of top k rules according
to their coverage. When classifying a sample T , those rules in the k trees which are satisfied by

















The effectiveness of CS4 has been tested on some UCI data sets [15] as well as some public
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gene expression profiles that are described by more than 10,000 features [62]. One of the main
works of this thesis is to do further comparison of CS4 with bagging, boosting, random forests
as well as SVM and k-NN using a huge number of experimental results obtained from various
biological data sets.
2.4 Chapter Summary
In this chapter, we introduced the concept of classification in data mining as well as the ways to
evaluate the classification performance. We selected to present in detail some of classification al-
gorithms — putting the emphasis on several methods using ensemble of decision trees, including
bagging, boosting, randomization tree, random forests and the newly invented CS4. Besides, two
widely used classifiers, SVM and k-NN were also described so that comparisons among decision
tree methods, kernel function approaches and instance-based techniques can be addressed in the
later chapters using experimental results.
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Chapter 3
Feature Selection for Data Mining
A known problem in classification (in general machine learning) is to find ways to reduce the
dimensionality of the feature space to overcome the risk of over-fitting. Data over-fitting happens
when the number of features is large (“curse of dimensionality”) and the number of training
samples is comparatively small (“curse of data set sparsity”). In such a situation, a decision
function can perform very well on classifying training data, but does poorly on test samples.
Feature selection is concerned with the issue of distinguishing signal from noise in data analysis.
3.1 Categorization of Feature Selection Techniques
Feature selection techniques can be categorized according to a number of criteria [46]. One pop-
ular categorization is based on whether the target classification algorithm will be used during the
process of feature evaluation. A feature selection method, that makes an independent assessment
only based on general characteristics of the data, is named “filter” [134]; while, on the other hand,
if a method evaluates features based on accuracy estimates provided by certain learning algorithm
which will ultimately be employed for classification, it will be named as “wrapper” [55, 134].
With wrapper methods, the performance of a feature subset is measured in terms of the learning
algorithm’s classification performance using just those features. The classification performance
is estimated using the normal procedure of cross validation, or the bootstrap estimator [134].
Thus, the entire feature selection process is rather computation-intensive. For example, if each
evaluation involves a 10-fold cross validation, the classification procedure will be executed 10
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times. For this reason, wrappers do not scale well to data sets containing many features [45].
Besides, wrappers have to be re-run when switching from one classification algorithm to another.
In contrast to wrapper methods, filters operate independently of any learning algorithm and the
features selected can be applied to any learning algorithm at the classification stage. Filters have
been proven to be much faster than wrappers and hence, can be applied to data sets with many
features [45]. Since the biological data sets discussed in the later chapters of this thesis often
contain a huge number of features (e.g. gene expression profiles), we concentrate on filter meth-
ods.
Another taxonomy of feature selection techniques is to separate algorithms evaluating the
worth or merit of a subset features from those of individual features. Most of the feature selection
methods introduced in this chapter evaluate how well an individual feature contributes to the
separation of samples in different classes and produce a simple feature ranking. However, there
is also one method in this chapter, correlation-based feature selection, that assesses and selects a
subset of features. We will also present a new feature selection algorithm, ERCOF, which first
evaluates features individually and then forms the final representative feature set by considering
the correlations between the features.
There are some other dimensions to categorize feature selection methods. For example,
some algorithms can handle regression problem, that is, the class label is numeric rather than
a discrete valued variable; and some algorithms evaluate and rank features independently from
class, i.e. unsupervised feature selection. We will restrict our study to the data sets with discrete
class label since this is the case of the biological problems analysed in later chapters of this thesis,
though some algorithms presented can be applied to numeric class label as well.
3.2 Feature Selection Algorithms
There are various ways to conduct feature selection. Let us start with introducing some often
used methods conducted by analysing the statistical properties of the data.
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3.2.1 T -test, signal-to-noise and Fisher criterion statistical measures
Highly consistent with the well-known ANOVA principle, a basic concept for identifying a rele-
vant feature from an irrelevant one is the following: if the values of a feature in samples of class
A are significantly different from the values of the same feature in samples of class B, then the
feature is likely to be more relevant than a feature that has similar values in A and B. More
specifically, in order for a feature f to be relevant, its mean value A
f
in A should be significantly
different from its mean value B
f
in B. However, if the values of a feature f varies greatly within
the same class of samples, even if A
f
differs greatly from B
f
, the feature f is not a reliable one.











2 of f in B should be small.
The classical t-statistic is constructed to test the difference between means of two groups
of independent samples. So if samples in different classes are independent, the t-statistic can be
used to find features that has big difference in mean level between the two classes. These features
can be then considered to have ability to separate samples between different classes.










where 1  i  n, m is the number of features and y
i
is the class label of X
i
. Each sample
belongs to one of two classes A (i.e. y
i
= A) and B (i.e. y
i
= B) (such as tumor v.s. normal).




stands for its value in sample i
(1  j  m). In addition, nA (resp. nB) is the number of samples in class A (resp. B). For
each feature f
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can be considered better than a feature f
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). Thus, when making feature selection, we can simply sort candidate features by their t
scores and pick those with largest scores. In [82], t score is used to select important genes for
classification after applying the algorithm of partial least squares to the original high dimension
gene expression data.
In [41, 116, 39], a slightly different statistical measure from t-test was proposed to find
discriminatory genes that can distinguish tumor cells from normal ones using gene expression


















As with t-test, when using signal-to-noise statistical measure, a feature f
j
can be considered
better than a feature f
l




), so we always pick those features with largest
scores. Compared with t-test, the statistical property of signal-to-noise is not fully understood.
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[68], Fisher criterion score is used to select genes to distinguish two subtypes of leukemia from
expression profilings.
T -test, signal-to-noise and Fisher criterion statistical measures are easy to compute and thus
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straightforward to use. However, there are three considerations that may make them ineffective
for feature selection [72]. The first consideration is that use of these tests are justified only
if it can be assumed that the data have a normal distribution, and this is almost not the case
of biological data. The second consideration is that the sample sizes nA and nB should be
sufficiently large; otherwise, underestimates of the standard deviations and variances will occur.





be two features. Suppose f
1




= 75 and has values ranging from 100 to 199 in class B with B
1
= 125. Suppose f
2
has
values ranging from 25 to 125 in class A with A
2
= 50 and has values ranging from 100 to 175
in class B with B
2





















. However, we note that the values of f
1
are distributed so that all those in A are
below 100 and all those in B are at least 100. In contrast, the values of f
2
in A and B overlap in
the range 100 to 125. Then clearly f
1
should be preferred. The effect is caused by the fact that
t, s and fisher are sensitive to all changes in the values of f , including those changes that may
not be important. When dealing with gene expression data, one of the pre-processing works is to
transform the data into the space of log-ratios by taking the logarithm of each gene (i.e. feature)
divided by the median of that gene across a set of experiments [85]. It has been shown that
the rankings of same set of candidate features, that based on t, s or fisher statistical measures,
might be different before and after this logarithm transformation.
3.2.2 Wilcoxon rank sum test
In order to avoid the assumption that feature values have to follow normal distribution, one can
use non-parametric tests. One of the best known non-parametric tests is Wilcoxon rank sum test,
or the equivalent Mann-Whitney test. Wilcoxon rank sum test [133] is an alternative to t-test for
testing the quality of two populations’ mean or medians. It is a kind of non-parametric test since
it is based on rank of samples rather than distribution parameters such as mean and standard
deviation. It does not require the two populations to conform to a normal distribution, but to
the same shape [105]. However, it may not be as powerful as t-test, signal-to-noise or Fisher
criterion statistical measures, if the normality assumption is correct [105].
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), can be obtained using
following procedure:








across all the n samples in ascending order.
(2) Assign rank (from 1) r(x
ij
) to each value x
ij
above and use average of the ranks for ties.
Then, 1  r(x
ij
)  n.
(3) Use the sum of the ranks for the class, which has smaller number of samples, as test
statistic, w(f
j













is the class label of sample X
i
. If the number of samples is same in each class,
the choice of which class to use for the test statistic is arbitrary.
To use the Wilcoxon rank sum test to decide if a feature f is relevant, we set up the null
hypothesis that: the values of f have the same continuous distribution in A and B. Then w(f) is
used to accept or reject the hypothesis. To decide whether to accept or reject the null hypothesis,
we compare w(f) with the upper and lower critical values derived from a significant level . For
small numbers of samples in class A and B, e.g. < 10, the critical values have been tabulated
and can be found in most of textbooks of statistics, such as [105]. If either nA or nB is larger
than what is supplied in the table, the following normal approximation can be used [105]. The


































is the z score for significant level . If a feature f ’s test w(f) falls in the range given
by the upper and lower critical values, then we accept the null hypothesis; otherwise, we reject
the hypothesis, and this indicates that the values of feature f have different distribution between
samples in class A and B. Thus, those features whose Wilcoxon rank sum test statistic rejects
the hypothesis will be considered as signals.
The non-parametric Wilcoxon rank sum test has several advantages over t-test, signal-to-
noise and Fisher criterion statistical measures [87]. The first one is its robustness. Because it uses
ranks rather than actual values of a feature, it is more robust to outliers. This feature is important
to biological data, which may need many steps of experiments in the laboratory and may have
many potential sources of error. The second advantage is related to data transformation, such as
normalization and logarithm transformations that are often used in preprocessing of microarray
gene expression data. The rank sum test is not affected by any of these transformations since the
ordering of the expression levels remains unchanged.
3.2.3 X 2 statistical measure
X
2 measure evaluates features individually by measuring the X 2-statistic with respect to the
class. Different from the preceding methods, X 2 measure can only handle features with discrete



















where k is the number of classes, A
ij
is the number of samples with ith value of f in jth class,
E
ij












is the number of samples having ith value of f , C
j
is the number of samples in the jth class,
and n is the total number of samples.
We consider a feature f
j
to be more relevant than a feature f
l







Obviously, the worst X 2 value is 0 if the feature has only one value. The degree of freedom
of the X 2-statistic measure is (w   1)  (k   1) [71]. With the degree of freedom known, the
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critical value for certain significant level can be found from most statistics books, such as [105].
However, note that, the value w might be varied from feature to feature.
To apply X 2 measure to numeric features, a discretization preprocessing has to be taken.
The most popular technique in this area is the state-of-art supervised discretization algorithm
developed by Fayyad and Irani [36] based on the idea of entropy. At same time, feature selection
can be also conducted as a by-product of discretization.
3.2.4 Entropy based feature selection algorithms
Entropy is a measure commonly used in information theory, which characterizes the (im)purity
of a collection of samples [112, 78]. Given a collection S, containing samples in k classes, the














is the proportion of S belonging to class i. There are several points worth noting.
1. The logarithm is base 2 because entropy is a measure of the expected encoding length
measured in bits [112].
2. In all calculations involving entropy, we define 0  log
2
0 = 0
3. Ent(S) reaches its minimum value 0, if all the samples of S belong to the same class. For





1 (i = A);
0 (i 6= A).
(3:15)
Thus, Ent(S) =  1  log
2
1 = 0.
4. Ent(S) reaches its maximum value log
2
k, if S contains equal number of samples in each
class. In this case, p
i
= 1=k, for any i 2 [1; k℄. Thus,





















Figure 3.1: Entropy function of a two-class classification, p
1
is the proportion of samples in one
class, with range [0,1].
Figure 3.1 shows the form of the entropy function when k = 2 (i.e. two classes), as p
1
varies
between 0 and 1.
Fayyad’s discretization algorithm
The essential idea of this discretization algorithm is to find some cut point(s) for a numeric
feature’s value range to make the resulting value intervals as pure as possible. Formally, let cut




. Then, the class information
entropy of the partition, denoted Ent(f; T; S), is given by [36]:

















); (j = 1; 2) is the class entropy of a subset S. Assuming there are k classes
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) be the proportion of samples in S
j
that have class C
i
. According to























is minimal amongst all the candidate cut points [36]. The selection of T
f
can be achieved by re-




until some stopping criteria is reached. A stopping
criteria is needed because otherwise, we can always achieve perfect entropy by partitioning the
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range into many small intervals, each containing exactly one sample. A commonly used stop-
ping criteria is the so-called minimal description length (MDL) principle described in [101, 36].















where n is the number of samples in the set S, and,
Gain(f; T; S) = Ent(S) Ent(f; T; S) (3:20)
and















is the number of class labels represented in the range S
i
. In the right side of (3.19),
the first component is the amount of information needed to specify the partitioning point; the
second one is a correction due to the need to transmit which classes correspond to upper and
lower subintervals [36, 134]. With MDL principle, a feature f can not be discretized, if there is
no such kind of cut point T whose Gain(f; T; S) (defined in (3.20)) is greater than or equal to
the right side of (3.19).
In [71], Setiono and Liu noted that discretization has the potential to perform feature selec-
tion among numeric features. If the distribution of a numeric feature’s value is relatively random,
then the feature would be treated as irrelevant to the classes and can be safely removed from
the data set. In this case, there is no suitable cut point to split feature’s value range, or, in other
words, the feature can be only discretized to a single value. On the other hand, if a resulting value
interval induced by the cut points of a feature contains only the same class of samples, then this
partitioning of this feature has an entropy value of 0. This is an ideal case since the feature can
clearly distinguish samples in the different classes. Please refer to Figure 3.2 for an illustration
on entropy measure, cut point and intervals. Generally, under the entropy measure, feature f
j
is more useful than feature f
l










; S). Thus, when using
entropy measure to select features, we sort the class entropy in an ascending order and consider
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h: class 1 sample, ฀: class 2 sample
(a) A feature with high entropy.
(b) A feature with low entropy.
(c) A feature with zero entropy.
interval 2interval 1
interval 2
h ฀ h ฀ h ฀ h h ฀ h h ฀     ฀
+f-f
h h h ฀ h h   h h         ฀ ฀ ฀ ฀ ฀
+f-f
Cut point
h h h h h h h          ฀ ฀ ฀ ฀ ฀       ฀
+f-f
h h h ฀ h h   h h         ฀ ฀ ฀ ฀        ฀
Cut point
interval 1
Figure 3.2: We place the values of a feature on the horizontal axis. There are 13 samples in two
classes, class 1 and class 2. (a) shows a feature that is a poor signal and there is no cut point can
be found to distinguish samples in the different classes; (b) shows a feature that is a potentially
good signal and indicates a possible cut point. (c) shows a feature that is a strongest signal and
indicates a cut point — different resulting intervals contains samples of different class.
those features with lowest values. In most of the cases, we are just interested in features having
cut point(s) found for their value range.
For discrete features, we still can use entropy measure to select features since the “cut
points” for each feature have been given naturally. Thus the class entropy of a feature f with w
















are the w subsets of samples resulting from partitioning of S by f and
Ent(S
i
) can be calculated from (3.18).
Actually, X 2 measure is one of the refinements of entropy measure. Other than the class





induced by the class entropy. Some other refinements include information gain measure and
39
information gain ratio measure that are used respectively in ID3 [96] and C4.5 [97] to induce the
splitting node of a decision tree.
Information gain and information gain ratio
Information gain is simply the expected reduction in entropy by partitioning the samples accord-
ing to this feature, that is the amount of information gained by looking at the value of this feature.
More precisely, the information gain Gain(f; S) of a feature f , relatively to a set of samples S,
is defined as
Gain(f; S)  Ent(S) Ent(f; T
f
; S) (3:23)
where Ent(S) can be calculated from equation (3.14) and Ent(f; T
f
; S) is the class entropy
of the feature (for a numeric feature f , T
f
is the best partition to f ’s value range under certain
criteria, such as MDL principle). Since Ent(S) is a constant once S is given, the information
gain and entropy measures are equivalent when evaluating the relevance of a feature. In contrast
to the rule “the smaller the class entropy value, the more important the feature is” that is used
in entropy measure, we consider a feature f
j
to be more relevant than a feature f
l
(l 6= j) if
Gain(f
j
; S) > Gain(f
l
; S). In fact, the ID3 [96] decision tree induction algorithm uses infor-
mation gain as the measure to pick discriminatory features for tree nodes. Besides, information
gain is also involved in some recent studies of feature selection on biological data. For exam-
ples, Xing et al [136] used it as one filter to select genes from gene expression data and the
winner of KDD Cup 2001 [25] also employed it as a measurement to reduce the dimensionality
of a feature space containing 139,351 binary features in a thrombin data set provided by Dupont
Pharmaceuticals Research Laboratories.
However, there is a natural bias in the information gain measure — it favors features with
many values over those with few values. An extreme example is a feature having different values
in different samples. Although the feature perfectly separates the current samples, it is a poor
predictor on subsequent samples. One refinement measure that has been used successfully is
called information gain ratio. The gain ratio measure penalizes features that with many values
by incorporating amount of split information, which is sensitive to how broadly and uniformly
40
the feature splits the data [78]:



















are the w subsets of samples resulting from partitioning of S by w-valued
discrete or w-value-intervaled numeric feature f . Then, the gain ratio measure is defined in





Note that split information is actually the entropy of S with respect to the values of feature f and
it discourages the selection of features with many values [78]. For example, if there are total num-
ber of n samples in S, the split information of a feature f
1
, which has different values in different
samples, is log
2
n. In contrast, a boolean feature f
2
that splits the same n samples exactly in half
will have split information of 1. If these two features produce the equivalent information gain,
then clearly feature f
2
will have a higher gain ratio measure. Generally, a feature f
j
is considered
to be more significant than a feature f
l
(l 6= j) if GainRatio(f
i
; S) > GainRatio(f
l
; S). When
using gain ratio measure (or information gain measure) to select features, we sort the values of
gain ratio (information gain) in an descending order and consider those features with highest
values.
3.2.5 Principal components analysis
Principal components analysis (PCA) [53] is widely used in signal processing, statistics and
neural computing. It selects features by transforming a number of original (high-dimensional)
features into a smaller number of uncorrelated features called principal components. The first
principal component accounts for as much of the variability in the data as possible, and each
succeeding component accounts for as much of the remaining variability as possible. The math-
ematical technique used in PCA is called eigen analysis [2]. The eigenvector associated with
the largest eigenvalue has the same direction as the first principal component; the eigenvector
associated with the second largest eigenvalue determines the direction of the second principal
component, and so on.
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Feature selection through PCA can be performed in following several steps.
(1) Calculating the covariance matrixC of a data collection X defined in Equation (3.1), where
X is a matrix with n rows (i.e. samples) and m columns (i.e. features). Each column data
of X may have to be normalized. Each element 
ij
(i; j = 1; 2;    ;m) of matrix C is the
linear correlation coefficient between the elements of columns (i.e. features) i and j of X





































mean and standard derivation of column i (j) of X , respectively. It is easy to prove that
the covariance matrix C is real and symmetric.
(2) Extracting eigenvalues 
i
(i = 1; 2;    ;m) by equation,
jC   
i
Ij = 0 (3:27)
where I is an identity matrix.
(3) Computing eigenvectors e
i







(4) Ranking eigenvectors according to the amount of variation in the original data that they












(5) Selecting features that account for most of the variation in the data. In this step, eigenvec-
tors (i.e. principal components) that account for some percentage (for example: 95%) of
the variance in the original data will be chosen while the rest features will be discarded.
Indeed, it can be proven that the representation given by PCA is an optimal linear dimension
reduction technique in the mean-square sense [53]. It is worth noting that, different from other
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methods introduced in this chapter, PCA is an unsupervised (in contrast to supervised) feature
selection method since it makes no use of the class attribute.
3.2.6 Correlation-based feature selection
All of the preceding measures evaluate features in terms of their individual relevance to separat-
ing samples in different classes. However, rather than ranking individual features, we can also
scores the worth of subsets of features. Correlation-based feature selection (CFS) [44] is such a
method which is built on the belief that “good feature subsets contain features highly correlated
with the class, yet uncorrelated with each other”. At the heart of the CFS algorithm is a sub-
set evaluation heuristic that takes into account not only the usefulness of individual features for
predicting the class, but also the level of inter-correlation among them [46].
CFS first calculates a matrix of feature-class and feature-feature correlations. Then a score












is the heuristic merit of a feature subset S containing k features, r
f
is the average
feature-class correlation, and r
ff
is the average feature-feature inter-correlation. The numerator
can be thought of as giving an indication of how predictive the subset of features are while the
denominator indicates how much redundancy there is among them [46].
In order to apply Equation (3.30), it is necessary to calculate the correlation between fea-
tures. In this step, CFS uses symmetrical uncertainties to estimate the degree of association
between discrete features or between features and classes [44]. The formula (3.31) below mea-
sures the inter-correlation between two features or the correlation between a feature and a class




























where the numerator is the information gain between features and classes, H(f) is the entropy of
the feature f defined in (3.14). CFS starts from the empty set of features and uses the best-first-
search heuristic with a stopping criterion of 5 consecutive fully expanded non-improving subsets.
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The subset with the highest merit found during the search will be selected.
3.2.7 Feature type transformation
At the end of introduction on feature selection methods, there are several points that need to be
addressed:
 Converting feature type from discrete to numeric. This kind of conversion will be useful for
those algorithms that can only handle numeric features, such as t-test, signal-to-noise, PCA
and so on. When dealing with a k-valued discrete feature, one can convert it to k binary
features. Each of these new features has a “1” for every occurrence of the corresponding
kth value of the original discrete feature, and a “0” for all other values [46]. Then the new
binary features are treated as numeric features.
 Converting feature type from numeric to discrete. Some feature selection methods, such
as X 2-statistic measure, need numeric features to be discretized. Fayyad’s algorithm de-
scribed in Section 3.2.4 or other discretization methods have to be applied.
 Dealing with multiple classes problem. If a data set contains more than two class samples,
a pairwised feature selection has to be conducted.
3.3 ERCOF: Entropy-based Rank sum test and COrrelation Filter-
ing
In this section, we will put forward a new strategy to conduct feature selection, mainly aiming
to find significant genes in supervised learning from gene expression data. In our strategy, we
combine the above presented methods of entropy measure and Wilcoxon rank sum test, as well
as Pearson correlation coefficient test together to form a three-phase feature selection process.
We name this combined feature selection process as ERCOF — stands for Entropy-based Rank
sum test and COrrelation Filtering.
In phase I, we apply Fayyad’s entropy-based discretization algorithm described in Sec-
tion 3.2.4 to all the numeric features. We will discard a feature, if the algorithm can not find a
suitable cut point to split the feature’s value range. One point needs to be emphasized here is that
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we will use numeric features all the way, though a discretization algorithm is involved to filter
out some features in this phase.
In phase II, we conduct Wilcoxon rank sum test only on features output from phase I.
For a feature f , the test statistical measure w(f) can be calculated by the way described in









and upper critical test values that given in Formula (3.11), we will reject the null hypothesis and
this indicates that the values of feature f are significantly different between samples in different




, the standard 5% or 1%
significant level is generally used. Therefore, by this phase, we are left with two groups of













. Features in same group are supposed to have similar
behavior — having relatively larger values in one class of samples and relatively smaller values
in another class of samples. In a gene expression data analysis, it is of a great interest to find
which genes are highly expressed in a special type of samples (such as tumor samples, or patients
with certain disease).
In phase III, for each group of features, we examine correlations of features within the
group. For those features that are in the same group and are highly correlated, we select only
some representatives of them to form the final feature set. In gene expression study, high cor-
relation between two genes can be a hint that the two genes belong to the same pathway, are
co-expressed or are coming from the same chromosome. “In general, we expect high correlation
to have a meaningful biological explanation. If, e.g. genes A and B are in the same pathway,
it could be that they have similar regulation and therefore similar expression profiles” [51]. We
propose to use more uncorrelated genes for classification since if we have lots of genes from one
pathway, the classification result might be skewed.
Since with entropy measure, one is more likely to select all the genes in a primary path-
way and neglect those of secondary pathways, we have to try to sort out the genes that passed
Phase I and Phase II filterings into pathways. Currently, we adopt the commonly used Pear-
son correlation coefficient to measure the correlation between features. It has been applied
to analyse gene expression data by some researchers [16, 40]. Pearson correlation coefficient
(also known as the centred Pearson correlation coefficient) is a linear correlation metric. In gen-
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value of r is between -1 and 1. In our case, we just consider two features to be correlated if
their correlation coefficient is 1 or near 1 and ignore negative correlations since the features in
same group are expected to have similar behavior. A threshold r













Given a group of features, we subgroup features in this group based on correlation coeffi-
cient. First, we sort the features according to their class entropy measure in an ascending order
(i.e., with best feature at first position). Then we pick up the best feature f
1
, and calculate its
Pearson correlation coefficient with all other features. Then we form a subgroup consisting of f
1
and all features that are correlated to f
1
. The features that have been assigned to this subgroup are
not considered again in the later rounds of correlation test. In the second round of subgrouping,
we pick up the best one from remaining features, and form another subgroup of features. This
correlation test proceeds until all the features in the group have been assigned to a subgroup.
Note that it is possible for a subgroup to have only one feature. So, the groups of features are
sub-grouped; in each subgroup, features are all correlated to a best feature such as f
1
. Figure 3.3
gives the pseudo codes of this method.
Next, we select representative features from each subgroup to form the final feature set.
In each subgroup, since the features are sorted by their class entropy measure, we calculate the
average of the entropy values of all these features (named mean entropy value of this subgroup)
and choose those top ones whose entropy measure is smaller than this mean entropy value. In
case of only one feature in a subgroup, this feature is automatically selected. These representative
features from all the subgroups are our final set of features. See Figure 3.4 for a whole picture of
feature identification and selection by ERCOF.
Using ERCOF in gene expression data analysis where there is often more than thousands
of features, we expect to identify of a subset of sharply discriminating features with little redun-
dancy. The entropy measure is effective for identifying discriminating features. After narrowing
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1. k = 1.











g and remove f
1
from F .
4. For each f
i
(i > 1)















and remove it from F ;
5. k = k + 1 and goto step 2 until F = ;.
Figure 3.3: Feature subgrouping by correlation testing. r

is the Pearson correlation coefficient
threshold, which should be near 1.0.
down by the Wilcoxon rank some test, the remaining features become sharply discriminating.
Then, with the correlation examination, some highly correlated features are removed to reduce
redundancy. We do not use CFS introduced in Section 3.2.6 in Phase III of ERCOF, because
CFS sometimes returns too few features to comprehensively understand the data set. For exam-
ple, CFS selects only one feature if the class entropy of this feature is zero. However, Pearson
correlation coefficient also has a shortcoming — the calculation of correlation is dependent on
the real values of features — it is sensitive to some data transformation operations. Therefore,
other algorithms are being implemented to group correlated features.
3.4 Use of Feature Selection in Bioinformatics
The feature selection techniques reviewed in the preceding sections have been used as a key
step in the handling of high-dimensional biomedical data. For example, their use is prevalent
in the analysis of microarray gene expression data (an extensive review on this can be found in
Chapter 4). Besides, they have been also used in the prediction of molecular bioactivity in drug
design [132], and more recently, in the analysis of the context of recognition of functional site in
DNA sequences [142, 72, 69].
One issue should be addressed here is the so-called “multiple comparisons problem” [85]
which happens when we select features by choosing a statistical confidence level (like standard
5% or 1%) for t-test, X 2-test, and other statistical measures. The description of the problem is:
when performing m multiple independent significance tests, each at the  level, the probability
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Figure 3.4: A diagram of ERCOF: Entropy-based Rank sum test and COrrelation Filtering, a
three-phase feature selection process combining concepts of entropy, Wilcoxon rank sum test
and Pearson correlation coefficient.
For example, suppose we consider m = 200 features and perform independent statistic tests to
each of them at the standard  = 5% level, then the probability of getting at least one significant
result is 1  0:95200 = 0:99996 [85]. So, when we get a significant feature among the tests, how
can we believe that it is “indeed” significant. In fact, under this setting, we would still expect to
observe approximately 10 (= 200  0:05) “significant” features, even when there were actually
no features that can distinguish the two classes. Obviously, the problem becomes serious when
the total number of considered features is large, which is the case in some biological data such
as gene expression profilings.
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A standard conservative solution to this problem is the Bonferroni correction [100], which
divides the test significant level by the number of tests, i.e. =m. In the above example, it will be
0:05=200 = 0:00025. Thus, for 200 features, the cutoff for significance would be 0.00025 instead
of previous 0.05! In spite of its simplicity, the Bonferroni method has some shortcomings [91].
The biggest problem is that it is too conservative: each individual test is held to an unreasonably
high standard and this will increase the probability of a Type II error where legitimate signal
features will fail to be discovered. On the other hand, the method is applicable only to tests with
known statistical distributions. For measures with unknown statistical distribution, permutation-
based approaches are practically used .
In a permutation-based method, the adjusted significant level (also known as p-values)
based on the number of tests undertaken is also computed, but in a way less conservative than
the Bonferroni method. When conducting permutation, we assume that there is no relationship
between features and classes so that new samples can be drawn by reassigning permuted class
labels to original data. The p-value then can be calculated based on the feature statistics on many
these kind of pseudo data sets. However, the conclusion that we really want to draw from the
permutation test might be: if we have selected w features using a particular statistic, what pro-
portion of these features are likely to be false positive? To make such a conclusion, one can
follow the steps illustrated in Figure 3.5 for a testing at  level. Alternatively, in stead of single
cutoff value, we can set up a series of thresholds and compute the p-value for each of them based
on the permutation test, so that a table T of threshold versus p-value can be created. If we want
no more than q% of the features selected in the original (non-permuted) experiment to be false





threshold to pick up features from original experiment.
Although the permutation is designed to take the place of the Bonferroni correction, it is
often found that the critical values determined in this method are nearly as conservative as those
based on the Bonferroni adjustment [85]. However, it has no assumption on the distribution of
the selected test statistic. As indicated earlier, another critical consideration of the permutation
test is that the procedure does not address whether features are correlated. In the case of a large
number of strongly correlated features versus a relative small number of samples, the test statistic
on each permutation will not significantly change. Then the permutation becomes meaningless.
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1. Select a statistic which will be used to measure differences between classes.
2. Determine the threshold of the statistic according to significant level .
3. Calculate the test statistic for each of total m features
4. Get the number of features selected by the threshold, record as w.
5. For ith permutation test iteration (i = 1; 2;    ; t):
generate a pseudo data set by randomly permuting the class labels of all the samples,
calculate the same test statistic for every feature,
record how many features are selected by the threshold, denote it as k
i
.







calculate p w to be the expected number of false positive.
Figure 3.5: A diagram of a permutation-based method for feature selection. In practice, the
significant level  is often set as 5% or 1%, the permutation times t should be very large, say
10,000 times, or for all possible permutations of the class labels.
Unfortunately, in many biological domain, features have strong correlations from sample to sam-
ple.
3.5 Chapter Summary
In this chapter, we reviewed feature selection techniques for data mining. There are two broad
categories of selection algorithms, filter and wrapper, and we indicated that filter approaches
are more suitable to be applied to solve biological problems. We presented a variety of filter
methods, such as t-statistic measure, Wilcoxon rank sum test, entropy-based measures, principal
components analysis and so on. We also put forward a new feature selection strategy, ERCOF,
which is a 3-phase feature filtering process aiming to identify a subset of sharply discriminating
features with little redundancy from gene expression profiles. The chapter was ended with a
discussion on using feature selection in bioinformatics.
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Chapter 4
Literature Review on Microarray Gene
Expression Data Analysis
One of the important recent breakthroughs in experimental molecular biology is microarray tech-
nology. This novel technology allows the monitoring of expression levels in cells for thousands of
genes simultaneously and has been increasingly used in cancer research [7, 41, 6] to understand
more of the molecular variations among tumors so that a more reliable classification becomes
possible.
There are two main types of microarray systems [35]: the cDNA microarrays developed
in the Brown and Botstein Laboratory at Stanford [32] and the high-density oligonucleotide
chips from the Affymetrix company [73]. The cDNA microarrays are also known as spotted ar-
rays [77], where the probes are mechanically deposited onto modified glass microscope slides us-
ing a robotic arrayer. Oligonucleotide chips are synthesized in silico (e.g., via photolithographic
synthesis as in Affymetrix GeneChip arrays). For a more detailed introduction and comparison
of the biology and technology of the two systems, please refer to [47].
Gene expression data from DNA microarrays are characterized by many measured variables
(genes) on only a few observations (experiments), although both the number of experiments and
genes per experiment are growing rapidly [82]. The number of genes on a single array is usually
in the thousands while the number of experiments is only a few tens or hundreds. There are
two different ways to view data: (1) data points as genes, and (2) data points as samples (e.g.
patients). In the way (1), the data is presented by expression levels across different samples, thus
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there will be a large number of features and a small number of samples. In the way (2), the data
is represented by expression levels of different genes, thus the case will be a large number of
samples with a few attributes. In this thesis, all the discussions and studies on gene expression
profiles are based on the first manner of data presentation.
Microarray experiments raise many statistical questions in many diversified research fields,
such as image analysis, experimental design, cluster and discriminant analysis, and multiple
hypothesis testing [35]. The main objectives of most microarray studies can be broadly classified
into one of the following categories: class comparison, class discovery, or class prediction [77].
 Class comparison is to establish whether expression profiles differ between classes. If they
do, what genes are differentially expressed between the classes, i.e. gene identification. For
example, which genes are useful to distinguish tumor samples from non-tumor ones.
 Class discovery is to establish subclusters or structure among specimens or among genes,
for example, to define previously unrecognized tumor subtypes [41, 140].
 Class prediction is to predict a phenotype using information from a gene expression pro-
file [77]. This includes assignment of malignancies into known classes (tumor or non-
tumor) or tumor samples into already discovered subtypes, prediction of patients outcome
such as which patients are likely to experience severe drug toxicity versus who will have
none, or which breast cancer patients will relapse within five years of treatment versus who
will remain disease free. Figure 4.1 shows a work flow of class prediction.
In this thesis, we will focus on the class comparison and class prediction. For these two
tasks, supervised analysis methods that use known class information are most effective [77]. In
practice, feature selection techniques are used to identify discriminatory genes while classifica-
tion algorithms are employed to build models on training samples and predict the phenotype of
blind test cases.
4.1 Preprocessing of Expression Data
As with most of the data fed to machine learning algorithms, gene expression data also need
necessary preprocessing before being further analysed. Based on the characteristics of the exper-
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Figure 4.1: A work flow of class prediction from gene expression data. A collection of expression
profiles with known class label (+ or -) is the input of a supervised learning algorithm. After
being trained on these profiles, the prediction model built by the learning algorithm will be able
to predict the class label of a new case of expression profile. The picture is captured from [77].
imental data, the normal preprocessing steps include scale transformation, data normalization,
missing value management, replicate handling and so on [49].
4.1.1 Scale transformation and normalization
In cDNA microarray experiments utilizing “spotted arrays”, the two mRNA samples, known as
targets, are reverse transcribed into cDNA (labeled using two different fluorophores — usually
a red fluorescent dye cyanine 5 and a green fluorescent dye cyanine 3), and mixed in equal
proportions and hybridized simultaneously to the glass slide [35]. Intensity values generated
from hybridization to individual DNA spots are indicative of gene expression levels. Then the
ratio of the red and green fluorescence for each spot is used to measure the change between
samples. In order to accurately and precisely measure gene expression changes, it is important to
understand sources of variance in expression data. In every microarray experiment, experimental
randomness and systematic variations [139] are the two main sources of variance. For example,
a well-known systematic variation originates the biases associated with the different fluorescent
dyes. If two identical mRNA samples are labeled with different dyes and hybridized to the same
slide, it is rare to have the dye intensities equal across all spots between these two samples [139].
Since we are looking at expression ratios, we expect the patterns in an asymmetrical scale:
over-expressions will have values between 1 and infinite while under-expression will between 0
and 1. In order to give the same weight to both over-expressions and under-expressions, we need
to transform the scale. A simple and common way is to do log-transformation. Normally this is
done by taking log
2
of the ratio, such as log
2
(Cy5=Cy3). Besides, considering data in log-space
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can also help reduce the effects of outliers [85].
In order to minimize systematic variations in gene expression levels of two co-hybridized
mRNA samples, normalization should be conducted for spotted cDNA microarrays. This will
help easily distinguish biological differences between two samples and make the comparison of
expression levels across slides reasonable. There are several ways to conduct normalization. For
example, in one of the general methods, the intensity values are normalized according to the
formula: NV = (V  Min)=(Max  Min), where NV is the normalized value, V the raw
value, Min (Max) the minimum (maximum) intensity among all samples for the gene. After the
normalization, each intensity value is to fall within the range of 0 to 1. Another common practice
is to center the data by the median or mean ratio, and possibly to scale the data by the standard
deviation [85]. Recently, Yang et al proposed a composite normalization procedure in [139],
based on robust local regression, to account for intensity and spatial dependence in dye biases
for different types of cDNA microarray experiments. They constructed a novel control sample
named MSP including all genes present on the microarray, and titrated it over the intensity range
of a microarray experiment. Under the composite idea, low intensity values will be normalized
based on all genes in the corresponding intensity range while higher values will be normalized
based on the MSP titration series.
When we illustrate our work on some gene expression profilings one by one in the next
chapter, we will indicate whether a preprocessing (log-transformation, normalization and so on)
has been conducted on a particular data set. However, basically, as stated in [85], the normaliza-
tion is not technically required, though it will help reduce the effects of varying dynamic range
from sample to sample for cDNA microarray data.
4.1.2 Missing value management
One of the characteristics of the gene expression profile is the existence of missing values in the
data set. There are diverse reasons that cause missing values, including insufficient resolution,
image corruption, or simply due to dust or scratches on the slide [125]. In practice, missing data
also occur systematically as a result of the robotic methods used to create them. Unfortunately,
many data analysis algorithms require a complete matrix of gene array values as input [125]. For
example, standard hierarchical clustering methods and k-means clustering are not robust to the
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excess of missing values since the calculations in the algorithms are based on a distance matrix.
Even with a few missing values, they may lose effectiveness. More strictly, some methods like
principal components analysis can not deal with missing values at all. Therefore, methods for
imputing missing data are needed, not only to minimize the effect of incomplete data on further
analyses, but also to increase the range of data sets to which learning algorithms will be applied.
There are some general solutions to impute missing values, though there is not a large
literature that were specific to gene expression data. Here, we list four commonly used strategies:
(1) filling blanks with zeros; (2) replacing with the gene’s average expression levels over all
experiments; (3) replacing with the median of the gene’s expression levels over all experiments;
(4) using weighted k-NN imputation method. The k-NN-based method is to use the k-nearest
neighbours to estimate the missing values, where k is a user-defined parameter. The selection of
“neighbours” can be done via calculating certain similarity metric between genes, such as widely
used Euclidean distance, Pearson correlation, variance minimization and etc [125]. For example,
if gene A has one missing value in experiment 1, the k-NN-based method will find k other genes,
which have a value present in experiment 1 and have most similar expression values to A in other
experiments. The values of these k nearest genes in experiment 1 are then averaged by a weight
metric and used as the estimated value of gene A in experiment 1. In the weighted average, the
contribution of each gene is weighted by similarity of its expression levels to gene A.
Troyanskaya et al [125] compared three missing value imputation methods by testing them
on three microarray data sets. Three imputation methods were simple gene average, weighted
k-NN and their proposed singular value decomposition (SVD) based method. The mechanism
of SVD-based algorithm is to (1) use singular value decomposition to obtain a set of mutually
orthogonal expression patterns that can be linearly combined to approximate the expression of all
genes in the data set, (2) refer these patterns as eigengenes (like principal components) and select
k most significant eigengenes by sorting their corresponding eigenvalue, (3) estimate a missing
value in gene A by regressing gene A against the k eigen genes and then use the coefficients
of the regression to reconstruct a replacement value from a linear combination of the k eigen
genes. Their results showed that weighted k-NN appeared to be the most accurate and robust
method, and both weighted k-NN and SVD-based techniques surpass the commonly used simple
average method. This conclusion is very natural since the winning methods take advantage of
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the correlation structure of the data to estimate missing expression values.
Although we can efficiently handle missing values in microarray data by using weighted k-
NN imputation method, the method itself requires that we have enough complete genes (clones)
(i.e. genes with no missing values) in the data set so that finding real neighbours can be ensured.
When there are too many missing values in an original data set, one can consider to filter some
genes based on amount of missing elements. For example, in a study on diffuse large-B-cell
lymphoma addressed in [60], genes (clones) having more than 20% missing values were removed
before any analysis being conducted. Please note that, in [6, 140], the missing values in the gene
expression data sets were excluded in the analyses.
4.1.3 A web-based preprocessing tool
An interactive web-based software for preprocessing microarray gene expression data was intro-
duced in [49], which was implemented in a Perl CGI script. Besides the functions mentioned
above, such as log-transformation, normalization and missing values management, it also pro-
vides a way to handle replicate. The replicate here means the same cDNA clone that spotted
several times or different cDNAs representing the same gene on the cDNA array. The usage
of replicates is mainly for quality checking. Generally, in an experiment, several expression
values of a replicated gene will be output, though only one is needed in the further analysis.
How to derive a proper expression level from several output values? The provided solution
is quite simple: using the average or the median value of all the replicates upon checking the
consistency among them. During the consistency checking, the median of all the values is cal-
culated and then the replicates whose expression value is beyond the threshold from the me-
dian are removed. The threshold is a user-defined value. The web interface of this tool is at
http://gepas.bioinfo.cnio.es/cgi-bin/preprocess.
4.2 Gene Identification and Supervised Learning
Supervised learning algorithms are used to establish models to classify samples in different
classes of gene expression profiles while gene identifications answer which genes are differ-
entially expressed between the classes, i.e. feature selection. Generally, gene identification is
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carried out before learning algorithms are used.
4.2.1 Gene identification
In a pioneer study in 1999, Golub et al [41] analysed gene expression profiles of 27 Acute Lym-
phoblastic Leukemia (ALL) samples and 11 Acute Myeloid Leukemia (AML) samples. They
identified genes with differential expression between ALL and AML samples using the signal-
to-noise measure that we introduced in Section 3.2.1 of Chapter 3. According to signal-to-noise













where (g) and Æ(g) are the mean and standard deviation of the gene expression values for gene
g for all the patients of class A (ALL) or class B (AML). Large positive value of s(g) indicates
strong correlation with class A whereas large negative value of s(g) indicates strong correlation
with class B [41]. Then an equal number of genes with positive and with negative correlation
values were selected to integrate into the learning algorithm. The number of informative genes
they chose was 50, but they stated in the paper that “the (prediction) results were insensitive to
the particular choice: predictors based on between 10 and 200 genes were all found to be 100%
accurate, reflecting the strong correlation of genes with the AML-ALL distinction”.
Similar to Golub et al, there were some other researchers who used statistical tools to dis-
cover differentially expressed genes between sample classes, such as t-statistic and its variation
(like signal-to-noise, Fisher criterion score), Wilcoxon rank sum test and so on. For examples,
in [12], genes selected by t-statistic were fed to a Bayesian probabilistic framework for sample
classification. Olshen et al [85] suggested to combine t-statistic, Wilcoxon rank sum test or the
X
2
-statistic with a permutation-based model to conduct gene selection. In their model, the sig-
nificance of genes is determined by the associated statistic and a critical value calculated on the
same statistic using the permuted labels. The permutation of sample class labels were conducted
for a few thousands times. Wilcoxon rank sum test is another measure favored by researchers
mainly due to its non-parametric characteristic.
Park et al built a scoring system in [87] to assign each gene a score based on training
samples. For a gene, they first sorted training samples according to the expression levels of this
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gene — from the smallest expression level to the largest one. Second, they swap the class labels
of the samples to make the gene into a perfectly discriminating marker — all high expression
values belong to one class of samples and all low expression values belong to the other class.
Then the score of the gene was the minimum number of the necessary swaps. Finally, a small set
of differently expressed genes, which had smaller score, were discovered. They claimed that this
scoring approach was robust to outliers and different normalization schemes because it used ranks
rather than actual expression levels. Essentially, this score is identical to Wilcoxon rank sum test
statistic [51]. Some researchers also conducted comparisons between Wilcoxon rank sum test
and some other statistical measures on gene selection. For example, Troyanskaya et al compared
t-statistic, Wilcoxon rank sum test and a heuristic method based on Pearson correlation in [126].
Their results showed that overall speaking, the rank sum test appeared most conservative, which
may be advantageous if the further biological or clinical usages of the identified genes are taken
into account.
Jaeger et al [51] designed three pre-filtering methods to retrieve groups of similar genes.
Two of them are based on clustering and one is on correlation. A statistical test then was applied
to these groups to finally select genes. The statistical tests used in their study included Fisher
criterion score, signal-to-noise, Wilcoxon rank sum test, t-statistic and TnoM (Thresholded-
number-of-Misclassifications), which calculates a minimal error decision boundary and counts
the number of misclassifications done with this boundary. Based on the test results on three
public gene expression data sets using the selected genes and support vector machines classifica-
tion algorithm, they concluded that feature selection can greatly help improve the classification
accuracy, but there is no absolute winner among their proposed pre-filtering methods and the
five statistical tests. Another comparison of using different statistics in gene identification was
conducted by Thomas et al in [121], they presented a statistical regression modeling approach to
discover genes that are differentially expressed between two classes of samples. Their modeling
approach used known sample group membership to focus on expression profiles of individual
genes. They tested their methodology on the AML-ALL leukemia data set of Golub [41] and
compared their results with those obtained using t-statistic or Wilcoxon rank sum test. Their
model made no distributional assumptions about the data and accounted for high false-positive
error rate. However, in practice, the Z-scores they proposed are expected to be similar to t-
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statistics, when the distribution of expression levels can be approximated by the normal distribu-
tion. In a recent review of several statistical methods in term of their effectiveness to discover
differentially expressed genes, Pan [86] compared t-statistic, the regression modeling approach
against a mixture model approach proposed by him. Different from t-statistic and the above
regression modeling approach that sets strong assumptions on the null distribution of the test
statistics, the mixture model estimated the null distribution directly. He pointed out that although
the three methods were all based on using the two-sample t-statistic or its minor variations, they
differed in how to associate a statistical significance level to the corresponding statistic so that
large differences in the resulting significance levels and the numbers of genes discovered were
possible [86]. The Bonferroni method described in Section 3.4 of Chapter 3 was used in his study
to adjust the significant level.
SAM (Significance Analysis of Microarrays), a software developed at Stanford Univer-
sity (http://www-stat.stanford.edu/˜tibs/SAM/), is designed to find significant
genes in a set of microarray experiments based on strong statistical study on genes [127]. SAM
first computes a statistic to each gene on the basis of change in gene expression relative to the
standard deviation of repeated measurements for the gene. Then for those genes whose statistic
is greater than an adjustable threshold, SAM uses permutations of the data to estimate the per-
centage of genes identified by chance (known as false discovery rate (FDR)). The threshold for
significance is determined by a tuning parameter Æ, chosen by the user based on FDR, or a fold
change parameter to ensure that the selected genes change at least a pre-specified amount [26].
Besides gene expression profiles for phenotype classification, SAM can be applied to other types
of experimental data [127]. For example, to identify genes whose expression correlates with sur-
vival time, the assigned score is defined in terms of Cox’s proportional hazards function, which
is a popular method for assessing a covariate’s effect on patients remain alive or censored dur-
ing the follow-up at the time of the study. To identify genes whose expression correlates with a
quantitative parameter (e.g. a numeric type class label), such as tumor stage, the assigned score
can be defined in terms of the Pearson correlation coefficient.
Besides statistical measures, other dimension reduction methods were also adopted to se-
lect genes from expression data. Nguyen et al [82] proposed an analysis procedure for gene
expression data classification, involving dimension reduction using partial least squares (PLS)
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and classification using logistic discrimination (LD) and quadratic discriminant analysis (QDA).
They compared PLS to the well known dimension reduction method of principal components
analysis (PCA). PCA reduced the high dimensional data to only a few gene components which
explained as much of the observed total gene expression variation as possible and PLS chose
components to maximize the sample covariance between the class and a linear combination of
the genes. The essential difference between these two methods is that PLS is a supervised method
while PCA is an unsupervised method since it selects features without regard to the class infor-
mation of the samples. For more about PCA, please refer to Section 3.2.5 in Chapter 3. After
applying PLS to original high dimension data, a simple t-statistics was used to conduct a further
gene selection. Finally, 50 genes were provided to the classification step.
4.2.2 Supervised learning to classify samples
Various machine learning algorithms have been applied to conduct classification from gene ex-
pression data. Let’s still start with the AML-ALL leukemia study conducted by Golub et al
in [41]. The classification method they proposed was a weighted gene voting scheme, which
was a combination of multiple “univariate” classifiers [43]. In detail, they defined a
g
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was the signal-to-noise measure of gene g that they used to select genes. When doing prediction
for a new sample T , let t
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), with a positive value indicating a vote for class A and a negative value
indicating a vote for class B. The total vote for class A was obtained by adding up the absolute
values of the positive votes over the selected informative genes, while the total vote for class B
was obtained by adding up the absolute values of the negative votes. In order to avoid arbitrary
prediction when the margin of victory is slight, they defined “prediction strength” (PS) to mea-
sure the margin of a winner class. A threshold of PS was established to minimize the chance of
making an incorrect prediction.
Dudoit et al [35] conducted a comparison of using some discriminant methods for classifi-
cation of gene expression data. These well-known classification methods included Fisher linear
discriminant analysis (FLDA), maximum likelihood discriminant rules (such as linear discrimi-
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nant analysis (LDA), diagonal quadratic discriminant analysis (DQDA) and diagonal linear dis-
criminant analysis (DLDA, also known as naive Bayes)), k-nearest neighbours (k-NN) classifier,
classification and regression trees (CART) and aggregating CART trees by boosting procedure.
Before classification, a gene filtering was performed based on the ratio of genes between-group





























was the class label of sample i and I() was an indicator function — equaling 1 if the




were the average ex-
pression level of gene j across all the samples and across samples belonging to class k only [35].
Then a certain number of genes with the largest BW ratios were selected for classification. They
did experiments on three data sets. Their results showed that k-NN classifiers and DLDA had the
lowest error rates, whereas FLDA had the highest. CART-based classifiers performed intermedi-
ately, with aggregated classifiers being more accurate than a single tree. They explained that the
poor performance of FLDA was most likely caused by the fact that data sets contained a large
number of genes but a limited number of samples. Under such a situation, the ratios of between-
group and within-group sums of squares and cross-products became quite unstable and provided
poor estimates of the corresponding population quantities. They also showed that the perfor-
mance of FLDA improved when the number of selected genes was decreased to 10. Although
CART-based classifiers did not achieve the best performance, they could exploit and reveal inter-
actions between genes as well as relationship between genes and phenotypes. Most importantly,
decision trees/rules output by these methods are easy to interpret and understand. In addition,
their results also demonstrated that the unstableness of a single classification tree on prediction
could be greatly improved when it was used in combination with aggregation techniques.
As mentioned previously in Chapter 2, support vector machines (SVM) have been exten-
sively used in biological data analysis. It is also playing a very active role in classifying gene
expression data. SVM has many mathematical features that make it attractive for gene expres-
sion analysis, such as its flexibility in choosing a similarity function, sparseness of solution when
dealing with large data sets, the ability to handle large feature spaces, and the ability to identify
outliers [23]. For example, in an early work done by some researchers in MIT [80], a linear
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SVM classifier with a rejection level based on confidence values was applied to classify Golub’s
AML-ALL subtypes leukemia disease. They achieved a better performance on this task than
Golub et al did [41]. Furey et al [39] further tested the efficiency of SVM on several other gene
expression data sets and also obtained good results. Both of them selected discriminatory genes
via signal-to-noise measure.
Besides the above techniques, Bayes model, a classical and effective method, has been
also applied to gene expression study. For example, two new Bayesian classification algorithms
were investigated in Li et al [68] which automatically incorporated a feature selection process.
The fundamental technique of the algorithms was a Baysian approach named automatic relevance
determination (ARD), which was employed to construct a classifier that was sparse in the number
of samples, i.e. the relevance vector machine (RVM). Li Y. et al [68] adopted the idea of ARD
to gene expression study. They developed two algorithms. One was the standard RVM with
sparsity obtained in the feature set. Another performed feature selection by isolating the feature
dependence in the log-marginal likelihood function. The conclusion they obtained was that these
algorithms had comparable performance to SVM when dealing with gene expression data.
4.2.3 Combing two procedures — wrapper approach
In some studies, procedures of gene selection and supervised learning were not separated dis-
tinctly. Similar to the wrapper approach illustrated in Chapter 3, identification of significant
genes were incorporated with learning process. For example, Weston et al [131] integrated fea-
ture selection into the learning procedure of SVM. The feature selection techniques they used
included Pearson correlation coefficients, Fisher criterion score, Kolmogorov-Smirnov test and
generalization selection bounds from statistical learning theory. Going a step further, Guyon et
al [43] presented an algorithm called recursive feature elimination (RFE), by which features were
successively eliminated during the training of a sequence of SVM classifiers.
There are some other examples of using the wrapper idea in gene expression data analysis.
Gene selection was performed in [50] by a sequential search engine, evaluating the goodness of
each gene subset by a wrapper method. The method executed the supervised algorithm to ob-
tain its accuracy estimation by a leave-one-out process. The supervised classification algorithms
reported in this paper included IB1 (i.e. 1-NN), Naive-Bayes, C4.5 and CN2. The paper demon-
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strated that the accuracy of all these learning algorithms was significantly improved by using the
gene selection procedure. Another example of using the wrapper method was [67], where Li et
al combined a genetic algorithm (GA) and the k-NN method to identify a subset of genes that
could jointly discriminate between different classes of samples. First, GA was used to obtain
many such “near optimal” subsets of differentially expressed genes independently. Then, the
relative importance of genes for sample classification were chosen by examining the frequency
of membership of the genes in these sets.
Culhane et al [31] applied Between-Group Analysis (BGA) to microarray data. BGA was
based on conducting an ordination of groups of samples, using a standard method such as corre-
spondence analysis (COA) or principal components analysis (PCA). For N groups, BGA could
find N  1 eigenvectors (or axes) to maximize the between-group variance. Each of eigenvectors
could be used as a discriminator to separate one of the groups from the rest. After a BGA, the
samples are separated along axes. The genes that were most responsible for separating the groups
were those with the highest or lowest coordinates along these axes. One advantage of BGA is
that it can be safely used with any combinations of numbers of genes and samples so that no
advanced gene selection is necessary.
PAM (Prediction Analysis for Microarrays), developed at Stanford University (http:
//www-stat.stanford.edu/˜tibs/PAM/), is a class prediction software for genomic
expression data mining. It performs sample classification from gene expression data based on
the nearest shrunken centroid method proposed by Tibshirani et al [123]. This method com-
putes a standardized centroid for each class — the average gene expression for each gene in each
class divided by the within-class standard deviation for that gene. This standardization has the
effect of giving higher weight to genes whose expression is stable within samples of the same
class [123]. The main feature of nearest shrunken centroid classification from standard nearest
centroid classification is that it ”shrinks” each of the class centroids toward the overall centroid
for all classes by an amount named threshold. The selection of the threshold can be determined
by the results of cross-validation for a range of candidate values. When classifying a new sam-
ple, it follows the usual nearest centroid rule, but using the shrunken class centroids. The idea of
shrinkage has two advantages: (1) it achieves better performance by reducing the effect of noisy
genes, and (2) it does automatic gene selection. In particular, if a gene is shrunk to zero for all
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classes, then it will be removed from further consideration. PAM has been applied to several
DNA microarray data sets to do classification [123, 124], such as small round blue cell tumor
data of childhood [54], diffuse large B-cell lymphoma [6], AML-ALL leukemia [41]. Recently,
PAM is also used to classify patients into appropriate clinical subgroups (e.g. high risk and low
risk groups) identified by clustering algorithms on gene expression profiles [11].
4.3 Applying Clustering Techniques to Analyse Data
Another early work on analyzing gene expression data was done by Alon et al [7]. Their data
contained the expression of the 2000 genes with highest minimal intensity across 62 tissues,
including 22 normal and 40 colon cancer. Their study was based on top down hierarchical clus-
tering, a method of unsupervised learning. They demonstrated two kinds of groupings that (1)
genes of related functions could be grouped together by clustering according to similar temporal
evolution under various conditions, and (2) different tissues formed different clusters, i.e. most
normal samples clustered together while most cancer samples clustered together. Although they
showed that some genes are correlated with the normal versus cancer separation, they do not
suggest a specific method of gene selection in the paper.
Since [7], quite a few researchers have applied clustering techniques to gene expression
data, including self organizing maps, simulated annealing and graph theoretic approaches. In [111],
the input data was represented as a weighted graph, where vertices corresponded to samples
and edge weights reflected pairwise similarity between the corresponding samples. Then the
weight of an edge was believed to reflect the likelihood that its endpoints originated from the
same clustering under some simplified probabilistic assumptions [111]. An algorithm named
CLICK (CLuster Identification Connectivity Kernels) was invented to partition the graph using
a minimum-cut algorithm, which minimizes the sum of the weights of the edges joining the two
parts. However, one disadvantage of this approach is that there is little guarantee that the algo-
rithm will not go astray and generate partitions that are highly unbalanced. To avoid this, Xing
et al [136] proposed CLIFF (CLustering via Interactive Feature Filtering) to combine clustering
and feature selection in a bootstrap-like process. Their algorithm interacted between feature fil-
tering process and clustering process in a such way that each process used the output of the other
process as an approximate input. They applied Approximate Normalized Cut, a graph partition
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algorithm, to generate a dichotomy of samples during each iteration. In the feature selection pro-
cess, they used the unsupervised independent feature modeling technique to rank all features in
terms of their power to discriminate. Then an initial partition based on the k most discriminative
features was generated (value k was pre-defined). Based on this partition, they applied supervised
algorithms, information gain ranking and Markov blanket filtering, to determine feature subset
from which new partition would be generated. In turn, the newly generated partition could be
used to further improve the feature selection. CLIFF was applied by another paper [135] to se-
lect genes from the leukemia data set [41] and good classification results were obtained via three
learning algorithms: a Gaussian classifier, a logistic regression classifier and a nearest neighbour
classifier.
In a recent work conducted by Xu et al [137], gene expression data was presented as a Min-
imum Spanning Tree (MST), a concept from graph theory. By this presentation, each cluster of
the expression data corresponded to one subtree of the MST, which rigorously converted a highly
computationally intensive multi-dimensional clustering problem to a simplified tree partitioning
problem. Based on the MST representation, they developed a number of efficient clustering al-
gorithms and integrated them into a software named EXCAVATOR (EXpression data Clustering
Analysis and VisualizATion Resource).
4.4 Patient Survival Analysis
Gene expression profiles with clinical outcome data enable monitoring of disease progression
and prediction of patient survival at the molecular level. A few published studies have shown
promising results for outcome prediction using gene expression profiles for certain diseases [102,
14, 129, 140, 88, 60].
Cox proportional hazard regression [30, 74] is a common method to study patient out-
comes. It has been used by Rosenwald et al to analyse survival after chemotherapy for diffuse
large-B-cell lymphoma (DLBCL) patients [102], and by Beer et al to predict patient out of lung
adenocarcinoma [14]. With this method, genes most related to survival are first identified by a
univariate Cox analysis, and a risk score is then defined as a linear weighted combination of the
expression values of the identified genes.
65
Ando et al [9] fed gene expression profiles to a fuzzy neural network (FNN) system to
predict survival of patients. Their method contained several steps. (1) Predicting the outcome
of each patient using one gene at one time. (2) Ranking genes by their accuracy — the gene
with the highest prediction accuracy had the highest rank. (3) Selecting partner genes for highest
ranked gene. They fixed the gene with the highest rank (named as “1st gene”) and used a similar
prediction method to select a partner gene (named as “2nd gene”) who gave the highest accuracy
in combination with the “1st gene”. Similarly, they fixed “1st gene” and the “2nd gene” to find
a 3rd gene. This procedure stopped after six rounds or when there was no gain on accuracy. (4)
Applying the procedure described in (3) to the ten highest ranked genes. (5) Using each of the ten
highest ranked genes and its selected partner genes to do prediction. (6) Optimizing the resulting
ten FNN models built on the combinatorial genes by the back-propagation method.
Park et al [88] linked gene expression data to patient survival times using the partial least
squares regression technique, which is a compromise between principal component analysis and
ordinary least squares regression. Shipp et al [114] employed the weighted voting algorithm to
identify cured versus fatal for outcome of diffuse large B-cell lymphoma. The algorithm calcu-
lated the weighted combination of selected informative marker genes to make a class distinction.
In a recent publication [60], LeBlanc et al developed a gene index technique to identify the
associations between gene expression levels and patient outcome. Genes were ordered based on
linking their expression levels both to patient outcome and to a specific gene of interest. To select
such a reference gene, one was recommended to consider the gene that had been identified to be
most strongly related to the outcome or suggested from external data such as a protein analysis
or other experimental work. The core of their proposal was to combine the correlation between
genes with the correlation between genes and patient outcome as well as class membership. They
demonstrated their method using the DLBCL data set collected by Rosenwald et al consisting of
160 patients [102].
4.5 Chapter Summary
Using gene expression data to analyse human malignancies has attracted many researchers these
years. In this chapter, we did an extensive review on the technologies applied to gene expression
studies, focusing on data preprocessing, gene selection and sample supervised learning. The op-
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erations of data preprocessing mainly include scale transformations, data normalization, missing
value management, replicate handling, and flat pattern filtering. In the studies of gene selection,
statistical methods were widely adopted while feature wrapper idea and clustering algorithms
also demonstrated their efficiency. To solve the classification problem arising from gene expres-
sion data, many traditional and newly invented supervised learning approaches have been applied
to distinguish tumor from non-tumor samples, one subtype from other subtypes of certain dis-
ease and so on. From the extensive literature review in this chapter, we can see that approaches to
gene expression data analysis were not uniform; indeed, almost every paper presented a different




Experiments on Microarray Data —
Phenotype Classification
In this chapter, our proposed gene selection process ERCOF (detailed technology description
can be found in Section 3.3 of Chapter 3) and the ensemble of decision trees method CS4 (Sec-
tion 2.3.4 of Chapter 2) will be applied to some bench-mark microarray gene expression and
proteomic data sets to classify phenotypes. Phenotype classification is typically performed on
binary type, such as tumor against non-tumor (i.e. normal). For each data set, experimental re-
sults using some other related feature filtering methods and classification algorithms will also be
presented, so that reasonable comparisons can be addressed.
5.1 Experimental Design
We test our methodology on several high-dimensional data sets, which were published recently
in Science, Nature, and other prestigious journals. All these data sets have been accumulated at
http://sdmc.i2r.a-star.edu.sg/rp/ and transformed into .data, .names format that
is widely used by the software programs for data mining, machine learning and bioinformatics.
See Appendix B for more detail about this data repository.
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5.1.1 Classifiers and their parameter settings
In order to compare CS4 with other ensemble of decision trees methods, Bagging, AdaBoostM1
and Random forests are also run on the same data sets. Widely used state-of-the-art machine
learning algorithms in gene expression analysis, support vector machines (SVM) and k near-
est neighbours (k-NN are tested as well. The software implementation of these classification
algorithms (except CS4) used in the experiments is Weka (Bagging, AdaBoostM1, SVM and
k-NN in version 3.2 and Random forests in version 3.3.6), a free (under GNU) machine learn-
ing software package written in Java and developed at University of Waikato in New Zealand
(http://www.cs.waikato.ac.nz/˜ml/weka/).
For most of the algorithm parameters, we adopt the default setting of Weka’s implementa-
tion. Particularly, Weka implemented SVM using sequential minimal optimization (SMO) algo-
rithm [93] to train the model (see section 2.3.2 for more information about SMO). Other default
settings of SVM include: conducting data normalization, using polynomial kernel functions, and
transforming the output into probabilities by a standard sigmoid function. Most of the time, the
linear kernel function is used unless stated otherwise. As for k-NN, we also use normalized data
and set the value of k to 3 (default value is 1)— i.e. 3 nearest neighbours (i.e. 3-NN) will be used
in prediction.
Breiman noted in [19] that most of the improvement from bagging is evident within ten
replications. Therefore, we set 20 (default value is 10) as the number of bagging iterations for
Bagging classifier, the number of maximum boost iterations for AdaBoostM1, and the number
of trees in the forest for Random forests algorithm. Below, we list the default settings in Weka
for these three classifiers.
 Bagging. The random seed for resampling is 1.
 AdaBoostM1. Use boosting by weighting.
 Random forests. The number of feature candidate to consider is int(log
2
m+1), where m
is the total number of features. The random seed to pick up a feature is 1.
In addition, the implementation of the base classifier C4.5 in Weka version 3.2 was based
on its revision 8, which was the last public version before it was commercialized. We follow
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the default settings that tree pruning and subtree raising are conducted. The CS4 algorithm was
implemented using Weka APIs (Version 3.2) and has been integrated into Weka package as one
of its classifiers. By default, we also build 20 trees from each time of learning. In case the
number of available features is less than 20, the number of trees will be decreased accordingly
and automatically.
5.1.2 Entropy-based feature selection
In the feature selections conducted by ERCOF, we select 5% significant level (for Wilcoxon rank
sum test) and 0.99 Pearson correlation coefficient threshold. For each data set, besides ERCOF,
we also try the following entropy-based filtering scenarios to conduct feature selection.
 All-entropy: choose all the features whose value range can be partitioned into intervals
by Fayyad’s discretization algorithm [36] (also see Section 3.2.4 of Chapter 3), i.e. all the
output features from the Phase I of ERCOF.
 Mean-entropy: choose features whose entropy measure is smaller than the mean entropy
value of all the genes selected by above “all-entropy” strategy [64].
 Top-number-entropy: choose a certain number of top-ranked features according to en-
tropy measure, such as top 20, 50, 100 and 200 genes.
In addition, performance on original intact data (i.e. whole feature space, no gene selection)
are also obtained and presented under column All in the result table of each data set. Please note
that the type of features is always numeric.
5.1.3 Performance evaluation
Since the number of samples (i.e. experiments) is small in gene expression profiles, we simply
use number of misclassified samples in each class as the main evaluator. The format of perfor-
mance presentation is Z(X : Y ), where X (or Y ) is number of misclassified samples in the first
(or second) class and Z = X + Y . Other evaluation measures, such as sensitivity, specificity
and precision are also calculated when necessary. In most of cases, we present results obtained
from a 10-fold cross validation on all samples of each data set. The samples are shuffled (with
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Figure 5.1: A process diagram for k-fold cross validation.
random seed 1) and stratified by Weka program version 3.2. In a 10-fold cross validation, since
the feature selection is conducted for each fold independently, the identified genes on same data
set will be vary from fold to fold. Figure 5.1 is a diagram of our process to conduct k-fold cross
validation on gene expression data. Especially, k-fold cross validation becomes leave-one-out
cross validation (LOOCV, also known as “jack-knife”) when k equals the number of samples.
5.2 Experimental Results
Here, we will present our experimental results of several public gene expression profiles and one
proteomic data set.
5.2.1 Colon tumor
This data set was first analysed by Alon et al in [7]. Its task is to distinguish cancer from normal
tissue using microarray data (Affymetrix oligonucleotide array). 2000 out of around 6500 genes
were selected based on the confidence in the measured expression levels. These 2000 genes have
72
Table 5.1: Colon tumor data set results (22 normal versus 40 tumor) on LOOCV and 10-fold
cross validation. Numbers presented in bold type is the best result achieved by the corresponding
classifier among 8 gene selection scenarios.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
LOOCV
SVM 10(5:5) 12(5:7) 9(4:5) 9(4:5) 8(4:4) 9(4:5) 13(8:5) 7(3:4)
3-NN 18(11:7) 10(5:5) 12(6:6) 10(6:4) 12(6:6) 10(5:5) 10(5:5) 10(4:6)
Bagging 10(7:3) 11(7:4) 11(7:4) 11(5:6) 11(5:6) 10(5:5) 10(5:5) 10(5:5)
AdaBoostM1 13(8:5) 11(6:5) 13(8:5) 13(8:5) 13(7:6) 13(8:5) 14(9:5) 11(6:5)
RandomForests 16(11:5) 15(10:5) 15(10:5) 14(8:6) 14(8:6) 15(8:7) 14(8:6) 13(8:5)
CS4 11(7:4) 11(7:4) 11(7:4) 12(7:5) 11(7:4) 11(7:4) 9(6:3) 12(4:8)
10-fold cross validation
SVM 11(5:6) 9(5:4) 9(5:4) 8(4:4) 8(4:4) 9(5:4) 10(5:5) 8(4:4)
3-NN 19(12:7) 9(5:4) 11(5:6) 12(8:4) 10(5:5) 10(5:5) 11(6:5) 9(5:4)
Bagging 12(7:5) 12(7:5) 10(5:5) 11(5:6) 12(7:5) 10(5:5) 9(4:5) 10(5:5)
AdaBoostM1 12(8:4) 10(5:5) 12(8:4) 14(8:6) 13(7:6) 13(8:5) 14(9:5) 9(5:4)
RandomForests 12(5:7) 13(6:7) 13(9:4) 15(9:6) 11(7:4) 13(8:5) 12(6:6) 12(7:5)
CS4 14(9:5) 11(7:4) 12(7:5) 13(8:5) 12(7:5) 9(5:4) 13(8:5) 10(5:5)
highest minimal intensity across the 62 tissues collected from colon-cancer patients, including
40 tumor biopsies from adenocarcinoma and 22 normal biopsies from healthy parts of the colons
of the same patients [7]. The raw data can be found at http://microarray.princeton.
edu/oncology/affydata/index.html.
Table 5.1 shows the performance of different classifiers among total 8 gene selection sce-
narios. For this data set, since it contains a relatively smaller number of samples, we list out both
LOOCV and 10-fold cross validation results.
There are 7 common genes selected by each fold ERCOF feature selection in 10-fold cross
validation test. Table 5.2 lists their feature series number, GenBank accession number, sequence
and name. Several of these identified features, such as features 377, 625 and 1772, were also
highlighted in [68], where Bayesian algorithms incorporating feature selection were applied to
the same data set. Particularly, the finding of feature 377, that corresponds to the mRNA for
uroguanylin precursor, is consistent with the statement in [84] that “guanylin and uroguanylin
are markedly reduced in early colon tumors with very low expression in adenocarcinoma of the
colon and also in its benign precursor, the adenoma”.
The best performance on LOOCV is achieved by SVM under ERCOF feature selection
scenario (7 biopsies are misclassified, including 3 normal and 4 tumor samples). So far, this is
also among the best prediction accuracy on this data set when compared with published results.
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Table 5.2: 7 common genes selected by each fold of ERCOF in 10-fold cross validation test for
colon tumor data set. UTR stands for untranslated region.
Feature Accession Sequence Name
number number
377 Z50753 gene H.sapiens mRNA for GCAP-II/uroguanylin precursor
780 H40095 3’ UTR MACROPHAGE MIGRATION INHIBITORY FACTOR (HUMAN)
513 M22382 gene MITOCHONDRIAL MATRIX PROTEIN P1 PRECURSOR (HUMAN)
625 X12671 gene Human gene for heterogeneous nuclear ribonucleoprotein (hnRNP)
core protein A1
1582 X63629 gene H.sapiens mRNA for p cadherin
1771 J05032 gene Human aspartyl-tRNA synthetase alpha-2 subunit mRNA, complete cds
1772 H08393 3’ UTR COLLAGEN ALPHA 2(XI) CHAIN (Homo sapiens)
Although CS4 performs worse than SVM does in terms of accuracy, it provides some learning
rules. For example, Figure 5.2 gives a decision tree output by CS4 on this data set. From this
tree, 5 rules can be derived directly:
(1) “If attribute625226.6, then the sample is normal”. There are 11 of normal samples
(labeled as “positive”) that satisfy this rule.
(2) “If attribute625>226.6 ^ attribute177282.0 ^ attribute377224.1, then the sample is
tumor”. This rule is true for 10 of the tumor samples (labeled as “negative”).
(3) “If attribute625>226.6 ^ attribute177282.0 ^ attribute377>224.1 ^ attribute625331.1,
then the sample is tumor”. This rule is true for 2 of the tumor samples.
(4) “If attribute625>226.6 ^ attribute177282.0 ^ attribute377>224.1 ^ attribute625>331.1,
then the sample is normal”. There are 10 of the normal samples that satisfy this rule.
(5) “If attribute625>226.6 ^ attribute1772>82.0, then the sample is tumor”. This is a domi-
nant rule for tumor samples since it is true for 28 (70%) of them; however, there is also 1
normal sample meets this rule.
5.2.2 Prostate cancer
Prostate tumors are among the most heterogeneous of cancers, both histologically and clini-
cally [115]. Here, we will study gene expression patterns from 52 tumor and 50 normal prostate
specimens. The data was obtained from oligonucleotide microarrays containing probs for ap-
proximately 12,600 genes and ESTs. According to the supplemental documents of [115], where
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Figure 5.2: A decision tree output from colon tumor data set. The upper part is the tree presented
in text format while the lower is the same tree in tree format. The pictures are captured from the
result panel of Weka. In this chapter, we will mostly use the text format to illustrate a decision
tree.
the data was first analysed, all expression files in a given experiment were scaled to a refer-
ence file based upon the mean average difference for all genes present on the microarray. All
genes with average differences (calculated by Affymetrix GeneChip software) below the mini-
mum threshold of 10 were set at the minimum threshold while the maximum threshold was set at
16,000. The raw data can be downloaded from http://microarray.princeton.edu/
oncology/affydata/index.html.
Table 5.3 shows our 10-fold cross validation performance on this prostate cancer data set.
SVM achieves 95% accuracy (5 errors out of total 102 samples, with 2 misclassified tumor sam-
ples and 3 misclassified normal samples) under both ERCOF and top 100 genes selected by
entropy measure. CS4 also obtains good accuracy as high as 93% with 7 classification errors. In
[115], greater than 90% LOOCV accuracy was claimed by using a small number of genes (from 4
to 256) selected by signal-to-noise measure and k-nearest neighbours classification algorithm. In
fact, our LOOCV accuracy under ERCOF is also 95% for SVM and 93% for CS4 using average
500 genes (detailed data not shown).
There are 54 common genes selected by each fold ERCOF feature selection in 10-fold cross
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Table 5.3: Prostate cancer data set results (52 tumor versus 50 normal) on 10-fold cross valida-
tion.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 7(5:2) 8(5:3) 6(4:2) 6(4:2) 7(4:3) 5(3:2) 7(3:4) 5(3:2)
3-NN 18(8:10) 10(6:4) 8(5:3) 9(3:6) 8(4:4) 7(4:3) 9(5:4) 8(5:3)
Bagging 10(8:2) 9(7:2) 10(5:5) 8(4:4) 8(4:4) 11(5:6) 9(5:4) 9(5:4)
AdaBoostM1 14(7:7) 10(6:4) 8(5:3) 9(5:4) 12(6:6) 14(3:11) 10(4:6) 10(6:4)
RandomForests 21(10:11) 11(7:4) 11(6:5) 9(5:4) 10(7:3) 9(5:4) 7(4:3) 10(5:5)
CS4 9(7:2) 9(7:2) 8(6:2) 8(4:4) 7(5:2) 9(6:3) 9(6:3) 8(6:2)
Table 5.4: Classification errors on the validation set of lung cancer data, consisting of 149 sam-
ples (15 MPM versus 134 ADCA).
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 1(0:1) 1(0:1) 0 1(0:1) 2(1:1) 1(0:1) 0 0
3-NN 3(2:1) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 0 1(1:0) 1(1:0)
Bagging 4(0:4) 5(0:5) 5(0:5) 20(3:17) 12(2:10) 8(1:7) 6(0:6) 6(0:6)
AdaBoostM1 27(4:23) 27(4:23) 27(4:23) 27(4:23) 27(4:23) 27(4:23) 27(4:23) 27(4:23)
RandomForests 5(0:5) 7(0:7) 3(2:1) 8(1:7) 3(1:2) 3(1:2) 2(0:2) 2(0:2)
CS4 3(1:2) 3(1:2) 3(1:2) 3(1:2) 3(1:2) 3(1:2) 3(1:2) 3(1:2)
validation test. Table A.1 in the Appendix lists their probe number, GenBank accession number,
and name. Some of them were also announced by [115] as significant genes to distinguish tumor
from normal prostate samples. For examples, AF037643, M17885, AL031228, and X07732 and
so on.
5.2.3 Lung cancer
This data set is about the distinction between malignant pleural mesothelioma (MPM) and adeno-
carcinoma (ADCA) of the lung by using the gene expression profiles on 181 tissue samples (31
MPM and 150 ADCA) obtained from oligonucleotide chips. Each sample is described by 12,533
genes. In [42], where this data was first studied, samples was divided into a training set consist-
ing 16 MPM and 16 ADCA, and a validation set containing the rest 149 samples. The raw data
can be found from http://www.chestsurg.org/microarray.htm. Table 5.4 shows
the errors on test set using our proposed scenarios.
This data set has several features: (1) The size of training set is small, but the number of
samples in each class is balanced. Test set contains more than three times samples than those in
the training set, and the number of MPM samples is only one ninth of that of ADCA samples. (2)
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There are as many as 16 genes having zero entropy value on training samples. This means that
using any one of them can separate MPM and ADCA completely. Thus, in the construction of a
C4.5 decision tree, a tree will contain only one feature and two rules, one rule for MPM samples
and another one for ADCA samples. In this case, since the base classifier C4.5 has no training
error, the algorithm of AdaBoostM1 will not proceed to generate new trees and therefore, it is
equivalent to C4.5. Unfortunately, none of these genes can 100% classify the samples in the
validation set alone — the best one misclassifies 4 samples. Table 5.5 gives the cut point for each
of these 16 genes that can separate MPM and ADCA samples in the training set completely, as
well as the testing error of C4.5 decision tree built only on that gene. The cut point is the middle
point of the gene’s boundary expression value in each class. For example: if the maximum
expression value of a gene having zero entropy in MPM class samples is 100 while the minimum
expression value of the same gene in ADCA samples is 500, then the cut point value of this gene
will be 300 and we say the gene has lower expression level in MPM samples and higher level
in ADCA samples. (3) Although there is no single gene that can give 100% correct prediction
on the testing samples, the combination of all of them will lead to a near perfect accuracy —
99.3% prediction accuracy with only one MPM sample misclassified by SVM and 3-NN. (4)
Furthermore, when more genes are considered, 100% accuracy on testing is achieved by SVM
using mean-entropy, top 200 entropy or ERCOF selected features, or by 3-NN using top 100
entropy measure genes.
In the study on the data set in [42], marker genes with a highly significant difference (p <
2  10
 6
; 8 fold) in average expression levels between 16 MPM and 16 ADCA training
samples were explored. From them, 8 genes with the most statistically significant differences
and a mean expression level > 600 in at least one of the two training sample sets were chosen
to form 15 expression ratio patterns. The best test accuracy reported was also 99.3% (with 1
error). Among the 8 significant genes, we find 3 of them with zero entropy. They are highlighted
with bold font in Table 5.6 where the probe name, GenBank accession number and gene name
of those 16 zero entropy genes are listed. The remaining 5 genes also have relatively smaller
entropy values, they are X56667 (GenBank accession number), entropy rank 31; X16662, rank
32; AJ011497, rank 33; AB023194, rank 37; and U43203, rank 56.
By the way, we also obtain the 10-fold cross validation results on this data set and list them
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Table 5.5: 16 genes with zero entropy measure in the training set of lung cancer data. Cut
point is the expression value of the gene that can be used to separate MPM and ADCA samples
completely. The column “lower” ( or “higher”) indicates the class that all of its samples have
their expression values of this gene not greater than (or greater than) the cut point.
Probe Name Cut Point Lower Higher Test Error
2047 s at 571.1 MPM ADCA 27(4:23)
266 s at 76.95 MPM ADCA 20(2:18)
32046 at 103.2 MPM ADCA 16(3:13)
32551 at 73.45 MPM ADCA 15(1:14)
33245 at 48.3 MPM ADCA 12(1:11)
33833 at 453.7 ADCA MPM 10(2:8)
35330 at 25.3 ADCA MPM 31(1:30)
36533 at 193.25 ADCA MPM 8(2:6)
37205 at 78.8 ADCA MPM 14(3:11)
37716 at 197.75 ADCA MPM 4(4:0)
39795 at 1167 ADCA MPM 14(1:13)
40936 at 430.6 ADCA MPM 9(3:6)
41286 at 41.5 MPM ADCA 28(2:26)
41402 at 54.6 MPM ADCA 26(2:24)
575 s at 149.75 MPM ADCA 8(1:7)
988 at 31 MPM ADCA 17(2:15)
in Table 5.7. Many scenarios have less than 4 misclassified samples, achieving overall accuracy
above 98%. Remarkably, random forests makes no error using mean-entropy selected genes.
5.2.4 Ovarian cancer
Different from other data sets studied in this chapter, this disease analysis is about using pro-
teomic spectra generated from mass spectrometer for ovarian cancer detection. The initial publi-
cation [92] on this new diagnostic approach was in Lancet in February 2002, in which analysis
of serum from 50 unaffected women and 50 patients with ovarian cancer were conducted and a
proteomic pattern that completely discriminated cancer from non-cancer was identified. As de-
scribed in [29], when we use proteomic patterns to diagnose disease, the sample drawn from the
patient is first applied to a protein chip which is made up of a specific chromatographic surface,
and then analysed via mass spectrometry. The result is simply a mass spectrum of the species
that bound to and subsequently desorbed from the array surface. The pattern of peaks within the
spectrum is studied to diagnose the source of the biological sample. A process diagram of how
to diagnose disease using proteomic patterns is captured from [29] and given in Figure 5.3. One
obvious advantage of this process is that raw biofluids, such as urine, serum and plasma, can be
directly applied to the array surface. On the other hand, as pointed out in [29], there are criticisms
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Table 5.6: GenBank accession number and name of 16 genes with zero entropy measure in the
training set of lung cancer data. Three genes in bold font were also selected by [42].
Probe Accession Gene name
name number
2047 s at M23410 Human plakoglobin (PLAK) mRNA, complete cds
266 s at L33930 Homo sapiens CD24 signal transducer mRNA, complete cds and 3 region
32046 at D10495 Homo sapiens mRNA for protein kinase C delta-type, complete cds
32551 at U03877 Human extracellular protein (S1-5) mRNA, complete cds
33245 at AF004709 Homo sapiens stress-activated protein kinase 4 mRNA, complete cds
33833 at J05243 Human nonerythroid alpha-spectrin (SPTAN1) mRNA, complete cds
35330 at AJ012737 Homo sapiens mRNA for filamin, muscle isoform
36533 at D83402 Homo sapiens gene for prostacyclin synthase
37205 at AB020647 Homo sapiens mRNA for KIAA0840 protein, partial cds
37716 at X05323 Human MRC OX-2 gene signal sequence
39795 at D63475 Human mRNA for KIAA0109 gene, complete cds
40936 at AI651806 Homo sapiens cDNA, 3’end
41286 at X77753 H.sapiens TROP-2 gene
41402 at AL080121 Homo sapiens mRNA; cDNA DKFZp564O0823 (from clone DKFZp564O0823)
575 s at M93036 Human (clone 21726) carcinoma-associated antigen GA733-2 (GA733-2) mRNA,
exon 9 and complete cds
988 at X16354 Human mRNA for transmembrane carcinoembryonic antigen BGPa (formerly TM1-CEA)
Table 5.7: 10-fold cross validation results on whole lung cancer data set, consisting of 31 MPM
and 150 ADCA samples.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 1(1:0) 1(1:0) 1(1:0) 1(1:0) 2(2:0) 2(2:0) 1(1:0) 1(1:0)
3-NN 11(11:0) 3(3:0) 2(2:0) 1(1:0) 2(2:0) 2(2:0) 2(2:0) 1(1:0)
Bagging 6(5:1) 6(5:1) 6(5:1) 7(5:2) 5(4:1) 5(4:1) 6(5:1) 6(5:1)
AdaBoostM1 6(3:3) 7(3:4) 5(2:3) 3(2:1) 2(1:1) 2(1:1) 3(2:1) 6(3:3)
RandomForests 2(2:0) 2(2:0) 0 1(1:0) 2(2:0) 1(1:0) 1(1:0) 1(1:0)
CS4 2(2:0) 2(2:0) 1(1:0) 3(3:0) 1(1:0) 2(2:0) 2(2:0) 1(1:0)
of using proteomic patterns for diagnostic purpose — mainly because the identity of the proteins
or peptides giving rise to the key m/z features is not known. However, this debate is beyond the
scope of this thesis.
After the first publication about using proteomic spectra to detect cancer, a series of new
data and discussions on proteomic patterns were put on the FDA-NCI Clinical Proteomics Pro-
gram Databank web site at http://clinicalproteomics.steem.com/.Recently (up-
dated in August 2003), an important development about using a higher resolution mass spectrom-
eter to generate proteomic patterns was announced publicly. Compared with the configuration of
the old Ciphergen instrument (about 100 to 200 spots), there is a tremendous increase in resolu-
tion of the new Q-Star instrument (>9000 at m/z 1500). Besides, mass accuracy is also improved










Figure 5.3: Disease diagnostics using proteomic patterns. Picture is from [29]. m/z stands for
mass to charge ratio and SELDI-TOF MS for surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry.
Here, we apply our proposed feature selection and machine learning approach to an ovarian
proteomic data set named “6-19-02”. This sample set included 91 controls and 162 ovarian
cancers. The raw SELDI (surface-enhanced laser desorption/ionization) data constructed using
the Ciphergen WCX2 ProteinChip had 15154 molecular m/z (mass to charge ratio) identities
ranging from 0.0000786 to 19995.513. The relative amplitude of the intensity at each m/z identity












where NV is the normalized value, V the raw value, V
min
the minimum and V
max
the maximum
raw data of the identity across all the samples, respectively. After this linear normalization, all
the m/z intensities fell within the range [0,1]. Table 5.8 lists the 10-fold cross validation results
on 253 samples with normalized intensities using our proposed scenarios. Notably, both SVM
and CS4 achieve 100% accuracy under certain feature selection methods. This may indicate that
machine learning technologies can also be used to find proteomic patterns.
In the above mentioned web site, associated with this “6-19-02” ovarian cancer data, there
was also a list of seven key m/z values which was announced as an example of the best models
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Table 5.8: 10-fold cross validation results on “6-19-02” ovarian proteomic data set, consisting of
162 ovarian cancer versus 91 control samples.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 0 0 0 4(1:3) 0 0 0 0
3-NN 15(6:9) 11(3:8) 10(3:7) 4(1:3) 2(0:2) 3(0:3) 4(0:4) 3(1:2)
Bagging 7(3:4) 6(3:3) 5(3:2) 7(4:3) 5(3:2) 6(3:3) 5(3:2) 6(3:3)
AdaBoostM1 10(4:6) 9(4:5) 8(4:4) 6(4:2) 4(4:0) 5(4:1) 6(4:2) 5(4:1)
RandomForests 19(6:13) 8(1:7) 5(0:5) 7(3:4) 3(0:3) 4(0:4) 6(1:5) 5(1:4)
CS4 0 0 1(0:1) 5(2:3) 1(0:1) 0 0 0
found to 100% correctly separate ovarian cancer and non-cancer samples. These m/z identities
are: MZ2760.6685, MZ19643.409, MZ465.56916, MZ6631.7043, MZ14051.976, MZ435.4652
and MZ3497.5508. However, among these seven M/Z values, we find 3 of them will be fil-
tered out by the Phase I of ERCOF, i.e. the entropy algorithm can not find cut point for their
value ranges. They are: MZ2760.6685, MZ19643.409 and MZ6631.7043. With the remaining
4 identities, SVM can still achieve 100% accuracy on 10-fold cross validation and some simple
rules are found to separate cancer and non-cancer samples completely by decision tree method.
For example, the simple rule, “if MZ435.46452>0.335733 ^ MZ465.56916<0.666745, then the
sample is ovarian cancer”, is true for 148 of 162 cancer samples.
A recent paper presented the work on this data set is [118], which used non-parametric
Wilcoxon rank sum test statistics and stepwise discriminant analysis to develop patterns and
rules from proteomic profiling. Using Wilcoxon test, the paper reported that 685 out of total
15154 m/z values differing between the cancer and non-cancer populations with a p-value of less
than 10 6. On the other hand, refer to our 10-fold cross validation results in Table 5.8, the top
50 entropy measure selected features can lead to a 100% accuracy and we further find there are
as many as 39 common m/z values among each time feature selection for 10 folds. These 39
m/z identities are all in the ERCOF selected common features for 10-fold cross validation. In the
Appendix, we list in Table A.3 these m/z values, their corresponding Wilcoxon test p-values and
entropy measure on the entire data set. The p-values are derived from the supplementary figures
of paper [118]. Notably, their Wilcoxon p-values are all very small (< 10 21). With these 39
m/z identities, CS4 outputs several decision trees, and each of them can separate cancer from
non-cancer completely. Figure 5.4 shows only four of them.
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Figure 5.4: Four decision trees output by CS4 using 39 common features selected by top 50 en-
tropy measure on 10-fold cross validation on ovarian cancer proteomic profiling. All these trees
are constructed on the entire 253 samples and can separate cancer and non-cancer completely.
5.2.5 Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lym-
phoma. Although around 40% of DLBCL patients are cured with current therapy and have pro-
longed survival, the remainder succumb to the disease [6]. Recently, DLBCL was widely studied
at molecular level using gene expression profilings [6, 102, 114]. Alizadeh et al [6] identified
two distinct forms of DLBCL which had gene expression patterns indicative of different stages
of B-cell differentiation. Germinal center B-like DLBCL expresses genes normally seen in ger-
minal center B cells, while activated B-like DLBCL expresses genes that are induced during in
vitro activation of peripheral blood B cells. They showed that patients with germinal center B-
like DLBCL had a significantly better overall survival than those with activated B-like DLBCL.
Thus, accurately classifying germinal center B-like DLBCL and activated B-like DLBCL will
help with survival prediction.
The DLBCL gene expression data studied in [6] contains 4026 genes across 47 samples,
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Table 5.9: 10-fold cross validation results on DLBCL data set, consisting of 24 germinal center
B-like DLBCL versus 23 activated B-like DLBCL.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 6(3:3) 3(1:2) 2(1:1) 6(4:2) 3(1:2) 4(2:2) 3(1:2) 2(1:1)
3-NN 13(1:12) 5(2:3) 5(2:3) 5(3:2) 5(3:2) 3(1:2) 5(2:3) 4(2:2)
Bagging 6(3:3) 6(3:3) 7(3:4) 8(3:5) 8(3:5) 8(3:5) 6(3:3) 8(3:5)
AdaBoostM1 11(4:7) 11(5:6) 10(4:6) 8(4:4) 9(4:5) 11(5:6) 10(4:6) 10(5:5)
RandomForests 5(4:1) 1(0:1) 4(3:1) 3(2:1) 4(3:1) 6(2:4) 3(2:1) 3(2:1)
CS4 5(2:3) 5(2:3) 5(2:3) 6(2:4) 4(2:2) 5(2:3) 5(2:3) 5(2:3)
including 24 germinal center B-like DLBCL and 23 activated B-like DLBCL. The data and
associated information can be found at http://llmpp.nih.gov/lymphoma/. The raw
data were originally filtered by several criteria and log-transformed (base 2). For details of data
preprocessing, please refer to [6]. Table 5.9 shows the 10-fold cross validation results on this
DLBCL data set under our proposed scenarios. The results demonstrate that, overall speaking,
germinal center B-like DLBCL and activated B-like DLBCL can be classified. Random forests
achieves best cross validation results — having only one sample misclassified using all entropy
measure selected genes. SVM still performs well — giving only two misclassified samples in
two cases. In addition, using ERCOF as feature selection method, the number of misclassified
samples in LOOCV test for SVM, CS4 and random forests are 2(1:1), 4(2:2) and 3(2:1), respec-
tively.
Table 5.10 lists the 9 common genes selected by each fold ERCOF feature selection in the
10-fold cross validation test. All of them are in the “list of best class-predicting genes supporting
the GC-B Like v.s. Activated B-Like class distinction” of paper [6] (see supplemental Figure 3
on the data web site given above). Besides, our identified genes are also highly consistent with
those reported in [126], where t-test, Wilcoxon rank sum test and a heuristic method were applied
to select genes on the same data set. Notably, we find that the GENE1207X (or FLIP), whose
products inhibit programmed cell death, highly expressed in activated B-like DLBCL. According
to [6], “FLIP is a dominant-negative mimic of caspase 8 (FLICE) which can block apoptosis
mediated by Fas and other death receptors.....FLIP is highly expressed in many tumor types and
its constitutive expression in activated B-like DLBCLs could inhibit apoptosis of tumor cells
induced by host T cells expressing Fas ligand”. On the other hand, simply using these 9 genes, 3-
NN and Random forests can separate 24 germinal center B-like DLBCL from 23 activated B-like
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Table 5.10: 9 common genes selected by each fold of ERCOF in 10-fold cross validation test on
DLBCL data set. The third column indicates the DLBCL sub-class that the gene was relatively
highly expressed.
GID Gene name HighlyExpressed in
GENE3328X Unknown UG Hs.136345 ESTs; Clone=746300 GC-B Like
GENE3314X *Unknown; Clone=1353041 GC-B Like
GENE1252X *Cyclin D2/KIAK0002=3’ end of KIAK0002 cDNA; Clone=1357360 activated B-like
GENE3325X Unknown UG Hs.120245 Homo sapiens mRNA for GC-B Like
KIAA1039 protein, partial cds; Clone=1268870
GENE3946X *PTP-1B=phosphotyrosyl-protein phosphatase; Clone=472182 activated B-like
GENE2106X Similar to intersectin=adaptor protein with two GC-B Like
EH and five SH3 domains; Clone=1339781
GENE2291X Unknown; Clone=1340742 activated B-like
GENE3258X *JAW1=lymphoid-restricted membrane protein; Clone=815539 GC-B Like
GENE1207X *FLICE-like inhibitory protein long form=I-FLICE=FLAME-1 activated B-like
=Casper=MRIT=CASH=cFLIP=CLARP; Clone=711633
DLBCL completely while both SVM and CS4 only misclassify one activated B-like DLBCL.
Figure 5.5 displays some decision trees output from running CS4 on these 9 genes.
5.2.6 ALL-AML leukemia
This leukemia data first reported by Golub et al [41] is among the most extensively analysed gene
expression profilings. Many researchers have tested their clustering, gene selection and/or clas-
sification algorithms on this bench mark data set [39, 136, 87, 123, 86, 85, 31, 68, 82, 51]. The
original training data consists of 38 bone marrow samples with 27 ALL (acute lymphoblastic
leukemia) and 11 AML (acute myeloid leukemia) from adult patients. The test data set con-
sisted of 24 bone marrow samples and 10 peripheral blood specimens from adults and children,
including 20 ALL and 14 AML. The gene expression profile were obtained from Affymetrix
high-density oligonucleotide microarrays containing 7129 probes for 6817 human genes. The
raw data can be downloaded from http://www.broad.mit.edu/cgi-bin/cancer/
datasets.cgi.
In Table 5.11, we list results on 34 test samples as well as 10-fold cross validation and
LOOCV on entire 72 samples using our proposed gene selection and classification scenarios.
Our best result of both testing and cross validation is to misclassify only one sample. In fact, this
misclassified AML sample was reported by most of other investigators.
ERCOF selects 280 genes from training set samples. Table A.4 in the Appendix lists
the probe and name of these genes. In [41], 50 genes found by signal-to-noise measurement
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Figure 5.5: Four decision trees output by CS4 using 9 common features selected by ERCOF on
10-fold cross validation on DLBCL data. All these trees are constructed on the entire 47 samples,
including 24 germinal center B-like DLBCL and 23 activated B-like DLBCL.
that most highly correlated with ALL and AML distinction from the training samples were re-
ported. Remarkably, 49 of them are also in our 280 genes list and indicated with bold font in
Table A.4. In addition, Olshen and Jain [85] reported 40 significant genes identified by t-test
with a permutation-based adjustment. These genes are all included in our list, but some of them
(13 out of 40) are not in Golub’s 50-gene list. On the other hand, there are 80 common genes
selected by ERCOF in each fold of 10-fold cross validation on the entire 72 samples. Fifty of
them are in the list of Table A.4 in the Appendix. Based on training set samples, there is one gene
(Zyxin) with zero entropy (1017.58 is the cut point and it highly expressed in AML samples).
However, with only this one gene, classification algorithms can not achieve good testing results
on validation set. At this point, Golub et al commented “in any case, we recommend using at
least 10 genes ...... Class predictors using a small number of genes may depend too heavily on
any one gene and can produce spuriously high prediction strengths”.
Using SAM described in Section 4.2.1, a statistical software designed for identifying signif-
icant genes in a set of microarray experiments, total of 2857 genes are output with the threshold
Æ at 0.4789. Table 5.12 lists the classification results on 34 testing samples using different top
genes ranked by SAM score. We can see that SVM, k-NN and random forests can not achieve
good testing results using SAM selected genes on this data set, but AdaBoostM1 achieves bet-
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Table 5.11: ALL-AML leukemia data set results (ALL versus AML) on testing samples, as well
as 10-fold cross validation and LOOCV on the entire set.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 5(0:5) 1(0:1) 1(0:1) 4(0:4) 5(1:4) 1(0:1) 1(0:1) 1(0:1)
3-NN 10(1:9) 6(0:6) 2(0:2) 3(0:3) 4(1:3) 2(0:2) 1(0:1) 1(0:1)
Bagging 3(0:3) 4(0:4) 4(0:4) 2(1:1) 4(0:4) 4(0:4) 4(0:4) 4(0:4)
AdaBoostM1 3(2:1) 3(2:1) 3(2:1) 3(2:1) 3(2:1) 3(2:1) 3(2:1) 3(2:1)
RandomForests 9(0:9) 4(0:4) 6(0:6) 4(1:3) 5(0:5) 2(0:2) 2(0:2) 3(0:3)
CS4 4(0:4) 4(0:4) 3(0:3) 2(1:1) 4(0:4) 3(0:3) 3(0:3) 3(0:3)
10-fold cross validation
SVM 1(0:1) 2(1:1) 2(1:1) 2(1:1) 5(2:3) 3(2:1) 2(1:1) 2(1:1)
3-NN 10(1:9) 2(0:2) 1(0:1) 4(3:1) 4(2:2) 4(2:2) 2(1:1) 2(0:2)
Bagging 5(0:5) 6(0:6) 5(0:5) 4(0:4) 6(1:5) 6(1:5) 6(1:5) 6(2:4)
AdaBoostM1 13(6:7) 11(5:6) 12(5:7) 6(3:3) 7(4:3) 10(6:4) 10(5:5) 9(4:5)
RandomForests 6(0:6) 5(0:5) 4(1:3) 4(0:4) 4(1:3) 3(0:3) 5(0:5) 5(2:3)
CS4 1(0:1) 2(0:2) 2(0:2) 3(1:2) 2(1:1) 1(0:1) 2(0:2) 2(1:1)
LOOCV
SVM 1(0:1) 1(0:1) 2(1:1) 4(2:2) 5(2:3) 4(2:2) 2(1:1) 1(0:1)
3-NN 10(1:9) 1(0:1) 1(0:1) 4(3:1) 5(3:2) 2(1:1) 3(2:1) 1(0:1)
Bagging 7(3:4) 6(1:5) 5(0:5) 5(0:5) 5(0:5) 6(1:5) 6(1:5) 5(1:4)
AdaBoostM1 11(6:5) 10(5:5) 11(5:6) 6(3:3) 6(3:3) 7(4:3) 10(5:5) 7(4:3)
RandomForests 8(0:8) 6(2:4) 4(1:3) 4(0:4) 5(2:3) 5(2:3) 6(3:3) 4(1:3)
CS4 2(1:1) 2(1:1) 2(1:1) 1(0:1) 1(0:1) 2(1:1) 2(1:1) 1(0:1)
ter results (with top 350, 280 or 200 genes) than using our proposed gene selection schemes.
Remarkably, bagging makes no testing error on top 350 SAM selected genes. As for CS4, the
performance is relatively stable by using 100 to 350 SAM selected genes. When we compare the
genes identified by SAM with those 280 selected by ERCOF, we only find 125 and 17 common
genes from all 2857 and top 280 SAM selected genes, respectively.
Using PAM described in Section 4.2.3, a class prediction software for genomic expression
data mining based on nearest shrunken centroid method, Tibshirani et al reported 2 misclassified
Table 5.12: ALL-AML leukemia data set results (ALL versus AML) on testing samples by using
top genes ranked by SAM score. *: the number is approximate to the number of all-entropy
selected genes; **: the number is approximate to the number of mean-entropy selected genes;
***: the number is approximate to the number of ERCOF selected genes.
Classifier 2857 800 350 280 200 100 50 20
SVM 3(0:3) 4(0:4) 4(1:3) 5(1:4) 6(2:4) 10(4:6) 11(3:8) 11(0:11)
3-NN 11(1:10) 11(1:10) 10(0:10) 10(0:10) 10(0:10) 11(0:11) 13(1:12) 12(0:12)
Bagging 2(0:2) 2(0:2) 0 2(1:1) 2(1:1) 2(1:1) 9(0:9) 8(1:7)
AdaBoostM1 3(0:3) 3(1:2) 1(0:1) 1(0:1) 1(0:1) 2(0:2) 12(4:8) 8(1:7)
RandomForests 13(0:13) 9(0:9) 8(0:8) 6(0:6) 6(0:6) 6(0:6) 11(0:11) 11(0:11)
CS4 6(1:5) 4(1:3) 2(0:2) 3(0:3) 4(0:4) 2(1:1) 8(0:8) 9(2:7)
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test samples by using only 21 genes with an amount of shrinkage Æ at 4.06 [123]. This Æ value is
not the optimal one where the minimum cross-validation errors occurs since there will be more
than 1000 genes associated with the optimal Æ value. Anyway, our classification results are very
competitive on this data set — misclassifying only 1 test sample.
5.2.7 Subtypes of pediatric acute lymphoblastic leukemia
Pediatric acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer.
However, with modern cancer therapy, its overall long-term event-free survival rates is as high
as 80% [140]. Treatment of pediatric ALL is based on the concept of tailoring the intensity of
therapy to a patient’s risk of relapse. Thus, it becomes very important to accurately assign indi-
vidual patients into specific risk groups; otherwise, it would cause under-treatment (which causes
relapse and eventual death) or over-treatment (which causes severe long-term side-effects). Al-
though current risk assignment is mainly dependent on a variety of clinical and laboratory param-
eters requiring an extensive range of procedures including morphology, immunophenotyping, cy-
togenetics, and molecular diagnostics, it has been noticed that the genetic alterations that under-
lie the pathogenesis of individual leukemia subtypes are also playing important roles [95, 140].
Though it looks identical under the microscope, pediatric ALL is a highly heterogeneous disease,
with as many as 6 different subtypes that have widely differing treatment outcome. The purpose
of the analysis on this data set is to accurately classify subtypes of pediatric ALL using gene
expression profiling so that the correct intensity of therapy can be delivered to ensure that the
child would have the highest chance for cure.
The data is a collection of 327 gene expression profiles of pediatric ALL diagnostic bone
marrows with Affymetrix oligonucleotide microarrays containing 12,600 probe sets [140]. The
raw data can be found from http://www.stjuderesearch.org/data/ALL1/. These
samples contain all known biologic ALL subtypes, including T lineage leukemias (T-ALL), B
lineage leukemias that contain t(9;22) (BCR-ABL), t(1;19) (E2A-PBX1), t(12;21) (TEL-AML1),
rearrangement in the MLL gene on chromosome 11, band q23 (MLL), and a hyperdiploid kary-
otype (i.e. > 50 chromosomes) (Hyperdip>50) [140]. In [140], where the data was first analysed,
327 samples were divided into two groups — a training group consisting of 215 samples and a
testing group consisting of 112 samples. Table 5.13 lists the number of samples of each subtype
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Table 5.13: Number of samples in each of subtypes in pediatric acute lymphoblastic leukemia
data set.
Subtype Number of training samples Number of testing samples total
T-ALL 28 15 43
E2A-PBX1 18 9 27
TEL-AML1 52 27 79
BCR-ABL 9 6 15
MLL 14 6 20
Hyperdip>50 42 22 64
Rest 52 27 79
Total 215 112 327
in training and testing groups, and the diagnostic samples that did not fit into any one of the above
subtypes are put under “Rest”.
In [140], classification was designed following a decision tree format, in which the first
decision was T-ALL (T lineage) versus non-T-ALL (B lineage) and then within the B lineage
subset. If a case is decided to be a non-T-ALL, it will be sequentially classified into the known
risk groups characterized by the presence of E2A-PBX1, TEL-AML1, BCR-ABL, MLL, and
lastly hyperdip>50. A very high prediction accuracy on the blinded test samples was achieved
for each ALL subtypes using SVM and genes selected by t-statistic, X 2-statistic or other met-
rics: 100% on T-ALL, E2A-PBX1 and MLL samples, 99% on TEL-AML1 samples, 97% on
BCR-ABL samples, and 96% on Hyperdip>50 samples. However, in this thesis, we will not fol-
low this tree structure to sequentially classify samples; instead, we will treat all subtypes equally
and distinguish one subtype samples from all the other samples. Therefore, for each of the 6
classification problems, number of training and testing samples are always 215 and 112, respec-
tively. For example, for subtype BCR-ABL, the 215 training samples consist of 9 BCR-ABL
cases versus 206 “OTHERS” while 112 testing samples consist of 6 BCR-ABL cases versus 106
“OTHERS”. The samples labeled as ”OTHERS” here include all the cases other than BCR-ABL.
Next, we will report classification results on the validation samples and 10-fold cross validation
on the entire data set under our proposed gene selection and classification scenarios.
T-ALL versus OTHERS
The training set contains 28 T-ALL and 187 OTHERS samples while the test set contains 15 T-ALL
and 97 OTHERS. Table 5.14 shows the results of this test. Under most of our scenarios, the T-
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Table 5.14: Pediatric ALL data set results (T-ALL versus OTHERS) on 112 testing samples, as
well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 0 0 0 0 0 0 0 0
3-NN 3(3:0) 0 0 0 0 0 0 0
Bagging 0 0 0 0 0 0 0 0
AdaBoostM1 0 0 0 0 0 0 0 0
RandomForests 4(4:0) 0 0 1(1:0) 0 0 1(1:0) 0
CS4 0 0 0 0 0 0 0 0
10-fold cross validation
SVM 1(1:0) 0 0 1(1:0) 0 0 0 0
3-NN 8(8:0) 3(3:0) 0 1(1:0) 1(1:0) 1(1:0) 0 1(1:0)
Bagging 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0)
AdaBoostM1 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0)
RandomForests 11(11:0) 0 0 0 0 0 1(1:0) 0
CS4 1(0:1) 1(1:0) 1(1:0) 0 2(1:1) 3(2:1) 2(2:0) 0
ALL samples can be distinguished completely from non-T-ALL cases. Remarkably, we find one
gene, AA919102 (GenBank accession number), has zero entropy value from training samples
with cut point 20062.86 (highly expressed in T-ALL cases) and this gene can also completely
separates T-ALL from all other ALL cases in the testing set. This gene was also reported in [140]
where other feature selection metrics were used. Besides, the genes selected by ERCOF in each
fold testing of 10-fold cross validation are highly consistent, having as many as 253 common
genes. However, it seems that using small amount of good features identified by entropy measure
is enough to separate T-ALL cases in this application, we list out in Table 5.15 the top 20 genes
found from training samples.
E2A-PBX1 versus OTHERS
The training set contains 18 E2A-PBX1 and 197 OTHERS samples while the test set contains 9
E2A-PBX1 and 103 OTHERS. Table 5.16 shows the results of this test. With feature selection,
the testing E2A-PBX1 samples can be distinguished completely from other subtypes of ALL
cases. Similarly, in 10-fold cross validation test, there are quite a few scenarios that achieve
100% accuracy. There are 5 genes whose entropy value is zero in training samples. With these
genes, all the classification algorithms can achieve 100% prediction accuracy on testing samples.
In table 5.17, we list all of them. In addition, all these 5 genes are in the “good genes list”
reported in [140] to distinguish E2A-PBX1 cases. In the supplemental documents of [140],
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Table 5.15: Top 20 genes selected by entropy measure from the training data set of T-ALL versus
OTHERS in subtypes of pediatric ALL study. The last column indicates the sample class in
which the gene is relatively highly expressed.
Probe Accession No. Description HighlyExp in
38319 at AA919102 Homo sapiens cDNA, 3’ end T-ALL
1096 g at M28170 Human cell surface protein CD19 (CD19) gene OTHERS
38242 at AF068180 Homo sapiens B cell linker protein BLNK mRNA, OTHERS
alternatively spliced
41723 s at M32578 Human MHC class II HLA-DR beta-1 mRNA (DR2.3), 5’ end OTHERS
32794 g at X00437 Human mRNA for T-cell specific protein T-ALL
37988 at M89957 Human immunoglobulin superfamily member B cell receptor OTHERS
complex cell surface glycoprotein (IGB) mRNA
37344 at X62744 Human RING6 mRNA for HLA class II alpha chain-like product OTHERS
38095 i at M83664 Human MHC class II lymphocyte antigen (HLA-DP) OTHERS
beta chain mRNA
38017 at U05259 Human MB-1 gene OTHERS
35016 at M13560 Human Ia-associated invariant gamma-chain gene OTHERS
36277 at M23323 Human membrane protein (CD3-epsilon) gene T-ALL
39318 at X82240 H.sapiens mRNA for Tcell leukemia/lymphoma 1 OTHERS
38147 at AL023657 Homo sapiens SH2D1A cDNA, formerly known as DSHP T-ALL
32649 at X59871 Human TCF-1 mRNA for T cell factor 1 (splice form C) T-ALL
38833 at X00457 Human mRNA for SB classII histocompatibility antigen OTHERS
alpha-chain
33238 at U23852 Human T-lymphocyte specific protein tyrosine kinase T-ALL
p56lck (lck) abberant mRNA
37039 at J00194 human hla-dr antigen alpha-chain mrna & ivs fragments OTHERS
38051 at X76220 H.sapiens MAL gene exon 1 (and joined CDS) T-ALL
38096 f at M83664 Human MHC class II lymphocyte antigen (HLA-DP) OTHERS
beta chain mRNA
2059 s at M36881 Human lymphocyte-specific protein tyrosine kinase T-ALL
(lck) mRNA
good genes identified by the self-organizing map (SOM) and discriminant analysis with variance
(DAV) programs to separate each of the six known subtypes ALL were reported.
TEL-AML1 versus OTHERS
The training set contains 52 TEL-AML1 and 163 OTHERS samples while the test set contains 27
TEL-AML1 and 85 OTHERS. Table 5.18 shows the results of this test. Although the validation
result on classification of TEL-AML is not as good as that of subtype T-ALL or E2A-PBX1,
there are still some proposed scenarios can accurately distinguish TEL-AML and non-TEL-AML
cases. Notably, using ERCOF selected features, SVM, 3-NN, Random forests and CS4 achieve
100% prediction accuracy on the testing samples. The number of features selected by ERCOF
from training cases is around 400 and they include 37 of 46 genes that reported in [140] to
separate TEL-AML1 from other subtypes of ALL cases under their proposed tree structure of
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Table 5.16: Pediatric ALL data set results (E2A-PBX1 versus OTHERS) on 112 testing samples,
as well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 0 0 0 0 0 0 0 0
3-NN 0 0 0 0 0 0 0 0
Bagging 0 0 0 0 0 0 0 0
AdaBoostM1 0 0 0 0 0 0 0 0
RandomForests 3(0:3) 0 0 0 0 0 0 0
CS4 0 0 0 0 0 0 0 0
10-fold cross validation
SVM 1(1:0) 1(1:0) 1(1:0) 0 0 0 0 0
3-NN 1(1:0) 1(1:0) 1(1:0) 0 0 1(1:0) 1(1:0) 0
Bagging 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0)
AdaBoostM1 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0)
RandomForests 16(16:0) 3(3:0) 1(1:0) 0 0 0 0 0
CS4 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 0
Table 5.17: Five genes with zero entropy measure on the training data set of E2A-PBX1 versus
OTHERS in subtypes of pediatric ALL study. The last column indicates the sample class in
which the gene is highly expressed (above the mean value across all the samples).
Probe Accession No. Description HighlyExpressed in
32063 at M86546 H.sapiens PBX1a and PBX1b mRNA E2A-PBX1
41146 at J03473 Human poly(ADP-ribose) synthetase mRNA E2A-PBX1
430 at X00737 Human mRNA for purine nucleotide E2A-PBX1
phosphorylase (PNP; EC 2.4.2.1)
1287 at J03473 Human poly(ADP-ribose) synthetase mRNA E2A-PBX1
33355 at AL049381 Homo sapiens mRNA; cDNA DKFZp586J2118 E2A-PBX1
(from clone DKFZp586J2118)
classification. In Table A.10 of the Appendix, we list these 37 highlighted genes. In Figure 5.6,
we present some decision trees output by CS4 using ERCOF selected features. It can be seen
that CS4 makes use of different features as root node and combines them to achieve a perfect
prediction accuracy on the testing samples.
BCR-ABL versus OTHERS
The training set contains 9 BCR-ABL and 206 OTHERS samples while the test set contains 6
BCR-ABL and 106 OTHERS. Table 5.19 shows the results of this test. Since the number of avail-
able BCR-ABL cases is very small, most error predications made are on BCR-ABL samples in
almost all the scenarios. This leads to a very low sensitivity, especially in 10-fold cross validation
test. However, under ERCOF and some other gene selection methods, SVM and CS4 still can
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Table 5.18: Pediatric ALL data set results (TEL-AML1 versus OTHERS) on 112 testing samples,
as well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 10(0:10) 0 0 2(1:1) 1(0:1) 1(0:1) 1(0:1) 0
3-NN 5(4:1) 0 0 1(1:0) 1(1:0) 1(1:0) 1(1:0) 0
Bagging 1(1:0) 2(2:0) 2(2:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 2(2:0)
AdaBoostM1 4(2:2) 4(3:1) 3(2:1) 2(2:0) 4(2:2) 4(3:1) 5(2:3) 4(3:1)
RandomForests 11(11:0) 0 1(1:0) 1(1:0) 2(2:0) 0 1(1:0) 0
CS4 2(1:1) 2(1:1) 2(1:1) 3(3:0) 1(1:0) 1(1:0) 1(1:0) 0
10-fold cross validation
SVM 4(1:3) 3(1:2) 4(1:3) 7(2:5) 8(2:6) 5(2:3) 5(2:3) 2(0:2)
3-NN 14(5:9) 4(0:4) 4(0:4) 8(3:5) 6(2:4) 7(3:4) 4(1:3) 3(0:3)
Bagging 12(5:7) 11(5:6) 10(4:6) 11(5:6) 10(4:6) 11(5:6) 11(5:6) 10(4:6)
AdaBoostM1 9(4:5) 13(7:6) 14(9:5) 8(3:5) 8(5:3) 13(10:3) 13(8:5) 10(4:6)
RandomForests 20(17:3) 7(3:4) 7(3:4) 5(0:5) 5(1:4) 4(0:4) 6(2:4) 4(1:3)
CS4 6(2:4) 6(2:4) 6(2:4) 10(5:5) 5(1:4) 6(2:4) 6(2:4) 5(1:4)
correctly predict most of the testing samples with only one BCR-ABL case misclassified. This
misclassified BCR-ABL sample was also reported by [140]. The number of features selected by
ERCOF from training cases is around 70 and they include 11 of 21 genes that reported in [140]
to separate BCR-ABL from other subtypes of ALL cases under their proposed tree structure of
classification. In Table 5.20, we list these 11 highlighted genes.
MLL versus OTHERS
The training set contains 14 MLL and 201 OTHERS samples while the test set contains 6 MLL
and 106 OTHERS. Table 5.21 shows the results of this test. Most of our scenarios achieve 100%
accuracy on testing samples to separate MLL from other subtypes of ALL cases. Using only 20
genes selected by entropy measure, SVM, 3-NN, Bagging and CS4 can make perfect prediction.
These genes can be found in Table A.11 of the Appendix. When we apply Pearson correlation
coefficient to the 20 genes (all of them can pass Wilcoxon rank sum test) , we filter out only one
gene . With the remaining 19 genes, 100% prediction can also be achieved. On the other hand,
there are 34 genes reported in [140] to be significant to separate MLL from other ALL subtypes
under their proposed tree structure classification. Among them, 24 genes are also selected by our
ERCOF and we list them in Table A.12 of the Appendix, where the genes with bold font are also
appear in Table A.11.
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Table 5.19: Pediatric ALL data set results (BCR-ABL versus OTHERS) on 112 testing samples,
as well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 4(4:0) 1(1:0) 2(1:1) 2(1:1) 2(1:1) 1(1:0) 1(1:0) 1(1:0)
3-NN 6(6:0) 3(3:0) 2(2:0) 1(1:0) 4(4:0) 4(4:0) 4(4:0) 2(2:0)
Bagging 5(5:0) 3(3:0) 2(2:0) 1(1:0) 4(4:0) 3(3:0) 3(3:0) 3(3:0)
AdaBoostM1 8(4:4) 5(1:4) 5(1:4) 5(1:4) 5(1:4) 5(1:4) 5(1:4) 5(1:4)
RandomForests 6(6:0) 6(6:0) 2(2:0) 1(1:0) 2(2:0) 6(6:0) 4(4:0) 2(2:0)
CS4 6(6:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0) 1(1:0)
10-fold cross validation
SVM 12(12:0) 8(6:2) 8(7:1) 6(5:1) 9(7:2) 4(4:0) 8(6:2) 6(5:1)
3-NN 15(14:1) 9(9:0) 10(9:1) 9(7:2) 10(9:1) 8(8:0) 10(10:0) 7(7:0)
Bagging 13(13:0) 12(11:1) 12(11:1) 10(10:0) 12(11:1) 11(11:0) 12(11:1) 10(10:0)
AdaBoostM1 22(13:9) 18(11:7) 15(10:5) 8(7:1) 15(10:5) 16(9:7) 16(10:6) 16(12:4)
RandomForests 15(15:0) 10(10:0) 7(7:0) 6(6:0) 7(7:0) 11(11:0) 12(12:0) 9(9:0)
CS4 8(8:0) 7(7:0) 6(6:0) 8(7:1) 5(5:0) 6(6:0) 7(7:0) 7(6:1)
Table 5.20: Eleven genes selected by ERCOF on training samples and reported in [140] to
separate BCR-ABL from other subtypes of ALL cases in pediatric ALL study. All these genes
are relatively highly expressed (above the mean value across all the samples) in BCR-ABL
samples.
Probe Accession No. Description
37600 at U68186 Human extracellular matrix protein 1 mRNA
38312 at AL050002 Homo sapiens mRNA; cDNA DKFZp564O222
39730 at X16416 Human c-abl mRNA encoding p150 protein
40051 at D31762 Human mRNA for KIAA0057 gene
40504 at AF001601 Homo sapiens paraoxonase (PON2) mRNA
34362 at M55531 Human glucose transport-like 5 (GLUT5) mRNA
36591 at X06956 Human HALPHA44 gene for alpha-tubulin, exons 1-3
40196 at D88153 Homo sapiens mRNA for HYA22
1635 at U07563 Human proto-oncogene tyrosine-protein
kinase (ABL) gene, exon 1a and exons 2-10
1636 g at U07563 Human proto-oncogene tyrosine-protein
kinase (ABL) gene, exon 1a and exons 2-10
330 s at HG2259- Tubulin, Alpha 1, Isoform 44
HT2348
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Figure 5.6: Six decision trees output by CS4 using ERCOF selected features on TEL-AML
subtype classification of pediatric ALL data.
Hyperdip>50 versus OTHERS
The training set contains 42 Hyperdip> 50 and 173 OTHERS samples while the test set contains
22 Hyperdip> 50 and 90 OTHERS. Table 5.22 shows the results of this test. Although the cross
validation results is not very encouraging, some of our scenarios still achieve 100% prediction
accuracy on the testing samples, such as SVM using all-entropy, mean-entropy, top 200 entropy
and ERCOF selected features. Based on training cases, ERCOF selects around 300 genes, which
include 19 of the 26 genes that reported in [140] to separate Hyperdip>50 from other subtype
ALL cases. These 19 highlighted genes are listed in Table A.13 of the Appendix.
A brief summary
As mentioned, different from [140] where the pediatric ALL data set was first analysed and
the classification was based on a given tree structure to sequentially classify a new case into a
subtype of ALL, our study focused on distinguishing a subtype of samples from all other cases.
Therefore, the number of samples in the different classes are more unbalanced in both training
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Table 5.21: Pediatric ALL data set results (MLL versus OTHERS) on 112 testing samples, as
well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 0 0 0 0 0 0 0 0
3-NN 2(2:0) 0 0 0 1(1:0) 0 0 0
Bagging 2(2:0) 1(1:0) 0 0 0 0 0 0
AdaBoostM1 4(2:2) 1(0:1) 1(0:1) 2(1:1) 2(1:1) 1(0:1) 1(0:1) 1(0:1)
RandomForests 5(5:0) 2(2:0) 1(1:0) 0 1(1:0) 0 1(1:0) 1(1:0)
CS4 0 0 0 0 0 0 0 0
10-fold cross validation
SVM 7(7:0) 2(2:0) 2(1:1) 7(6:1) 2(1:1) 0 2(1:1) 2(2:0)
3-NN 9(9:0) 5(5:0) 4(3:1) 8(7:1) 7(6:1) 8(8:0) 5(4:1) 4(2:2)
Bagging 10(9:1) 9(8:1) 8(7:1) 8(7:1) 9(8:1) 9(8:1) 8(7:1) 5(5:0)
AdaBoostM1 13(7:6) 14(9:5) 18(13:5) 14(12:2) 12(10:2) 14(12:2) 18(13:5) 13(6:7)
RandomForests 18(18:0) 10(10:0) 7(7:0) 9(8:1) 7(6:1) 8(7:1) 9(9:0) 9(9:0)
CS4 7(6:1) 5(4:1) 6(5:1) 7(6:1) 10(7:3) 5(4:1) 5(4:2) 4(4:0)
Table 5.22: Pediatric ALL data set results (Hyperdip>50 versus OTHERS) on 112 testing sam-
ples, as well as 10-fold cross validation on the entire 327 cases.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
Test
SVM 18(18:0) 0 0 4(1:3) 4(1:3) 1(0:1) 0 0
3-NN 4(3:1) 2(0:2) 0 5(1:4) 1(1:0) 2(2:0) 2(1:1) 3(1:2)
Bagging 6(4:2) 6(4:2) 5(4:1) 6(4:2) 7(4:3) 9(4:5) 8(4:4) 6(3:3)
AdaBoostM1 10(4:6) 12(3:9) 10(4:6) 5(3:2) 2(1:1) 3(1:2) 2(2:0) 10(4:6)
RandomForests 9(8:1) 3(2:1) 3(2:1) 5(2:3) 3(2:1) 3(2:1) 2(1:1) 1(1:0)
CS4 4(3:1) 4(3:1) 3(2:1) 8(3:5) 5(1:4) 2(1:1) 2(1:1) 3(2:1)
10-fold cross validation
SVM 11(8:3) 9(6:3) 11(9:2) 15(8:7) 15(10:5) 15(10:5) 18(11:7) 8(6:2)
3-NN 21(16:5) 13(9:4) 16(13:3) 15(9:6) 14(9:5) 17(11:6) 12(9:3) 12(8:4)
Bagging 19(16:3) 19(15:4) 20(16:4) 17(11:6) 17(12:5) 18(12:6) 18(14:4) 19(15:4)
AdaBoostM1 23(14:9) 24(16:8) 14(10:4) 17(9:8) 17(10:7) 14(9:5) 17(11:6)) 14(9:5)
RandomForests 31(28:3) 19(15:4) 15(12:3) 17(11:6) 14(10:4) 18(13:5) 15(10:5) 13(9:4)
CS4 14(10:4) 14(10:4) 15(11:4) 20(10:10) 17(9:8) 17(10:7) 12(9:3) 14(10:4)
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Table 5.23: Total number of misclassified testing samples over six subtypes of pediatric ALL
study. Number with bold font in each row indicates the best result achieved by the corresponding
classifier.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 32 1 2 8 8 3 2 1
3-NN 20 5 2 8 7 7 6 5
Bagging 14 12 9 8 12 13 12 11
AdaBoostM1 26 22 19 13 13 13 13 20
RandomForests 38 11 7 8 8 9 9 4
CS4 12 7 6 12 7 4 4 4
and testing sets, which is easier to cause bias in prediction. However, some of our proposed
classification algorithms and feature selection methods still achieved excellent testing results on
all the six known subtypes classification. In addition, for 10-fold cross validation on the entire
data set we also obtained very good results on classification of subtypes T-ALL, E2A-PBX1 and
MLL.
In Table 5.23, for each of our scenarios, we add up the number of misclassified testing
samples over all six known subtypes. Remarkably, SVM, Random forests and CS4 achieved their
best prediction accuracy under ERCOF — misclassified 1, 4 and 4 testing samples, respectively.
In addition, we also demonstrated the advantage of CS4 by presenting some of the decision trees
output by the algorithm.
5.3 Comparisons and Discussions
We have conducted more than one thousand experiments on six gene expression profiles and one
proteomic data set using proposed feature selection and classification methods. From the large
amount of results presented above, we can address various comparisons and discussions. In the
following comparisons, we will use the results of these 20 tests: (1) 10-fold cross validation on
colon tumor, prostate cancer, lung cancer, ovarian disease, DLBCL, ALL-AML leukemia and six
subtypes of pediatric ALL (total 12 tests); (2) validation on the testing samples of lung cancer,
ALL-AML leukemia and six subtypes of pediatric ALL (total 8 tests).
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5.3.1 Classification algorithms
We employed six classification algorithms in the experiments, four ensemble of decision trees
methods, SVM and k-NN.
Comparison among ensemble of decision trees methods
First, let’s do a comparison among the four ensemble of decision trees classification methods —
Bagging, AdaBoostM1, Random forests and CS4. Table 5.24 shows the best classifier(s) (of these
four methods) for each experiment under different feature selection scenarios. From the summary
in the last row of the table, We can see that under every proposed feature selection scenario, the
performance of CS4 was much superior than that of Bagging and AdaBoostM1. Besides, CS4
performed much better than Random forests did under four feature selection scenarios and did
equally good under the other cases. On the other hand, because CS4 only makes use of unchanged
original training samples (in contrast to bootstrapped data), the decision trees/rules output are
more reliable. This concern is crucial in bio-medical applications, such as understanding and
diagnosis of a disease.
Note that, AdaBoostM1 performed poorly in these experiments. The main reason is that,
when its base classifier C4.5 makes no training error, AdaBoostM1 only constructs a single tree
and thus loses the power of combining different decision trees. A typical example can be found
in the prediction on lung cancer validation samples where AdaBoostM1 made 27 misclassified
predictions under every feature selection scenario, which in fact, is the same as C4.5. Recall that,
with the training samples of this data set, there are 16 genes having zero entropy value. This leads
to a very simple decision tree consisting only one feature and having 100% training accuracy.
Unfortunately, this feature is not good enough to give good prediction on testing samples. By the
way, let’s explore more on the prediction power of combining decision trees in CS4.
Power of combining decision trees in CS4
In each experiment, CS4 built 20 decision trees using different features as the root node. First,
let’s look at the prediction power of each single decision tree. Table 5.25 illustrates the number
of misclassified training and testing samples of each single tree in the experiments on the pedi-
atric ALL data to classify TEL-AML1 and Hyperdip>50 subtypes using ERCOF selected genes.
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Table 5.24: Comparison among four ensemble of decision trees methods under different feature
selection scenarios using the results of the 640 (=4x8x20) experiments on the six gene expres-
sion profiles and one proteomic data set. Symbol “C” stands for Bagging classifier, “D” for
AdaBoostM1, “E” for Random forests, and “F” for CS4. Each cell indicates the symbol(s) of the
classifier(s) that achieved best performance in the relevant experiment under the corresponding
feature selection scenario. For each feature selection scenario, the last row indicates the total
number of experiments that individual decision tree based classifier achieved best prediction ac-
curacy (including tie cases). If we add up the numbers across eight feature selection scenarios,
the final result is — Bagging 42, AdaBoostM1 36, random forests 72 and CS4 108.
Experiment All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
ColonTumor C,D,E D C C E F C D
Prostate F C,F D,F C,F F E,F E F
Lung test F F E,F F E,F E,F E E
Lung E,F E,F E E E E E E,F
Ovarian F F F F F F F F
DLBCL E,F E E E E,F F E E
ALLAML test C,D D D,F C,F D E E D,E,F
ALLAML F F F F F F F F
Pediatric ALL data — test
T-ALL C,D,F C,D,E,F C,D,E,F C,D,F C,D,E,F C,D,E,F C,D,F C,D,E,F
E2A-PBX1 C,D,F C,D,E,F C,D,E,F C,D,E,F C,D,E,F C,D,E,F C,D,E,F C,D,E,F
TEL-AML1 C E E C,E C,F E C,E,F E,F
BCR-ABL C F F C,E,F F F F F
MLL F F C,F C,E,F C,F C,E,F C,F C,F
Hyperdip>50 F F E,F D,F D F D,E,F E
Pediatric ALL data — 10-fold cross validation
T-ALL C,D,F E E E,F E E E E
E2A-PBX1 C,D,F C,D,F C,D,E,F E E E E E,F
TEL-AML1 F F F E E,F F E E
BCR-ABL F F F E F F F F
MLL F F F F E F F F
Hyperdip>50 F F D C,D,E C,D,F D F E
Sum C: 8 C: 4 C: 5 C: 9 C: 5 C: 3 C: 5 C: 3
D: 6 D: 5 D: 6 D: 4 D: 5 D: 3 D: 3 D: 4
E: 3 E: 6 E: 9 E: 11 E: 10 E: 10 E: 11 E: 12
F: 16 F: 15 F: 14 F: 12 F: 13 F: 14 F: 11 F: 13
From the figures displayed in the table, we can observe that: (1) these single decision trees con-
structed using different good features as root node possess similar merit with little difference.
Although some single trees gave much better prediction (e.g. tree no. 5) while other trees did
very bad (e.g. tree no. 2) on the same test (TEL-AML1 versus OTHERS), there are no rules that
can be drawn across experiments. Especially, the first tree is not always the best one. (2) A single
tree can achieve good training accuracy, but poor testing results, such as tree no. 1 and tree no.
2 of the test on Hyperdip>50. (3) A single tree contains fewer number of features so that it is
easy to be understood and interpreted. However, as shown in Figure 5.4, 5.5 and 5.6, different
trees produce different rules so that the single coverage constraint problem in a single tree can
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Table 5.25: The training and testing errors of 20 single decision trees generated by CS4 using
ERCOF selected features on testings of TEL-AML1 versus OTHERS and Hyperdip>50 versus
OTHERS in pediatric ALL data set. The row “No. features” gives the number of features used
in the tree.
Tree No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
TEL-AML1 versus OTHERS — testing
Train 0 3 0 1 1 2 2 3 0 3 0 1 1 0 1 1 3 0 2 2
Test 8 12 3 5 1 5 8 8 4 6 5 11 8 4 9 4 11 2 7 7
No. features 4 3 4 4 4 3 4 4 5 3 5 5 5 6 5 5 3 6 4 4
Hyperdip>50 versus OTHERS — testing
Train 0 0 2 1 2 1 3 3 3 1 1 1 0 0 1 2 3 1 0 1
Test 10 10 11 11 7 15 13 11 6 10 8 15 7 13 7 7 12 9 9 8



















Figure 5.7: Power of ensemble trees in CS4 — number of combined trees versus number of
misclassified testing samples.
be rectified. Single coverage constraint means every training sample is covered by exactly one
rule [66].
Secondly, we examine the performance of combining these single trees. For the test on
TEL-AML1 versus OTHERS, if we combine the first four trees, CS4 will make 6 mistakes; if we
combine the first five trees, the number of mistake predictions drops to 1 and to 0 when using the
first seven trees. In Figure 5.7, we plot the curves of number of combined trees versus number of
misclassified testing samples for TEL-AML1 and Hyperdip>50 subtypes prediction. The curves
show an obvious decreasing trend on the number of testing errors when first several trees are
combined to give prediction and after that, the accuracy tends to be stable. Therefore, intuitively,
we see the power of using our ensemble of decision trees method CS4. Besides, the two curves
also demonstrate that 20 trees are enough to give good prediction.
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Table 5.26: Comparison between CS4 and SVM under different feature selection scenarios
using the results of the 320 (=2x8x20) experiments on the six gene expression profiles and one
proteomic data set. Symbol “A” stands for SVM classifier and “F” for CS4. Each cell indicates
the symbol(s) of the classifier(s) that achieved best performance in the relevant experiment
under corresponding feature selection scenario. For each feature selection scenario, the last row
indicates the total number of experiments in which SVM performed better, CS4 did better and
the tie case. If we add up the numbers across feature selection scenarios, the final result is —
SVM won 86, CS4 won 22, and tie 52.
Experiment All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
ColonTumor A A A A A A A A
Prostate A A A A A,F A A A
Lung test A A A A A A A A
Lung A A A,F A F A,F A A,F
Ovarian A,F A,F A A A A,F A,F A,F
DLBCL F A A A,F A A A A
ALLAML test F A A F F A A A
ALLAML A,F A,F A,F A F F A,F A,F
Pediatric ALL data — test
T-ALL A,F A,F A,F A,F A,F A,F A,F A,F
E2A-PBX1 A,F A,F A,F A,F A,F A,F A,F A,F
TEL-AML1 F A A A A,F A,F A,F A,F
BCR-ABL A A F F F A,F A,F A,F
MLL A,F A,F F A,F A,F F A,F A,F
Hyperdip>50 F A A A A A A A
Pediatric ALL data — 10-fold cross validation
T-ALL A,F A F F A A A A,F
E2A-PBX1 A,F A,F A A A A A A,F
TEL-AML1 A A A A F A A A
BCR-ABL F F A A F A F A
MLL A,F A A,F A,F A A A A
Hyperdip>50 A A A A A A F A
Sum A:7 A:13 A:12 A:12 A:9 A:12 A:11 A:10
F:5 F:1 F:3 F:3 F:6 F:2 F:2 F:0
Tie:8 Tie:6 Tie:5 Tie:5 Tie:5 Tie:6 Tie:7 Tie:10
Comparison of CS4 with SVM and k-NN
First, we compare CS4 with SVM. Table 5.26 lists the classifier(s) (of SVM and CS4) that
achieved best validation accuracy for each experiment. Overall speaking, the performance of
SVM is superior to that of CS4.
Secondly, similarly, we compare CS4 with k-NN. Table 5.27 lists the classifier(s) (of k-NN
and CS4) that achieved best validation accuracy for each experiment. Among 160 cases, k-NN
won 48, CS4 won 55, and tie 57. The performance of CS4 is slightly better than that of k-NN.
SVM is the representative of the classifiers built on kernel functions while k-NN is the most
typical instance-based learning algorithm. Different from decision tree methods which use only
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Table 5.27: Comparison between CS4 and k-NN under different feature selection scenarios
using the results of the 320 (=2x8x20) experiments on the six gene expression profiles and one
proteomic data set. Symbol “B” stands for k-NN classifier and “F” for CS4. Each cell indicates
the symbol(s) of the classifier(s) that achieved best performance in the relevant experiment
under corresponding feature selection scenario. For each feature selection scenario, the last row
indicates the total number of experiments in which K-NN performed better, CS4 did better and
the tie case. If we add up the numbers across feature selection scenarios, the final result is —
k-NN won 48, CS4 won 55, and tie 57.
Experiment All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
ColonTumor F B B B B B B B
Prostate F F B,F F F B B,F B,F
Lung test B,F B B B B B B B
Lung F F F B F B,F B,F B,F
Ovarian F F F B F F F F
DLBCL F B,F B,F B F B B,F B
ALLAML test F F B F B,F B B B
ALLAML F B,F B F F F B,F B,F
Pediatric ALL data — test
T-ALL F B,F B,F B,F B,F B,F B,F B,F
E2A-PBX1 B,F B,F B,F B,F B,F B,F B,F B,F
TEL-AML1 F B B B B,F B,F B,F B,F
BCR-ABL B,F F F B,F F F F F
MLL F B,F B,F B,F F B,F B,F B,F
Hyperdip>50 B,F B B B B B,F B,F B,F
Pediatric ALL data — 10-fold cross validation
T-ALL F F B F F B B F
E2A-PBX1 B,F B,F B,F B B B,F B,F B,F
TEL-AML1 F B B B F F B B
BCR-ABL F F F F F F F B,F
MLL F B,F B F B F B,F B,F
Hyperdip>50 F B F B B B,F B,F B
Sum B:0 B:6 B:9 B:10 B:6 B:6 B:5 B:6
F:15 F:7 F:5 F:6 F:10 F:6 F:3 F:3
Tie:5 Tie:7 Tie:6 Tie:4 Tie:4 Tie:8 Tie:12 Tie:11
a small subset of features, SVM and k-NN involve all the features in their classification models.
Although the overall performance of SVM is better than that of CS4, prediction models built by
SVM are difficult to understand, interpret and apply to practical disease diagnosis. In this aspect,
CS4 has its big advantage over SVM.
SVM — linear versus quadratic kernel
“Will quadratic polynomial kernel functions perform better?” To answer this question, we apply
SVM with the quadratic polynomial kernel function to the data sets. The results show that in
most of cases, SVM with quadratic kernel function performs the same as that with the simple
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linear kernel; and in some cases, it even does worse. For the experiments described in this
chapter, quadratic kernel seldom performs better than linear kernel. For example, among the
twenty experiments using ERCOF selected features, linear kernel achieved better accuracy in 7
of them while they tied in the rest 13 cases (detailed data is not shown). Note that, quadratic
kernels need much more time on training process, especially for high-dimensional data.
5.3.2 Feature selection methods
The experimental results show that for all the classifiers, in most of cases, they performed better
(or not worse) with the selected features than they did with the original feature space. In the
following discussions, we will focus on comparing our ERCOF with other proposed entropy-
based feature selection methods.
Comparison of ERCOF with all-entropy and mean-entropy
Since ERCOF is built on all-entropy (the Phase I feature filtering of ERCOF), first, let’s compare
the performance of ERCOF and all-entropy. Table 5.28 lists the feature selection method(s) (of
ERCOF and all-entropy) that achieved best validation accuracy for each experiment. Among 120
cases, all-entropy won 4, ERCOF won 60, and tie 56. Obviously, the performance of ERCOF is
better than that of all-entropy.
In our previous work presented in [64], mean-entropy method was claimed to be superior
to all-entropy on high-dimensional biomedical data. Next, we will compare the performance
of ERCOF with mean-entropy. Table 5.29 lists the feature selection method(s) (of ERCOF and
mean-entropy) that achieved best validation accuracy for each experiment. Among 120 cases,
mean-entropy won 18, ERCOF won 42, and tie 60. Overall speaking, the performance of ERCOF
is better than that of mean-entropy, though among 50% of cases they had equal performance.
Note that, compared with all-entropy, mean-entropy and ERCOF use fewer features. To
have an intuitive sense of amount of features selected by these three methods, in Table 5.30 we
list number of features in the original data sets as well as in the dimensional-reduced data sets.
From the table, we can see that:
(1) Feature reduction is mostly done by the entropy measure. As our “base” selection method,
entropy measure (i.e. All-entropy) on the average filters out as many as 88.5% (=1-11.5%)
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Table 5.28: Comparison between ERCOF and all-entropy under six different classifiers using the
results of the 240 (=2x6x20) experiments on the six gene expression profiles and one proteomic
data set. Symbol “A” stands for feature selection using all-entropy method and “C” for ERCOF.
Each cell indicates the symbol(s) of the feature selection method(s) that achieved minimum
number of misclassified samples in the relevant experiment using relevant classifier. For each
classifier, the last row indicates the total number of experiments in which all-entropy performed
better, ERCOF did better and the tie case. If we add up the numbers across classifiers, the final
result is — all-entropy won 4, ERCOF won 60, and tie 56.
Experiment SVM 3-NN Bagging AdaBoostM1 RandomForests CS4
ColonTumor C A,C C C C C
Prostate C C A,C A,C C C
Lung test C A,C A A,C C A,C
Lung A,C C A,C C C C
Ovarian A,C C A,C C C A,C
DLBCL C C A C A A,C
ALLAML test A,C C A,C A,C C C
ALLAML A,C A,C A,C C A,C A,C
Pediatric ALL data — test
T-ALL A,C A,C A,C A,C A,C A,C
E2A-PBX1 A,C A,C A,C A,C A,C A,C
TEL-AML1 A,C A,C A,C A,C A,C C
BCR-ABL A,C C A,C A,C C A,C
MLL A,C A,C C A,C C C
Hyperdip>50 A,C A A,C C C C
Pediatric ALL data — 10-fold cross validation
T-ALL A,C C A,C A,C A,C C
E2A-PBX1 C C A,C A,C C C
TEL-AML1 C C C C C C
BCR-ABL C C C C C A,C
MLL A,C C C C C C
Hyperdip>50 C C A,C C C A,C
Sum A:0 A:1 A:2 A:0 A:1 A:0
C:8 C:12 C:5 C:10 C:14 C:11
Tie:12 Tie:7 Tie:13 Tie:10 Tie:5 Tie:9
of the features in original data. From the above performance analysis, this round of heavy
dimensionality reduction not only brings us much faster speed of classification, but also
leads to more accurate predictions.
(2) During the second phase of filtering in ERCOF, 33% of all-entropy selected features are
further removed by Wilcoxon rank sum test. After this round of narrow down, the remain-
ing features become sharply discriminating.
(3) After the correlation checking in Phase III, the final ERCOF keeps only 4.5% representa-
tive features of original data. This means that 40% of the highly correlated features left in
Phase II are deducted in this round of filtering.
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Table 5.29: Comparison between ERCOF and mean-entropy under six different classifiers
using the results of the 240 (=2x6x20) experiments on the six gene expression profiles and one
proteomic data set. Symbol “B” stands for feature selection using mean-entropy method and “C”
for ERCOF. Each cell indicates the symbol(s) of the feature selection method(s) that achieved
minimum number of misclassified samples in the relevant experiment using relevant classifier.
For each classifier, the last row indicates the total number of experiments in which mean-entropy
performed better, ERCOF did better and the tie case. If we add up the numbers across classifiers,
the final result is — mean-entropy won 18, ERCOF won 42, and tie 60.
Experiment SVM 3-NN Bagging AdaBoostM1 RandomForests CS4
ColonTumor C C B,C C C C
Prostate C B,C C B C B,C
Lung test B,C B,C B B,C C B,C
Lung B,C C B,C B B B,C
Ovarian B,C C B C B,C C
DLBCL B,C C B B,C C B,C
ALLAML test B,C C B,C B,C C B,C
ALLAML B,C B B C B B,C
Pediatric ALL data — test
T-ALL B,C B,C B,C B,C B,C B,C
E2A-PBX1 B,C B,C B,C B,C B,C B,C
TEL-AML1 B,C B,C B,C B C C
BCR-ABL C B,C B B,C B,C B,C
MLL B,C B,C B,C B,C B,C B,C
Hyperdip>50 B,C B B B,C C B,C
Pediatric ALL data — 10-fold cross validation
T-ALL B,C B B,C B,C B,C B,C
E2A-PBX1 C C B,C B,C C C
TEL-AML1 C C B,C C C C
BCR-ABL C C C B B B
MLL B,C B,C C C B C
Hyperdip>50 C C C B,C C C
Sum B:0 B:3 B:6 B:4 B:4 B:1
C:7 C:9 C:4 C:5 C:10 C:7
Tie:13 Tie:8 Tie:10 Tie:11 Tie:6 Tie:12
(4) Number of features selected by mean-entropy is very close to that by ERCOF — only 40%
of all-entropy selected features are kept. Note that, overall speaking, both mean-entropy
and ERCOF performed better than all-entropy did.
Comparison of ERCOF with top-number-entropy
For each data set, we also did experiments on some numbers of top features selected by entropy
measure. Here, for each test, we will pick up the best one of them to compare with ERCOF.
Table 5.31 shows that among 120 comparisons, ERCOF won 17, the best top-number-entropy
won 45, and they did equally good in more than 50% of them. However, the best top-number-
entropy is different from data to data and from classifier to classifier. There is no regular pattern
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Table 5.30: Number of features selected by each method. For a cross validation, the average
number of the selected features in each fold’s test is used. Column All gives the number of
features in the original intact data. Under ERCOF, the number of remaining features after
Wilcoxon rank sum test (i.e. Phase II) is given in Column after RST while the final number of
selected features (i.e. Phase III) is in Column Final. The percentage of the selected features on
original feature space is indicated in the brackets. The last row Average is the average percentage
across the total 20 tests.
Experiment All All-entropy Mean-entropy ERCOF
after RST Final
ColonTumor 2000 131(6.6%) 58(2.9%) 77(3.9%) 58(2.9%)
Prostate 12600 1429(11.3%) 528(4.2%) 963(7.6%) 516(4.1%)
Lung test 12533 2173(17.3%) 777(6.2%) 1116(8.9%) 673(5.4%)
Lung 12533 4530(36.1%) 1747(13.9%) 3169(25.3%) 1728(13.8%)
Ovarian 15154 5930(39.1%) 2752(18.2%) 4016(26.5%) 2847(18.8%)
DLBCL 4026 392(9.7%) 141(3.5%) 199(4.9%) 112(2.8%)
ALLAML test 7129 866(12.1%) 350(4.9%) 519(7.3%) 280(3.9%)
ALLAML 7129 890(12.5%) 397(5.6%) 618(8.7%) 322(4.5%)
Pediatric ALL data — test
T-ALL 12558 1309(10.4%) 415(3.3%) 869(6.9%) 458(3.7%)
E2A-PBX1 12558 718(5.7%) 235(1.9%) 404(3.2%) 235(1.9%)
TEL-AML1 12558 1309(10.4%) 427(3.4%) 721(5.7%) 461(3.7%)
BCR-ABL 12558 84(0.6%) 31(0.2%) 84(0.6%) 76(0.6%)
MLL 12558 327(2.6%) 124(0.9%) 147(1.2%) 86(0.6%)
Hyperdip>50 12558 914(7.3%) 328(2.6%) 691(5.5%) 315(2.5%)
Pediatric ALL data — 10-fold cross validation
T-ALL 12558 1667(13.3%) 731(5.8%) 1329(10.6%) 695(5.5%)
E2A-PBX1 12558 1021(8.1%) 401(3.2%) 604(4.8%) 326(2.6%)
TEL-AML1 12558 1563(12.4%) 698(5.6%) 1351(10.8%) 748(5.6%)
BCR-ABL 12558 147(1.2%) 56(0.5%) 96(0.7%) 50(0.4%)
MLL 12558 519(4.1%) 147(1.2%) 350(2.8%) 196(1.6%)
Hyperdip>50 12558 1222(9.7%) 536(4.3%) 1013(8.1%) 787(6.3%)
Average 11.5% 4.6% 7.7% 4.5%
to follow. To further illustrate this point, for each of six classifiers, in Figure 5.8, we draw the
plots of top number of entropy selected features versus number of prediction errors on the testing
samples of the ALL-AML leukemia data set and Hyperdip>50 subtype of the pediatric ALL data
set. From the plots, there is no optimal number of features can be found.
After above comparisons, we can claim that ERCOF is an efficient way to select features
from high-dimensional gene expression data. In Phase I of ERCOF, entropy-based method elim-
inates those genes who do not separate the samples well, but you have observed that using all-
entropy selected genes does not give the best results. This implies that some features with small
entropy are not useful. To avoid restricting ourselves to an arbitrary cut off (like top-number-
entropy), in Phase II of ERCOF, we resort to a non-parametric statistical test to help decide
which of the genes left in Phase I are more relevant than others. The Phase III of ERCOF corre-
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Table 5.31: Comparison between ERCOF and top-number-entropy (i.e. top 20, 50, 100 and
200) under six classifiers using the results of the 600 (=5x6x20) experiments on the six gene
expression profiles and one proteomic data set. Symbol “C” stands for ERCOF and “D” for the
best feature selection of top-number-entropy. Each cell indicates the symbol(s) of the feature
selection method(s) that achieved best performance in the relevant experiment using relevant
classifier. For each classifier, the last row indicates the total number of experiments in which
ERCOF performed better, top-number-entropy did better and the tie case. If we add up the
numbers across classifiers, the final result is — ERCOF won 17, the best top-number-entropy
won 45, and tie 58.
Experiment SVM 3-NN Bagging AdaBoostM1 RandomForests CS4
ColonTumor C,D C C C D D
Prostate C,D D D D D D
Lung test C,D D C,D C,D C,D C,D
Lung C,D C,D D D C,D C,D
Ovarian C,D D D D D C,D
DLBCL C D D D C D
ALLAML test C,D C,D D C,D D D
ALLAML C,D C,D D D D D
Pediatric ALL data — test
T-ALL C,D C,D C,D C,D C,D C,D
E2A-PBX1 C,D C,D C,D C,D C,D C,D
TEL-AML1 C C D D C,D C
BCR-ABL C,D D D C,D D C,D
MLL C,D C,D C,D C,D D C,D
Hyperdip>50 C,D D C,D D C D
Pediatric ALL data — 10-fold cross validation
T-ALL C,D C,D C,D C,D C,D C,D
E2A-PBX1 C,D C,D C,D C,D C,D C
TEL-AML1 C C C,D D C,D C,D
BCR-ABL D C C,D D D D
MLL D C C D D C
Hyperdip>50 C C,D D C,D C D
Sum C:4 C:5 C:2 C:1 C:2 C:3
D:2 D:7 D:9 D:10 D:9 D:8
Tie:14 Tie:8 Tie:9 Tie:9 Tie:9 Tie:9
sponds to some biological considerations — sorting out the features into pathways and for each
pathway, picking out sufficient number of genes to represent that pathway.
5.3.3 Classifiers versus feature selection
Here, we will discuss two issues: (1) which feature selection method is in favour of which clas-
sification algorithm, and (2) sensitivity of the classifiers to the feature selection methods. To
have an overall and intuitive feeling of the relationship between the performance of classifiers
and feature selection methods, for each of the classifiers, we count for each of the feature selec-






















































































(B) Hyperdip>50 subtype of pediatric ALL data
Figure 5.8: Plots of top number of features versus number of errors made on testing samples
of (A) ALL-AML leukemia data and (B) Hyperdip>50 subtype of pediatric ALL data. In (A),
mean-entropy and all-entropy selected 350 and 866 features from training data, respectively. In
(B), mean-entropy and all-entropy selected 328 and 914 features, respectively. The two plots on
the left side are drawn for four ensemble of decision trees classifiers while the two on the right
side are for SVM and 3-NN.
misclassified samples across the 20 validation tests on the six gene expression profiles and one
proteomic data set. The results are summarized in Table 5.32.
Now, we start to address the first issue. In terms of both total winning times and number
of misclassified samples, among eight feature selection methods, ERCOF is the best for SVM,
3-NN, Random forests and CS4. Besides, under ERCOF, Bagging achieved its smallest total
number of misclassified samples. AdaBoostM1 performed relatively better using top 20 features
selected by entropy measure, but compared with the other five classifiers, its performance is not
good. As mentioned earlier, the main reason might be that boosting loses its power of using multi-
ple decision trees when the single C4.5 tree has no error on training samples. When this happens,
boosting is equivalent to the single tree C4.5 method. Unfortunately, in high-dimensional data,
we often see that single C4.5 trees have perfect training accuracy. A special case is that there
are features having zero entropy value on training samples, such as lung cancer data and T-ALL,
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Table 5.32: A summary of the total winning times (including tie cases) of each classifier (under
different feature selection methods) across the 20 validation tests on the six gene expression
profiles and one proteomic data set. The number with bold font in each row indicates the feature
selection method that owns most winning times for the relevant classifier. In the brackets, there
is the total number of misclassified samples across the same 20 validation tests. Similarly, the
figure with bold font in the brackets in each row is the minimum number of total misclassified
samples among feature selection methods for the classifier.
Classifier All All-entropy Mean-entropy Top-number-entropy ERCOF
20 50 100 200
SVM 4(100) 9(52) 11(48) 6(76) 6(74) 11(52) 11(59) 16(38)
3-NN 1(187) 5(87) 8(77) 6(88) 4(81) 6(77) 5(73) 12(61)
Bagging 7(123) 5(117) 8(115) 11(123) 11(122) 7(122) 9(114) 8(112)
AdaBoostM1 5(191) 8(181) 8(166) 11(138) 10(144) 10(157) 9(162) 10(154)
RandomForests 0(228) 5(111) 5(93) 6(96) 7(83) 8(96) 5(90) 9(80)
CS4 5(87) 6(77) 6(76) 7(101) 10(81) 9(74) 8(74) 12(66)
E2A-PBX1 subtypes of pediatric ALL data.
Let’s move to the second issue. From Table 5.32, we observe that some classifiers are
sensitive to the feature selection. The good examples are SVM and k-NN — their classification
performances were improved significantly by using selected features; however, on the other hand,
they could not achieve good performance either if the feature space is too small. Thus, feature
selection is important to SVM and k-NN when dealing with high-dimensional biomedical data.
This conclusion is in consistent with the principles of the both algorithms that all the features are
used in the classification models. Again, ERCOF is a suitable feature selection method for these
two classifiers. Different from SVM and k-NN, decision tree methods do not use all the input
features in their classification models (i.e. decision trees) so that they are relatively not sensitive
to the feature selection. For example, Bagging and CS4 performed quite reasonably well on the
original intact data. As illustrated in Table 5.25, a decision tree often contains very few number
of features, say around 5 in each tree. We called these features as built-in features [65]. The
selection of these built-in features is dependent on the individual decision tree algorithms. For
example, information gain ratio measure is employed by C4.5, our base decision tree classifier.
This round of feature selection conducted by the classifier itself might be one of the main reasons
that classifiers based on decision tree are relatively resistant to other “pre-feature-selections”.
Nevertheless, properly selecting features can also help improve the performance of ensemble
of decision trees methods — Random forests and CS4 achieved very good classification results
using ERCOF selected features.
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5.4 Chapter Summary
In this chapter, we applied some entropy-based feature selection methods and classification tech-
niques to six gene expression profiles and one proteomic data. These data sets are described by at
least 2000 features and some of them are by more than 12,000 features. For each data set, we car-
ried out various experiments and compared our results with the published ones (where available).
The large amount of experimental results showed that in most of cases, our proposed methods
achieved comparable or better classification performance than those previously reported. Be-
sides, we also listed the good features (i.e. genes for all the data sets except ovarian disease)
identified by our method, compared them with literature, and related some of them with the dis-
ease studied. To emphasize the advantages of decision trees methods in bio-medical domain, we
presented many simple, explicit and comprehensible trees learned from the data.
We also addressed various comparisons among classifiers and feature selection methods. In
the aspect of classifiers, SVM demonstrated its power on classification accuracy and our ensem-
ble of decision trees method CS4 also achieved good results. Among the decision tree methods,
the performance of CS4 is superior to Bagging, AdaBoostM1 and Random forests. The main
advantage of CS4 over SVM is that its output is easy to be interpreted and applied to practical
disease diagnosis. We also clearly observed the performance improvements of all the classi-
fiers under the proposed feature selection scenarios. Among the various entropy-based feature
selection methods, ERCOF has demonstrated its efficiency and robustness when dealing with




Experiments on Microarray Data —
Patient Survival Prediction
In this chapter, a new computational process for patient survival prediction using microarray gene
expression data will be presented. Different from all previous works, in the first step, we carefully
form the training set samples by selecting only short-term survivors who died within a short
period and long-term survivors who were still alive after a relatively long follow-up time. This
idea is motivated by our belief that short-term and long-term survivors are more informative and
reliable (than those cases in between) for building and understanding the relationship between
genes and patient survival. In the second step, ERCOF is used to identify genes most associated
with survival. In the third step, a linear kernel support vector machine (SVM) is trained on the
selected samples and genes to build a scoring model. The model assigns each validation sample
a risk score to predict patient survival.
6.1 Methods
We will describe in detail the new method for patient survival prediction, focusing on selecting
an informative subset of training samples and building SVM-based scoring function.
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6.1.1 Selection of informative training samples
One of the main features of our new method is to select informative training samples. Since our
focus is on the relationship between gene expression and survival, the survival time associated
with each sample plays an important role here — two types of extreme cases, patients who died in
a short period (termed as “short-term survivors”) and who were alive after a long period (termed
as “long-term survivors”), should be more valuable than those in the “middle” status. Thus, we
use only a part of samples in training and this is clearly different from other approaches that use
all training samples.
Formally, for a sample T , if its follow-up time is F (T ) and its status at the end of follow-up
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are two thresholds of survival time for selecting short-term and
long-term survivors. Note that long-term survivors also include those patients who died after the
specified long period.




, can vary from disease to disease, from data set to data set.
For example, in the survival study of early-stage lung adenocarcinomas that will be presented
later, we choose short-term survivors as those who died within one follow-up year (i.e. 
1
is
1 year) and long-term survivors as those who were alive after five follow-up years (i.e. 
2
is 5
years). There are total 31 extreme training samples (10 short-term survivors and 21 long-term
survivors) among a total of 86 available primary lung adenocarcinomas. These 21 long-term
survivors include 2 patients whose status at the end of follow-up time was “dead”, but follow-up





are that the informative subset should (1) contain enough training samples for learning
algorithms to learn (typically >15 samples in each class and total is between one third and one
half of all available samples), but (2) not have too many samples to avoid including non-extreme
cases.
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After choosing informative training samples, we apply ERCOF to them to identify genes
most associated with survival status. With the selected samples and genes, in the next step, we
will build a scoring function to estimate the survival risk for every patient.
6.1.2 Construction of an SVM scoring function
The regression scoring function proposed for survival risk estimation is based on support vector
machines (SVM) described in Section 2.3.2 of Chapter 2. Recall that the final discriminant
function f(T ) for a test sample T given in Formula (2.3) of Chapter 2. If the linear kernel
function is used, f(T ) will become a linear combination of the expression values of the identified
genes. In this study, we map class label of “short-term survivors” to 1 and “long-term survivors”
to -1. Note that f(T ) > 0 if the sample T is more likely to be a “short-term survivor”, and
f(T ) < 0 if the sample T is more likely to be a “long-term survivor”.






Thus, f(T ) is normalized by s(T ) into the range (0; 1). Note that the smaller the s(T ) value is,
the better survival the patient corresponding to sample T will have. We term s(T ) the risk score
of T .
If one only categorizes patients into high risk or low risk groups, the value 0.5 is a natural
cutoff for s(T ), where if s(T ) > 0:5 then the patient corresponding to sample T will have higher
risk; otherwise, the patient will have lower risk. If more than two risk groups are considered —
such as high, intermediate, and low — then other cutoffs can be set based on the risk scores of
training samples. E.g., in training set, if most of short-term survivors have a risk score greater
than r
1













high risk, if s(T ) > r
1
low risk, if s(T ) < r
2
intermediate risk, if r
2







< 0:5, and they can be derived from the risk scores assigned to the
training samples.
To evaluate the results, after assigning patients into different risk groups, we draw Kaplan-
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Meier plots [8] to compare the survival characteristics between groups.
6.1.3 Kaplan-Meier analysis
Kaplan-Meier analysis estimates a population survival curve from a set of samples. A survival
curve illustrates the fraction (or percentage) survival at each time. Since in realistic clinical trial
it often takes several years to accumulate the patients for the trial, patients being followed for
survival will have different starting times. Then the patients will have various length of follow-up
time when the results are analysed at one time. Therefore, the survival curve can not be estimated
simply by calculating the fraction surviving at each time. For example, in the following study of
lung adenocarcinomas, the patients follow-up time is varying from 1.5 months to 110.6 months.
A Kaplan-Meier analysis allows estimation of survival over time, even when patients drop
out or are studied for different lengths of time [1]. For example, an alive patient with 3 years
follow-up time should contribute to the survival data for the first three years of the curve, but
not to the part of the curve after that. Thus, this patient should be mathematically removed from
the curve at the end of 3 years follow-up time and this is called “censoring” the patient. On a
Kaplan-Meier survival curve, when a patient is censored, the curve does not take a step down as
it does when a patient dies; instead, a tick mark is generally used to indicate where a patient is
censored and each death case after that point will cause a little bit larger step down on the curve.
An alternative way to indicate a censored patient is to show the number of remaining cases “at
risk” at several time points. Patients who have been censored or died before the time point
are not counted as “at risk”. In Figure 6.1, picture (A) is a complete sample of Kaplan-Meier
survival curve with a tick mark representing a censored patient (captured from http://www.
cancerguide.org/scurve_km.html), while picture (B) illustrates how to calculate the
fraction of survival at a time (captured from [1]).
To compare the survival characteristics between different risk groups for our survival pre-
diction study, we draw Kaplan-Meier survival curves of the risk groups in one picture and use
logrank test to compare the curves. The logrank test generates a p-value testing the null hypoth-
esis that the survival curves are no difference between two groups. The meaning of p-value is
that “if the null hypothesis is true, what is the probability of randomly selecting samples whose




Figure 6.1: Samples of Kaplan-Meier survival curves. (A) is an example of a Kaplan-Meier
survival curve. This group of patients has a minimum follow-up of a little over a year. (B) is an
illustration on how to calculate the fraction of survival at a time.
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Figure 6.2: A process diagram of patient survival study, including three training steps as well as
testing and results evaluation.
survival curves are generated by GraphPad Prism (http://www.graphpad.com) and we
always indicate the two-tailed p-value. Figure 6.2 shows a diagram of patient survival prediction
using our proposed method.
6.2 Experiments and Results
We apply the procedure of survival study above to two gene expression data sets.
6.2.1 Lymphoma
Survival after chemotherapy for diffuse large-B-cell lymphoma (DLBCL) patients was previ-
ously studied by Rosenwald et al [102] using gene expression profiling and Cox proportional-
hazards model. In that study, expression profiles of biopsy samples from 240 patients were
used [102]. The data include a preliminary group consisting of 160 patients and a validation
group of 80 patients, each of them is described by 7399 microarray features.
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Survival curves showing clear distinction
As an initial step, we pre-process the data to remove those genes that are absent in more than
10% of the experiments in the preliminary group. There remains 4937 features after having 2462
genes removed.
Then, we select short-term survivors and long-term survivors to construct an informative
subset of training samples. For this study, we set 
1
= 1 year and 
2
= 8 years in Formula
(6.1). Among the preliminary 160-patient group, 47 short-term survivors (who died within one
follow-up year) and 26 long-term survivors (who were alive after eight follow-up years) are thus
chosen. So, a total of 73 samples are in this informative subset of training samples (46% of the
preliminary group) .
In the second step, we apply ERCOF to these 73 samples and identify 78 genes that are
related to patient survival status at 5% significant level (for Wilcoxon rank sum test) and 0.99
Pearson correlation coefficient threshold. Some of our selected genes are also listed in Table 2
of [102], where these genes were found to be significantly associated with survival (p < 0:01).
E.g., AA805575 (GenBank accession number) is in germinal-center B-cell signature, X00452
and M20430 in MHC class II signature, and D87071 is in lymph-node signature. The gene
signatures were formed by a hierarchical clustering algorithm in [102]. Besides, some top-ranked
genes (with smaller entropy value) identified by ERCOF are also in one of these gene signatures.
E.g., BC012161, AF061729 and U34683 are in proliferation signature, BF129543 is in germinal-
center B-cell signature, and K01144 and M16276 are in MHC class II signature.
In the third step, an SVM model is trained on the 73 extreme training samples with the 78
identified features. We find that the well-learned linear kernel SVM can separate the 47 short-
term survivors and 26 long-term survivors completely — the lowest risk score assigned to the
short-term survivors is above 0.7 and most of the long-term survivors has risk score lower than
0.3. Then, we calculate risk scores for all the other samples, namely the remaining (non-extreme)
87 samples in the original preliminary group and the 80 samples in the validation group. These
167 samples are treated as our test set.
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(A) Test cases (p < 0:0001) (B) All cases (p < 0:0001)
Figure 6.3: Kaplan-Meier plots illustrate the estimation of overall survival among different risk
DLBCL patients in the testing set containing 167 samples (Panel (A)) and all 240 samples (Panel
(B)). The risk groups are formed on our SVM-based scoring function. A tick mark on the plot
indicates that one sample is censored at the corresponding time. The 5-year overall survival for
high risk versus low risk groups of patients for testing samples is 32% versus 91%, for all samples
is 20% versus 95%.
















high risk, if S(T ) > 0:7
intermediate-high risk, if 0:5 < S(T )  0:7
intermediate-low risk, if 0:3  S(T )  0:5
low risk, if S(T ) < 0:3
(6:4)
where the threshold 0.5 is the mean value of 0.7 and 0.3. The Kaplan-Meier curves of overall
survival are drawn in Figure 6.3, where we can see clear differences at the five-year survival rates
for the high risk and low risk groups, in both testing sample set (Panel (A)) and all samples (Panel
(B)). Although we cannot see distinct overall survival between the two intermediate groups, the
5-year survival rates of these two groups are obviously different from that in the high risk group
or the low risk group. This also suggests that three or two risk groups would be sufficient for
these DLBCL samples. So in the rest of this study, we simply merge high and intermediate-high
risk patients into a single high risk category, and low and intermediate-low risk patients into a
single low risk category.
Having the risk score, when a new case comes, we will be able to assign it to the corre-
sponding risk group easily. This kind of prediction was not addressed in [102] where the DL-
BCL patients were ranked by their gene-expression-based outcome-predictor score but divided
into several groups with equal number of samples. For an example: 80 samples in the validation
group were stratified according to the quartiles of the scores with each of quartiles consisting of
20 patients. With that kind of categorization, one cannot find an explicit measure to evaluate a
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new case.
Comparison with International Prognostic Index
Various clinical features — such as stage, performance status, lactate dehydroginase levels —
which are known to be strongly related to patient survival, have been combined to form the
International Prognostic Index (IPI) [113]. The IPI has been effectively adopted to separate
aggressive lymphomas into several groups with significantly different responses to therapy and
survival. Since IPI is only built on the consideration of clinical factors, it provides little insight
into disease biology [60].
The risk score obtained from our method is based on gene expression in biopsy specimens
of the lymphoma, so it is an independent predictor from IPI. In fact, we find that patients in the
high IPI group — and similarly for the intermediate and the low IPI groups — when partitioned
by our risk score into high risk and low risk categories, have significantly different outcomes.
In Figure 6.4, Kaplan-Meier plots show significant difference on overall survival for our high
risk and low risk groups among the patients with IPI low (and similarly for intermediate and
high) risk index. In particular, among 21 IPI high risk patients in our testing set, 15 of them are
assigned by our method to the high risk category and 6 of them to the low risk category. When
we check the survival status of these patients, we find 14 of the 15 patients belonging to our high
risk category are indeed dead while only 2 of the 6 patients belonging to our low risk category are
dead. Similarly, for all 32 patients in the whole data set with high IPI, 23 of them (22 dead) are
assigned by our method to the high risk category and 9 (5 dead) of them are assigned to low risk
category. This suggests that our method may be a more effective predictor of DLBCL survival
outcome than the IPI.
6.2.2 Lung adenocarcinoma
Adenocarcinoma is the major histological subtype of non-small cell lung cancer (NSCLC). There
is a need to better predict tumor progression and clinical outcome in lung adenocarcinoma. The
lung adenocarcinoma data set contains 86 primary lung adenocarcinomas. These experiments
include 67 stage I and 19 stage III tumors, each of them is described by 7129 genes. The data
set was first analysed in [14] where a risk index was derived based on the top 50 good genes
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(A) IPI low - test cases (p = 0:0063) (B) IPI intermediate - test cases (p = 0:0003)
(C) IPI high - test cases (p = 0:0195) (D) IPI low - all cases (p < 0:0001)
(E) IPI intermediate - all cases (p < 0:0001) (F) IPI high - all cases (p = 0:0182)
Figure 6.4: Kaplan-Meier Estimates of survival among high risk and low risk DLBCL patients
(according to our method) in each IPI defined group. Plots (A), (B) and (C) are based on 167
testing samples while (D), (E) and (F) are for all 240 cases.
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(A) Test cases (p = 0:0036) (B) All cases (p < 0:0001)
Figure 6.5: Kaplan-Meier plots illustrate the estimation of overall survival among high risk and
low risk lung adenocarcinoma patients in the testing set containing 55 samples (Panel (A)) and
all 86 samples (Panel (B)).
that were identified to be most related to survival by univariate Cox analysis. In that study, tests
were conducted by randomly splitting 86 samples into equal sized training and testing sets and
by “leave-one-out” cross validation.
First, we form our training set by setting 
1
= 1 year and 
2
= 5 years in Formula (6.1).
10 short-term survivors and 21 long-term survivors are thus chosen. Applying ERCOF to these
31 training samples, we find 402 genes that are related to outcome. Our top-ranked feature by
entropy measure, the ATRX gene, is a putative transcription regulator. It is also reported by
Borczuk et al in their recent paper [17] on NSCLC. Our second-ranked gene, ENPP2, is part of
stress pathways involved in oncogenesis. Yang et al [138] also detected it in NSCLC.
Then we train a linear kernel SVM to obtain the weight for each identified gene based on
the training data. The trained SVM can separate these 31 samples very well, assigning very high
risk scores to short-term survivors (lowest score is as high as 0.73) while very low risk scores to
long-term survivors (highest score is as low as 0.25).
After training, we calculate risk score for each of the remaining 55 samples which are used
for test purpose. These samples are then classified as high risk group consisting samples T with
s(T ) > 0:5, or as low risk group consisting samples T with s(T )  0:5. The Kaplan-Meier
curves in Figure 6.5 show clear difference of survival for patients in our high and low risk groups
for both testing cases and all cases. Since we pick out all short-term and long-term survivors
to form the training set, there is no “death” event happened in the first 12 months time and no
sample censored after 60 months time in the plot drawn only on the test cases (Panel (A)).
In order to understand the relationship between our prediction and tumor stage (I or III). We
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(A) Stage I - test cases (p = 0:0344) (B) Stage I - all cases (p < 0:0001)
(C) Stage III - test cases (p = 0:3007) (D) Stage III - all cases (p = 0:1622)
Figure 6.6: Kaplan-Meier plots illustrate the estimation of overall survival among high risk and
low risk lung adenocarcinoma patients conditional on tumor stage.
also draw Kaplan-Meier curves to delineate survival difference between our high and low risk
patients conditioned on tumor stage. From Figure 6.6, we can see that outcomes of patients with
stage I lung adenocarcinoma in our high and low risk groups differ from each other, for both test
cases (Panel(A)) and all cases (Panel(B)). Again remarkably, for 13 stage III cases in the testing
set, we assigned 11 (5 dead, 6 alive) of them to high risk group, and the 2 of them assigned to
low risk group were all alive at the end of the follow-up time. Among all 19 stage III cases, 17
(11 dead, 6 alive) of them were assigned to high risk group according to our risk score.
6.3 Discussions
In the step of training set construction, we select only two extreme cases — long-term and short-
term survivors. See Table 6.1 for size change trends from the original training samples to the
informative training samples on DLBCL and lung adenocarcinomas data sets. The figures illus-
trate that we used a small part of samples as training.
On the other hand, if we do not select those extreme cases, and instead use all available
training samples, then what will be the results? To illustrate this, we select genes and train SVM
model on the 160 samples in the preliminary group of DLBCL study. Although the training
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Table 6.1: Number of samples in original data and selected informative training set. (*):
there are 48 DLBCL samples, whose relevant patient was dead at the end of follow-up time,
are selected as informative, 47 of them are short-term survivors while 1 of them is long-term
survivor. (**): there are 12 lung adenocarcinomas, whose corresponding patients were dead,
are selected as informative, 10 of them are short-term survivors while 2 of them are long-term
survivors.
Application Data set Status Total
Dead Alive
DLBCL Original 88 72 160
Informative 47+1(*) 25 73
Lung Original 24 62 86
adenocarcinoma Informative 10+2(**) 19 31
(A) All genes (p = 0:21) (B) ERCOF selected genes (p = 0:38)
Figure 6.7: Kaplan-Meier plots illustrate no clear difference on the overall survival among high
risk and low risk DLBCL patients formed by the 80 validation samples based on their risk scores
that assigned by our regression model built on all 160 training samples. (A) Using all genes. (B)
Using genes selected by ERCOF.
accuracy is good, Kaplan-Meier plots do not show significant survival difference between the
high and low risk groups formed by the 80 validation samples based on their risk scores that
assigned by the trained SVM model. In detail, using all 4937 genes, the p value of the survival
curves is 0.21 ((A) in Figure 6.7); using 40 genes selected by ERCOF, the p value is 0.38 ((B) in
Figure 6.7). Therefore, we claim that our proposed idea of selecting informative training samples
is an effective method.










values in our study. In Table 6.2, p-value (of the logrank test) associated with





from DLBCL study are listed. All results are based on ERCOF selected genes. We can see
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greater than 8 years), we can
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(years) on DLBCL study. All results





p-value No. short-term survivors No. long-term survivors No. genes
1 5 0.2962 47 57 121
1 7 0.0110 47 36 79
1 8 0.0067 47 26 78
1 9 0.0570 47 22 40
2 8 0.0049 61 26 55
3 8 0.0761 76 26 51
achieve better predictions by selecting extreme samples. (2) A better p-value (0.0049) obtained
at 
1
=2 years and 
2
=8 years than that we reported in Section 6.2.1 for 
1
= 1 year and 
2
=
8 years. However, when we trace back to the risk scores of training samples, one of the long-
term survivors selected under 
1
=2 years and 
2
=8 years has a risk score as high as 0.73. In
addition, the number of selected short-term survivors is 2.4 times of the number of long-term




can be further refined by
running cross-validation on training samples.
In the step of gene identification, built on statistical knowledge, our three-phase filtering
process discards many unrelated genes and only keeps a small number of informative representa-
tives. According to our experience on gene expression data analysis, generally, entropy measure
can filter out about 90-95% of the total number of genes [64]. This point has been verified again
in this study on survival prediction: entropy measure retains only 132 genes in DLBCL study
(there are around 5000 genes after removing missing values) and 884 genes in lung adenocar-
cinoma study (original data contain 7129 genes). After further filtering by Wilcoxon rank sum
test and Pearson correlation coefficient test, the final selected genes are with smaller size and
less correlated with each other. Table 6.3 shows the number-change trend of features from the
entropy selection, to Wilcoxon test, and to correlation coefficient selection. It can be seen that
the feature reduction is mostly by the entropy selection.
For comparison, in DLBCL study, we also do experiments using all the 4937 genes, the 132
genes output from the Phase I of ERCOF, and the 84 genes output from the Phase II of ERCOF.
The results show that in each of these cases, the overall survival difference between the high
and low risk groups formed by our risk scores on the testing samples can be seen as well. In
Figure 6.8, we draw the corresponding Kaplan-Meier survival curves. Although the model built
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Table 6.3: Number of genes left after feature filtering for each phase of ERCOF. The percentage
in the brackets indicates the proportion of the remaining genes on original feature space. (*): the
number is after removing genes who were absent in more than 10% of the experiments.
Gene selection DLBCL Lung adenocarcinoma
Original 4937(*) 7129
Phase I 132 (2.7%) 884 (12.4%)
Phase II 84 (1.7%) 591 (8.3%)
Phase III 78 (1.6%) 402 (5.6%)
on 3-phase ERCOF makes use the smallest number of genes, it achieves best p value. Again, the
good results also demonstrate the effectiveness of selection the informative samples. In addition,
in the study of lung adenocarcinoma, using all genes (i.e. without gene selection) cannot predict
outcome at all (p > 0:1).
In the step of prediction, a simple linear kernel SVM is trained on the selected samples and
genes to build a regression model. The model then assigns each validation sample a risk score
to predict patient outcome. Based on the training results, we can derive explicit thresholds (e.g.,
0.5, 0.3, 0.7) of our risk score to categorize patients into different risk groups. Thus, when a new
case comes, we are able to assign it to the corresponding risk group easily according to its risk
score. This prediction ability is important in patient survival study.
For both studies on DLBCL and lung adenocarcinoma, we associate our results with some
clinical features. For example, in the DLBCL study, our high and low risk groups also demon-
strate significantly different outcomes in the analysis of patients with low or intermediate risk
according to their International Prognostic Index (IPI) scores constructed on some clinical fea-
tures. E.g., for patients having high IPI, we assign most of them into our high risk category and
some into our low risk category, and our assignment is better correlated to survival outcome of
these patients. Some of the genes identified to have strong association with survival by ERCOF
also fall within four biologic groups defined on the basis of gene expression signatures. In the
lung adenocarcinoma study, most of the samples are from stage I tumors. Among these sam-
ples, although our high and low risk groups differ significantly from each other, we put quite
a few of them into high risk group. This finding “indicates the important relationship between
gene expression profiles and patient survival, independent of disease stage”, which is one of the
conclusions drawn in [14].
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(A) All genes (p = 0:0095) (B) Genes of Phase I ERCOF (p = 0:0147)
(C) Genes of Phase II ERCOF (p = 0:009) (D) Genes of Phase III ERCOF (p = 0:0067)
Figure 6.8: Kaplan-Meier plots illustrate the estimation of overall survival among high risk and
low risk patients in the validation group of DLBCL study. (A) Using all 4937 genes. (B) Using
132 genes output from the Phase I of ERCOF. (C) Using 84 genes output from the Phase II of
ERCOF. (D) Using 78 genes output from the Phase III of ERCOF.
6.4 Chapter Summary
In this chapter, we have applied statistical and machine learning technologies to predict patient
survival using gene expression profiles. Different from other works, we first picked out extreme
cases to form the training set, consisting of only short-term survivors and long-term survivors.
Naturally, if there are genes indeed associated with outcome, then the different expression values
of these genes should be monitored by analysing these two types of samples. Secondly, ERCOF
was applied to the selected informative samples to identify genes most associated with survivals.
Thirdly, linear kernel SVM was trained on the selected samples and genes to form a regression
model, which can calculate a risk score to each sample. Our proposed methodology was tested
on two gene expression profiles: diffuse large-B-cell lymphoma and lung adenocarcinoma. For
both studies, the Kaplan-Meier plots showed clear survival difference on high and low risk group
patients that formed by the assigned risk scores.
126
Chapter 7
Recognition of Functional Sites in
Biological Sequences
Not all biomedical data contain explicit signals or features as those in the classification problems
arised by gene expression profilings. For example, DNA sequences and protein sequences rep-
resent the spectrum of biomedical data that possess no explicit features. Generally, a genomic
sequence is just a string consisting of the letters “A”, “C”, “G”, and “T” in a “random order”.
Yet a genomic sequence possesses biologically meaningful functional sites, which play impor-
tant roles in the process of protein synthesis from DNA sequences. Figure 7.1 shows a picture
of this process (captured from the “bioinformatics class notes” of Dr. Nina Rosario L. Rojas
at http://aegis.ateneo.net/nrojas/). This process can be divided into two stages:
transcription and translation.
1. Transcription. In this stage, the information in DNA is passed on to RNA. This takes place
when one strand of the DNA double helix is used as a template by the RNA polymerase
to create a messenger RNA (mRNA). Then this mRNA moves from the nucleus to the
cytoplasm. In fact, in the cell nucleus, the DNA with all the exons and introns of the gene
is first transcribed into a complementary RNA copy named “nuclear RNA” (nRNA). This
is indicated as “primary transcription” in the picture of Figure 7.1. Secondly, non-coding
sequences of base pairs (introns) are eliminated from the coding sequences (exons) by
RNA splicing. The resulting mRNA is the edited sequence of nRNA after splicing. The
coding mRNA sequence can be described in terms of a unit of three nucleotides called a
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Figure 7.1: Process of protein synthesis.
codon.
2. Translation. In this stage, the information that has been passed to RNA from DNA is used
to make proteins. At the initiation phase of translation, ribosome binds to the mRNA when
it reaches an AUG (adenine, uracil, guanine) sequence on the RNA strand in a suitable
context. The ribosome is made of protein and ribosomal RNA (rRNA). The start codon
AUG is called translation initiation site (TIS) and is only recognized by the initiator tRNA
(transfer RNA). After binding to the mRNA, the ribosome proceeds to the elongation phase
of protein synthesis by sequentially binding to the appropriate codon in mRNA to form
base pairs with the anticodon of another tRNA molecule. Hence, with the ribosome moving
from codon to codon along the mRNA, amino acids are added one by one, translated into
polypeptide sequences. At the end, the newly formed strand of amino acids (complete
polypeptide) is released from the ribosome when a release factor binds to the stop codon.
This is the termination phase of translation.
The functional sites in DNA sequences include transcription start site (TSS), translation
initiation site (TIS), coding region, splice site, polyadenylation (cleavage) site and so on that are
associated with the primary structure of genes. Recognition of these biological functional sites
in a genomic sequence is an important bioinformatics application [72].
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In order to apply traditional machine learning techniques to above functional sites recogni-
tion problem, we propose a 3-step work flow as follows. In the first step, candidate features are
generated using k-gram nucleotide acid or amino acid patterns and then sequence data are trans-
formed with respect to the newly generated feature space. In the second step, a small number of
good features are selected by a certain algorithm. In the third step, a classification model is built
to recognize the functional site.
7.1 Method Description
The first and the most important step of our method is to generate a new feature space under which
the original sequences can be transformed to the format to which general machine learning tools
can be easily applied.
7.1.1 Feature generation
We generate the new feature space using k-gram (k = 1; 2; 3; :::) nucleotide or amino acid pat-
terns. A k-gram is simply a pattern of k consecutive letters, which can be amino acid symbols
or nucleic symbols [143, 72]. We use each k-gram nucleotide or amino acid pattern as a new
feature. For example, nucleotide acid pattern “TCG” is a 3-gram pattern while amino acid pat-
tern “AR” is a 2-gram pattern constituted by an alanine followed by an arginine. Our aim is to
recognize functional site in a sequence by analysing k-gram patterns around it. Generally, up-
stream and down-stream k-gram patterns of a candidate functional site (for example, every ATG
is a candidate of translation initiation site) are treated as different features. Therefore, if we use
nucleotide patterns, for each k, there are 2 4k possible combinations of k-gram patterns; if we
use amino acid patterns, since there are 20 standard amino acids plus 1 stop codon symbol, there
are 2  21k possible k-gram patterns for each k. If the position of each k-gram pattern in the
sequence fragment is also considered, then the number of features will increase dramatically. We
call these features as position-specific k-gram patterns. Besides, k-gram can also be restricted
those in-frame ones.
The frequency of a k-gram pattern is used as the value of this feature. For example,
1. UP-X (DOWN-X), which counts the number of times the letter X appears in the up-stream
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(down-stream) part of a functional site in its nucleotide acid or amino acid sequence.
2. UP-XY (DOWN-XY), which counts the number of times the two letters XY appear as a
substring in the up-stream (down-stream) part of a functional site in its nucleotide acid or
amino acid sequence.
where X and Y range over the 4 nucleotide acid letters or the standard 20 amino acid letters and
the special stop codon symbol.
In the framework of the new feature space, the initial nucleotide sequences need to be
transformed. The transformation is constructed as follows. Given a DNA nucleotide sequence, a
sequence window is set aside for each candidate functional site with it in the center and certain
bases up-stream (named as up-stream window size) and certain bases down-stream (named as
down-stream window size). If a candidate functional site does not have enough up-stream or
down-stream context, we pad the missing context with the appropriate number of dont-care (“?”)
symbols.
If features are made from amino acid patterns, we will code every triplet nucleotides, at
both up-stream and down-stream of the centered candidate functional site in a sequence window,
into an amino acid using the standard codon table. A triplet that corresponds to a stop codon is
translated into a special “stop” symbol. Thus, every nucleotide sequence window is coded into
another sequence consisting of amino acid symbols and “stop” symbol. Then the nucleotide or
amino acid sequences are converted into frequency sequence data under the description of our
new features. Later, the classification model will be applied to the frequency sequence data,
rather than the original cDNA sequence data or the intermediate amino acid sequence data.
7.1.2 Feature selection and integration
In most cases, the number of candidate features in the feature space is relatively big. It is reason-
able to expect that some of the generated features would be irrelevant to our prediction problem
while others are indeed good signals to identify the functional site. Thus, in the second step,
feature selection is applied to the feature space to find those signals most likely to help in dis-
tinguishing the true functional site from a large number of candidates. Besides, feature selection
also greatly speeds up the classification and prediction process, especially when the number of
130
samples is large. Among the many feature selection techniques presented in Chapter 3, we em-
ploy the simple entropy measure (Section 3.2.4) in our following two applications. As used in
gene expression data analysis (with name “all-entropy”), we choose all the features whose value
range can be partitioned into intervals by Fayyad’s discretization algorithm [36] (Section 3.2.4
of Chapter 3).
To achieve the ultimate goal of predicting the true functional site, our next step is to integrate
the selected features by a classification algorithm. At this step, in the following two applications,
we will focus on the results achieved by support vector machines (SVM) (with linear or quadratic
polynomial kernel function) and our ensemble method CS4. Detailed techniques of SVM and
CS4 can be found in Section 2.3.2 and Section 2.3.4 of Chapter 2, respectively.
In the following two sections, we will make use of our proposed work flow to predict
translation initiation site and polyadenylation signals.
7.2 Translation Initiation Site Prediction
7.2.1 Background
The translation initiation site (TIS) prediction problem is about how to correctly identify TIS in
mRNA, cDNA, or other types of genomic sequences. At the translation stage of protein synthesis
process, in eukaryotic mRNA, the context of the start codon (normally “AUG”) and the sequences
around it are crucial for recruitment of the small ribosome subunit. Thus, the characterization
of the features around TIS will be helpful in a better understanding of translation regulation and
accurate gene predication of coding region in genomic and mRNA/cDNA sequences. This is an
important step in genomic analysis to determine protein coding from nucleotide sequences.
Since 1987, the recognition of TIS has been extensively studied using biological approaches,
data mining techniques, and statistical models [56, 57, 58, 89, 59, 103, 83, 145, 90, 48, 142]. Ped-
ersen and Nielsen [89] directly fed DNA sequences into an artificial neural network (ANN) for
training the system to recognize true TIS. They achieved a result of 78% sensitivity on start
ATGs (i.e. true TISs) and 87% specificity on non-start ATGs (i.e. false TISs) on a vertebrate
data set, giving an overall accuracy of 85%. Zien et al [145] studied the same vertebrate data
set, but replaced ANN with support vector machines (SVM) using different kinds of kernel func-
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tions. They believe that carefully designed kernel functions are useful for achieving higher TIS
prediction accuracy. One of their kernel functions is called “locality-improved” kernel, which
emphasizes correlations between any two sequence positions that are close together, and a span
of 3 nucleotides up- and down-stream is empirically determined as optimal. Recently, Hatzigeor-
giou [48] built a multi-step ANN system named “DIANA-TIS” to study the recognition problem.
This ANN system combines a consensus ANN and a coding ANN with the ribosome scanning
model. They obtained an overall accuracy of 94% on a data set containing full-length human
cDNA sequences. All of these methods use nucleotide sequence data directly; they do not gen-
erate any new and explicit features for the differentiation between true and false TISs.
There are some related works that use statistical features. The program ATGpr [103] uses
a linear discriminant function that combines some statistical features derived from the sequence.
Each of those features is proposed to distinguish true TIS from false TIS. In a more recent
work [83], an improved version of ATGpr called ATGpr sim was developed, which uses both
statistical information and similarities with other known proteins to obtain higher accuracy of
fullness prediction for fragment sequences of cDNA clones. In our previous study [72], the same
vertebrate data set was analyzed by generating features using nucleotide acid patterns.
7.2.2 Data
We collected three data sets for this study.
The first data set (data set I) is provided by Dr. Pedersen. It consists of vertebrate sequences
extracted from GenBank (release 95). The sequences are further processed by removing possible
introns and joining the remaining exon parts to obtain the corresponding mRNA sequences [89].
From these sequences, only those with an annotated TIS, and with at least 10 up-stream nu-
cleotides as well as 150 down-stream nucleotides are considered in our studies. The sequences
are then filtered to remove homologous genes from different organisms, sequences added multi-
ple times to the database, and those belonging to same gene families. Since the data are processed
DNA, the TIS site is ATG — that is, a place in the sequence where “A”, “T”, and “G” occur in
consecutive positions in that order. We are aware that some TIS sites may be non-ATG; however,
this is reported to be rare in eukaryotes [59] and is not considered in this study.
An example entry from this data set is given in Figure 7.2. There are 4 ATGs in this
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Figure 7.2: An example annotated sequence from data set I. The 4 occurrences of ATG are
underlined. The second ATG is the TIS. The other 3 ATGs are non-TIS. The 99 nucleotides
up-stream of the TIS are marked by an overline. The 99 nucleotides down-stream of the TIS
are marked by a double overline. The “.”, “i”, and “E” are annotations indicating whether the
corresponding nucleotide is up-stream (.), TIS (i), or down-stream (E).
example. The second ATG is the TIS. The other 3 ATGs are non-TIS (false TIS). ATGs to the
left of the TIS are termed up-stream ATGs. So the first ATG in the figure is an up-stream ATG.
ATGs to the right of the TIS are termed down-stream ATGs. So the third and fourth ATGs in the
figure are down-stream ATGs. The entire data set contains 3312 sequences. In these sequences,
there are a total number of 13375 ATGs, of which 3312 ATGs (24.76%) are true TISs, while
10063 (75.24%) are false. Of the false TISs, 2077 (15.5%) are up-stream ATGs.
The second data set (data set II) is provided by Dr. Hatzigeorgiou. The data collection
was first made on the protein database Swissprot. All the human proteins whose N-terminal
sites are sequenced at the amino acid level were collected and manually checked [48]. Then the
full-length mRNAs for these proteins, whose TIS had been indirectly experimentally verified,
were retrieved. The data set consists of 480 human cDNA sequences in standard FASTA format.
In these sequences, there are as many as 13581 false TIS, 96.59% of total number of ATGs.
However, only 241 (1.8%) of them are up-stream ATGs.
Besides these two data sets that have been analyzed by others, we also formed our own
genomic data set (data set III) by extracting a number of well-characterized and annotated human
genes of Chromosome X and Chromosome 21 from Human Genome Build30 [70]. Note that we
eliminated those genes that were generated by other prediction tools. The resulting set consists
of 565 sequences from Chromosome X and 180 sequences from Chromosome 21. These 745
sequences containing true TIS are used as positive data in our experiment. Meanwhile, in order
to get negative data, we extracted a set of sequences around all ATGs in these two chromosomes
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but excluded annotated ones.
7.2.3 Feature generation and sequence transformation
As every 3 nucleotides code for an amino acid, in this study, we use k-gram (k = 1; 2) amino
acid patterns as candidate features. Thus, there are 924 (= (21 + 212) 2) possible amino acid
patterns, i.e. new features.
In the sequence transformation, we set both up-stream window size and down-stream win-
dow size to 99 bases — given a cDNA or mRNA nucleotide sequence containing ATGs, a window
is set for each ATG with the ATG in the center and 99 bases up-stream and 99 bases down-stream
(excluding the ATG itself) aside. As such, for data set I, we get 3312 sequence windows contain-
ing true TIS and 10063 containing false TIS; for data set II, 480 sequence windows containing
true TIS and 13581 containing false TIS. All the windows have same size, i.e. containing 201
nucleotides. For ease of discussion, given a sequence window, we refer to each position in the
sequence window relative to the target ATG of that window. The “A” in the target ATG is num-
bered as +1 and consecutive down-stream positions — that is, to the right — from the target ATG
are numbered from +4 onwards. The first up-stream position — that is, to the left — adjacent
to the target ATG is –1 and decreases for consecutive positions towards the 5’ end — that is, the
left end of the sequence window [72]. These sequence windows containing nucleotide letters are
further transformed to amino acid sequences by coding every triplet nucleotides into an amino
acid or a stop codon. At last, the amino acid sequences are converted into frequency sequence
data under the description of feature space.
Apart from the k-gram amino acid patterns, we also derive three new features from some
known bio-knowledge: two are based on the famous Kozak’s consensus matrix and one is on the
scanning model. From the original work for the identification of the TIS in cDNA sequences,
Kozak developed the first weight matrix from an extended collection of data [56]. The consensus
motif from this matrix is GCC[AG]CCATGG, where (1) a G residue tends to follow a true TIS,
which indicates that a “G” appears in position +4 of the original sequence window; (2) a purine
(A or G) tends to be found 3 nucleotides up-stream of a true TIS, which indicates that an “A” or
a “G” appears in position -3 of the original sequence window. Also, according to the ribosome
scanning model [27, 57, 4], an mRNA sequence is scanned from left (5’) to right (3’), and the
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scanning stops as soon as an ATG is recognized as TIS. The rest of the ATGs in the mRNA
sequence to the right of this ATG are then treated as non-TIS. To incorporate these knowledge
to our feature space, we add three Boolean features “DOWN4-G”,“UP3-AorG” and “UP-ATG”.
Here, UP-ATG means whether an in-frame up-stream ATG exists. In a nucleotide sequence
window extracted for each candidate TIS, we call those 3-grams in positions   , -9, -6, and -3,
the in-frame up-stream 3-gram patterns; and those 3-grams in positions +4, +7, +10,   , the
in-frame down-stream 3-gram patterns. Finally, there are 927 features in the new feature space.
After this process of feature generation and data transformation, we get 3312 true TIS
samples and 10063 false TIS samples from data set I, 480 true TIS samples and 13581 false
TIS samples from data set II. Each sample is a vector of 924 integers and three boolean values.
Figure 7.3 presents a diagram for the data transformation with respect to our new feature space.
7.2.4 Experiments and results
To verify the effectiveness of our method from different aspects, we designed a series of experi-
ments on the three data sets:
a. Conducting computational cross validations in data set I and data set II separately.
b. Selecting features and building classification model using data set I. Applying the well-
trained model to data set II to obtain a blind testing accuracy.
c. Incorporating the idea of ribosome scanning into the classification model.
d. Applying the model built in experiment-b to genomic sequences.
Validation in different data sets
To strictly compare with the results presented in [142, 72], we conduct the same 3-fold cross
validation. Table 7.1 shows our results on the data set I and data set II using the features selected
by the entropy-based algorithm. With the simple linear kernel function, SVM achieves accuracy
of 92.04% at 81.13% sensitivity and 95.63% specificity on data set I. This is better than the
accuracy of 89.4% at 74.0% sensitivity and 94.4% specificity, which is the previous best result
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1, 3, 5, 0, 4, … 6, 2, 7, 0, 5, … N, N, N, False
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Figure 7.3: A diagram for data transformation aiming for the description of the new feature
space.
63.33% sensitivity and 99.66% specificity. Note that we can not find previously reported results
on this data set under similar cross validation.
Validation across two data sets
The good cross validation results achieved within the individual data set encourage us to extend
our study to span the two data sets. In this experiment, we use the whole data set I as training
data to select features and build the classification model, then we evaluate the well-trained model
on data set II to get a test accuracy.
To reduce the similarity between the training and testing data, a BLAST search between the
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Table 7.1: The results by 3-fold cross validation on the two data sets (experiment-a).
SVM(linear/quad) means the classification model is built by linear/quadratic polynomial kernel
function.
Data Algorithm Sensitivity Specificity Precision Accuracy
I SVM(linear) 81.13% 95.63% 85.93% 92.04%
SVM(quad) 80.19% 96.17% 87.34% 92.22%
CS4 76.18% 96.14% 86.67% 91.20 %
II SVM(linear) 63.33% 99.66% 86.86% 98.42%
SVM(quad) 71.25% 99.42% 81.24% 98.46%
CS4 83.54% 97.67% 55.93% 97.19%
Table 7.2: Classification accuracy when using data set I as training and data set II as testing
(experiment-b). The row of II** is the testing accuracy on data set II before similar sequences
being removed.
Data Algorithm Sensitivity Specificity Precision Accuracy
I (train) SVM(linear) 80.68% 96.75% 89.10% 92.77%
SVM(quad) 86.05% 98.14% 93.84% 95.15%
CS4 85.54% 97.91% 93.10% 94.85%
II (test) SVM(linear) 96.28% 89.15% 25.31% 89.42%
SVM(quad) 94.14% 90.13% 26.70% 90.28%
CS4 92.02% 92.71% 32.52% 92.68%
II** (test) SVM(linear) 95.21% 89.74% 24.69% 89.92%
SVM(quad) 94.38% 89.51% 24.12% 89.67%
CS4 87.70% 93.26% 28.60% 92.11%
data set I and II is performed. Two sequences are considered similar if they produce a BLAST
hit with an identity > 75%. We find 292 similar sequences and removed them from data set II.
As a result, after being removed similar sequences, data set II contains 188 real TIS, while there
are total number of 5111 candidates [70].
We train SVM model on data set I and obtain training accuracy 92.77% at 80.68% sensi-
tivity and 96.75% specificity. Using this model, we get a test accuracy of 89.42% at 96.28%
sensitivity and 89.15% specificity on data set II. We note that the testing accuracy on the original
data set II (without the removal of the similar sequences) is quite similar. See Table 7.2 for a
summary of these results.
Remarkably, this cross-validation spanning the two data sets achieves a much better sensi-
tivity on data set II than that obtained in the 3-fold cross-validation on this data set. A reason
may be that only 3.41% of candidate ATGs in data set II are true TISs, which leads to an ex-
tremely unbalanced numbers of samples between the two classes. However, this bias is rectified
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significantly by the model built on data set I where the population size of true TIS versus false
TIS is more balanced.
Incorporation of scanning model
Hatzigeorgiou [48] reported a high accuracy on data set II by an integrated method which com-
bines a consensus ANN with a coding ANN together with a ribosome scanning model. The
model suggests to scan from the 5’ end of a cDNA sequence and predicts TIS at the first ATG in
a good context [27, 57, 4]. The rest of the ATGs in the cDNA sequence to the right of this ATG
are then automatically classified as non-TIS. Thus, one and only one ATG is predicted as TIS per
cDNA sequence.
We also incorporate this scanning model into our experiment. This time, in a sequence,
we test ATGs in turn from left to right, until one of them is classified as TIS. A prediction on a
sequence is correct if and only if the TIS itself is predicted as a TIS. Since the scanning model
indicates that the first ATG that in an optimal nucleotide context would be TIS, a higher prediction
accuracy is expected if only up-stream ATGs and true TIS are used in training. Thus, we ignore
all down-stream ATGs in data set I and obtain a new training set containing only true TISs and
their up-stream ATGs. Then feature selection and classification model learning are based on this
new training data. Table 7.3 shows our results with scanning model being used.
Under this scanning model idea, Artemis reported that 94% of the TIS were correctly pre-
dicted on data set II [48]. As mentioned in her paper [48], the data set was split into training and
testing parts in some way, the results reported there are not directly comparable with our results.
Testing on genomic sequences
In order to further evaluate the feasibility and robustness of our method, we apply our model
built in experiment-b to our own prepared data (data set III), which contain gene sequences of
Chromosome X and Chromosome 21. Using the simple linear kernel function, SVM gives 397
correct prediction out of a total of 565 true TISs found in Chromosome X while 132 correct
prediction out of a total of 180 true TISs in Chromosome 21. The sensitivities are 70.27% and
73.33%, respectively. To obtain the specificity of our models, we randomly select the same
number of sequences containing non-start ATGs (false TIS) from our own extracted negative
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Table 7.3: Classification accuracy under scanning model when using data set I (3312 sequences)
as training and data set II (188 sequences) as testing (experiment-c). The row of II** is the
testing accuracy on data set II before similar sequences being removed (480 sequences). NoCor-
rectlyPredicted is the number of sequences whose TIS is correctly predicted.
Data Algorithm NoCorrectlyPredicted Accuracy
I SVM(linear) 3161 95.44%
(train) SVM(quad) 3156 95.29%
CS4 3083 93.09%
II SVM(linear) 174 92.55%
(test) SVM(quad) 172 91.49%
CS4 176 93.62%
II** SVM(linear) 453 94.38%

















Figure 7.4: ROC curve of SVM and CS4 on prediction TIS in genomic data Chromosome X and
Chromosome 21 (experiment-d). The SVM model is built on the linear kernel function. The area
under the ROC curve: SVM 0.837, CS4 0.772.
data set. SVM correctly predicts 626 of these 745 non-start ATGs, obtaining a specificity at
84.02%. In the same test, CS4 achieves 52.48% sensitivity and 89.80% specificity. One point
needs to be addressed here is that in this validation, we remove the feature built on the ribosome
scanning model since that model is not true for genomic data. To illustrate the tradeoff between
the prediction sensitivity and specificity, Figure 7.4 gives the ROC curves of SVM and CS4




“What are the key features to predict TIS?” To answer this question, let us have a look of an
interesting discovery on the features selected in the 3-fold cross validation on data set I in our
experiment-a. Table 7.4 shows the ranking positions of the 10 top-ranked features based on their
entropy value for the each fold. Observe that they are the same features though their ordering is
slightly different from one fold to another. This suggests that these features, or exactly amino acid
patterns, are indeed patterns around true or false TISs. Furthermore, “UP-ATG” can be explained
by the ribosome scanning model [27, 4] — seeing such an up-stream ATG makes the candidate
ATG less likely to be the TIS. “DOWN-STOP” is the in-frame stop codons down-stream from
the target ATG and it is consistent with the biological process of translating in-frame codons
into amino acids stops upon encountering an in-frame stop codon — seeing such a down-stream
stop codon makes the candidate protein improbably short. “UP3-AorG” is correspondence to the
well-known Kozak consensus sequence [56]. Most of the other features were also identified in
our previous study [142], in which the feature space is built directly on nucleotides. Remarkably,
these amino acid patterns, except “DOWN-L”, all contain “G” residue. Note also that “UP-M”
is one of the top features in each fold, but we exclude it as it is redundant given that UP-ATG is
true if and only if UP-M > 0. The significance of these features is further verified when we find
that both sensitivity and specificity drop down greatly if these features are all excluded from the
classification model. However, we do not observe obvious decrease when we remove any one of
them from the model. This may suggest that in real biological process of translation there are
some factors other than Kozak consensus that may regulate the recognition of TIS.
In addition to the result when only selected features are used, we also obtain cross-validation
results on the whole feature space (i.e. without feature selection). We find that using the whole
feature space can not let us achieve better results on all of our experiments. For example, SVM
with linear kernel function achieves accuracy 90.94% at 79.86% sensitivity and 94.58% speci-
ficity for data set I when running 3-fold cross validation on data set I. This result is not as good
as that on the selected features.
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Table 7.4: Ranking of the top 10 features based on their entropy value as relevant in each of
the 3 folds of data set I. Feature “UP-ATG” indicates whether an in-frame up-stream ATG exists
(boolean type). Feature “UP3-AorG” tests whether purine A or G tends to be found 3 nucleotides
up-stream of a true TIS (boolean type). Feature “UP(DOWN)-X” counts the occurrence that an
in-frame (relative to the candidate ATG) triplet coding for the amino acid letter X appears in the
up-stream (down-stream) part of a candidate ATG. Feature “DOWN-STOP” is the occurrence of
in-frame stop codons down-stream of a candidate ATG.
Fold UP- DOWN- UP3- DOWN- DOWN- UP- DOWN- DOWN- DOWN- UP-
ATG STOP AorG A V A L D E G
1 1 2 4 3 6 5 8 9 7 10
2 1 2 3 4 5 6 7 8 9 10
3 1 2 3 4 5 6 8 9 7 10
Classification algorithms
For the classification methods, overall speaking, SVM performs slightly better than our CS4
method, in terms of prediction accuracy. However, CS4 achieves very good sensitivity when
running 3-fold cross validation on data set II where the number of true TISs is much less than the
number of false TISs. On the prediction of TIS in genomic sequences, the performance of CS4
is close to that of SVM. This can be illustrated by the ROC curves drawn in the Figure 7.4 — the
areas under the curves are SVM 0.837 and CS4 0.772, respectively. Besides, decision trees can
output comprehensive rules to disclose the essence of learning and prediction. Some discovered
interesting and biologically sensible rules with large coverage are listed below.
1. If UP-ATG=‘Y’ and DOWN-STOP>0, then prediction is false TIS.
2. If UP3-AorG=‘N’ and DOWN-STOP>0, then prediction is false TIS.
3. If UP-ATG=‘N’ and DOWN-STOP=0 and UP3-AorG=‘Y’, then prediction is true TIS.
On the other hand, in our series of experiments, SVM built on quadratic polynomial ker-
nels do not show much advantage over those built on simple linear kernel functions. Note that
quadratic kernels need much more time on training process.
Comparison with model built on nucleotide acid patterns
In [142], data set I was studied using k-gram nucleotide acid patterns and several classification
methods including SVMs, Naive Bayes, Neural Network and decision tree. In that study, feature
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selection was also conducted, but by CFS (Correlation-based Feature Selection) which is intro-
duced in Section 3.2.6 of Chapter 3. The best accuracy achieved on the 3-fold cross validation
was 89.4% at 74.0% sensitivity and 94.4% specificity when some 3-gram nucleotide acid pat-
terns were used. This result is not as good as that presented in this section — 92.45% accuracy
at 80.19% sensitivity and 96.48% specificity. However, the good features selected by these two
experiments are highly consistent. Besides those 3 features built on bio-knowledge, CFS picked
out down-stream TAA (stop codon), TAG (stop codon), TGA (stop codon), CTG (amino acid
L), GAC (D), GAG (E) and GCC (A). If we code these 3-gram nucleotide patterns into 1-gram
amino acid patterns, we will find they are all among the best features listed in Table 7.4. On
the other hand, although there are no 2-gram amino acid patterns among the 10 best features in
Table 7.4, some of them are indeed included in the set of selected features that has been used to
achieve better results in this study. Note that, our previous study [142] also illustrated that using
4-gram, 5-gram nucleotide acide patterns could not help improve the prediction performance.
Comparison with ATGpr
As mentioned earlier, ATGpr [103, 83] is a TIS prediction program that makes use of a linear
discriminant function, several statistical measures derived from the sequence and the ribosome
scanning model. It can be accessed via http://www.hri.co.jp/atgpr/. When search-
ing TIS in a given sequence, the system will output several (5 by default) ATGs in the order of
decreasing confidence. Let us take the ATG with highest confidence as TIS. Then for the 3312
sequences in our data set I, ATGpr can predict correctly true TIS in 2941 (88.80%) of them. This
accuracy is 6.64% lower than that we achieved. For our data set II, true TIS in 442 (92.0%) of
480 sequences are properly recognized, which is about 2.38% lower than the accuracy obtained
by us. Our results quoted here are based on SVM model using the linear kernel function.
When we feed the genomic data used in our experiment-d to ATGpr, the program gives cor-
rect TIS predictions on 128 (71.11%) of 180 Chromosome 21 gene sequences and 417 (73.81%)
of 565 Chromosome X gene sequences, giving the overall sensitivity as 73.15%. On the other
hand, ATGpr achieves 70.47% prediction accuracy on the same number of negative sequences
that were used in our experiment-d. From the ROC curves shown in Figure 7.4, we can find our
prediction specificities are around 80% (SVM) and 73% (CS4) when sensitivity is 73.15% —
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9.5% and 2.5% higher than that of ATGpr on specificity. This indicates that our program may
also outperform ATGpr when dealing with genomic data sequences.
7.3 Polyadenylation Signal Prediction
7.3.1 Background
The general polyadenylation machinery of mammalian cells has been well studied for decades.
The polyadenylation (poly(A)) reaction of mammalian pre-mRNAs proceeds in two phases: the
cleavage of pre-mRNA and the addition of poly(A) tail to the newly formed 3’ end. The cleav-
age reaction requires the cleavage/poly(A) specificity factor (CPSF), the cleavage stimulation
factor (CStF), the cleavage factors I and II (CF I and CF II), and poly(A) polymerase (PAP) in
most cases. CPSF, PAP and poly(A) binding protein 2 are involved in poly(A) [144]. The as-
sembly of the cleavage/poly(A) complex, which contains most or all of the processing factors
and the substrate RNA, occurs cooperatively. CPSF consists of four subunits and binds to the
highly conserved AAUAAA hexamer up-stream of the cleavage site. CStF, which is necessary
for cleavage but not for the addition of poly(A) tail, interacts with the U/GU rich element located
down-stream of the AAUAAA hexamer. Two additional factors, the cleavage factor I and II (CF
I and CF II) act only in the cleavage step. CF I has been purified to homogeneity and shown to
be an RNA-binding factor. CF II has been only partially purified so far, and its function is not
known.
After the formation of the cleavage/polyadenylation complex, the selection of poly(A) site
is primarily determined by the distance between a hexameric poly(A) signal (PAS) of sequence
AAUAAA (or a one-base variant) and the down-stream element(denoted as DSE). The spacing
requirements for the PAS and DSE reflect the spatial requirements for a stable interaction be-
tween CPSF and CStF. The DSE is poorly conserved and two main types have been described
as a U-rich, or GU-rich element, which locates 20 to 40 bases down-stream of the cleavage site
(for reviews, please refer to [28, 144, 141]). DSE is present in a large proportion of genes and
can affect the efficiency of cleavage [75, 141]. Although in a few cases, an up-stream element
(denoted as USE) is required for the poly(A) signal to be fully activated [5, 18, 79], the position
and sequence of the USE are undefined. In summary, the organization of mammalian poly(A)
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Figure 7.5: Schematic representation of PAS in human mRNA 3’end processing site. Distances
are as described in [28].
sites may have an unexpected flexibility and their activity depends on not only the hexameric
signal but also the up/down elements. Figure 7.5 is a schematic representation of PAS in human
mRNA 3’end processing site [144].
There are several software programs that have been developed to detect PASes in human
DNA and mRNA sequences by analysing the characteristics of up-stream and down-stream se-
quence elements around PASes. In one of early studies, Tabaska and Zhang [119] developed
a program named Polyadq, which finds PASes using a pair of quadratic discriminant functions.
Besides, they also created a database of known active poly(A) sites and trained their program on
280 mRNA sequences and 136 DNA sequences. In their tests of finding PASes, they claimed a
correlation coefficient of 0.413 on whole genes and 0.512 in the last two exons of genes. Polyadq
is available at http://argon.cshl.org/tabaska/polyadq_form.html. Recently,
Legendre and Gautheret [61] used bioinformatics analysis of EST and genomic sequences to
characterize biases in the regions encompassing 600 nucleotides around the cleavage site. The
computer program they developed is called Erpin which uses 2-gram position-specific nucleotide
acid patterns to analyse 300 bases up-stream and down-stream region of a candidate PAS. Being
trained by 2327 terminal sequences, Erpin was reported to achieve a prediction specificity of
75.5% to 90.4% for a sensitivity of 56% on several sets of validation data. The program can be
found at http://tagc.univ-mrs.fr/pub/erpin/.
In this study, we will apply our method to characterize the features in the regions encom-
passing 200 nucleotides around the PAS, i.e. with PAS in the centre and both up-stream window
size and down-stream window size as 100 bases.
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7.3.2 Data
In a series of experiments, a large number of sequences are used to train and test our classification
model. They are from two sources.
(1) Training and testing sequences used by program Erpin [61]. The training set contains 2327
terminal sequences including 1632 “unique” and 695 “strong” poly(A) sites. The testing
set consists of 982 positive sequences containing annotated PASes from EMBL and four
sets of same sized negative sequences: 982 CDS sequences, 982 intronic sequences of the
first intron, 982 randomized UTR sequences of same 1st order Markov model as human
3’ UTRs, and 982 randomized UTR sequences of same mono nucleotide composition as
human 3’ UTRs. The 2327 training sequences can be downloaded from http://tagc.
univ-mrs.fr/pub/erpin/ and have been trimmed in accordance to our window
segments i.e. every sequence contains 206 bases, having a PAS in the center. We obtained
testing data sets from Dr Gautheret via personal communication.
(2) Human RefSeq mRNA data set: we obtained 312 human mRNA sequences from RefSeq
[94] release 1. Each of these sequences contains a “polyA-signal” feature tag carrying an
“evidence=experimental” label. We use these sequences to build model for PAS prediction
in mRNA sequences. Besides, we also extracted a set of human mRNA sequences from
RefSeq containing a “polyA-site” feature tag carrying an “evidence=experimental” label.
In this set, we removed the sequences that have been included in the training set used
in building our model. We use these sequences for testing purpose assuming that the
annotated PAS positions are correct. Our negative data set was generated by scanning for
the occurrences of AATAAA at coding region and those AATAAA sites near the end of
sequence were excluded purposely.
7.3.3 Experiments and Results
First, we use simple 1-gram, 2-gram and 3-gram nucleotide acid patterns to construct feature
space [69]. Thus, there are 168 (= (4 + 42 + 43) 2) features.
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Table 7.5: Validation results by different programs on a set of 982 annotated UTR sequences
from the EMBL database [61]. TP is the number of true positives. FN is the number of false
negatives.
Program TP FN Sensitivity
Erpin 549 433 55.9%
Polyadq 547 435 55.7%
Ours 553 429 56.3%
Preliminary results
In the first experiment, we use the 2327 sequences introduced in [61] (data source (1)) as our
true PAS training data. To obtain negative sequences, same sized false PAS data is randomly
selected from our own extracted negative data set (data source (2)). Using entropy-based feature
selection algorithm and linear kernel SVM classifier, the sensitivity and specificity of 10-fold
cross-validation on training data are 89.3% and 80.5%, respectively. In order to compare with
other programs, we test our model on the same validation sets whose testing results on programs
Erpin and Polyadq were reported in [61]. As described in data source (1) , these validation sets
include true PASes sequences came from 982 annotated UTRs and four same sized control sets
known not to contain PASes: coding sequences (CDS), introns and randomized UTRs (simply
shuffled UTRs and 1st order Markov model UTRs). For a direct comparison, we also adjust the
prediction sensitivity on the 982 true PASes to around 56.0% so that evaluation can be made on
the predictions for those four control sets.
Table 7.5 shows the validation results on true PASes and Table 7.6 illustrates the results on
four control sets. Figure 7.6 is the ROC curve for this series of tests. All the numbers regarding to
the performance of programs Erpin and Polyadq in Table 7.5 and Table 7.6 are copied or derived
from [61]. The results in Table 7.6 demonstrate that our model can give better performance than
Erpin and Polyadq did on false PASes prediction of CDS, intron and simple shuffling sequences,
and almost same prediction accuracy on sequences with 1st order Markov randomization.
In this experiment, we select 113 features via entropy measure. These features are then
integrated with SVM to form the classification and prediction model. Table 7.7 lists the top
10 of these features ranking by their entropy values (the less the entropy value is, the more
important the feature is). Some of these top features can be interpreted by those reported motifs,
for example, it clearly visualizes both USE and DSE as characterized by G/U rich segments since
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Table 7.6: Validation results by different programs on different sequences not contain-
ing PASes: coding sequences (CDS), introns, and two types of randomized UTR se-
quences (simple shuffling and 1st order Markov simulation) [61]. TN is the number of





. Calculations of Precision and CC use TP and
FN from Table 7.5.
Data set Program TN FP Specificity Precision CC
CDS Erpin 880 102 89.6% 84.3% 0.483
Polyadq 862 120 87.8% 82.0% 0.459
Ours 887 95 90.3% 85.4% 0.497
Introns Erpin 741 241 75.5% 69.5% 0.320
Polyadq 718 264 73.1% 67.5% 0.293
Ours 775 207 78.9% 72.8% 0.363
Simple shuffling Erpin 888 94 90.4% 85.4% 0.494
Polyadq 826 156 84.1% 77.8% 0.415
Ours 942 40 95.9% 93.3% 0.570
Markov 1st order Erpin 772 210 78.6% 72.3% 0.354
Polyadq 733 249 74.6% 68.7% 0.309


















Figure 7.6: ROC curve of our model on some validation sets described in [61] (data source (1)).
UP-TGT, UP-T, DOWN-TGT, DOWN-T, UP-TG and UP-TT are among top features.
Model for prediction PAS in mRNA sequences
When we apply our model to 312 true PASes that were extracted from mRNA sequences by
ourselves (data source (2)), the results obtained are not good — only around 20% of them can
be predicted correctly. Besides, the program Erpin performs even worse on these PASes — with
prediction accuracy at only 13%. These poor results may indicate that the good features used
in the model for PAS prediction in DNA sequences are not efficient for mRNA. Therefore, we
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Table 7.7: The top 10 features selected by entropy-based feature selection method for PAS clas-
sification and prediction in human DNA sequences.
Rank 1 2 3 4 5 6 7 8 9 10
Feature UP DOWN UP UP DOWN DOWN UP UP DOWN UP
-TGT -A -T -AG -TGT -T -TG -TT -AA -A
decide to build another model for mRNA sequences without poly(A) tails. This model is also
expected to provide a new way for predicting the mRNA cleavage site/poly(A) addition site.
Since the new model is aimed to predict PASes from mRNA sequences, we only consider
the up-stream elements around a candidate PAS. Therefore, there are only 84 features (instead
of 168 features). To train the model, we use 312 experimentally verified true PASes and same
number of false PASes that randomly selected from our prepared negative data set. The validation
set comprises 767 annotated PASes and same number of false PASes also from our negative data
set but different from those used as training (data source (2)). This time, we achieve reasonably
good results. Sensitivity and specificity for 10-fold cross-validation on training data are 79.5%
and 81.8%, respectively. Validation result is 79.0% sensitivity at 83.6% specificity. Besides, we
observe that the top ranked features are different from those listed in Table 7.7 (detailed features
not shown).
Since every 3 nucleotides code for an amino acid when DNA sequences translate to mRNA
sequences, it is legitimate to investigate if an alternative approach that generating features based
on amino acids can produce more effective PASes prediction for mRNA sequence data. In fact,
this idea is also encouraged by the good results we achieved in the TIS prediction described in
the previous section.
Similarly as what we did in TIS prediction, we transform the up-stream nucleotides of a
sequence window set for each cadidate PAS into an amino acid sequence segment by coding
every triplet nucleotides as an amino acid or a stop codon. The feature space is constructed by
using 1-gram and 2-gram amino acid patterns. Since only up-stream elements around a candidate
PAS are considered, there are 462 (= 21+212) possible amino acid patterns. In addition to these
patterns, we also present existing knowledge via an additional feature — denoting number of T
residue in up-stream as “UP-T-Number”. Thus, there are 463 candidate features in total.
In the new feature space, we conduct feature selection and train SVM on 312 true PASes














Figure 7.7: ROC curve of our model on PAS prediction in mRNA sequences.
sensitivity with 94.1% specificity. When apply the trained model to our validation set contain-
ing 767 true PASes and 767 false PASes, we achieve 94.4% sensitivity with 92.0% specificity
(correlation coefficient is as high as 0.865). Figure 7.7 is the ROC curve of this validation. In
this experiment, there are only 13 selected features and UP-T-Number is the best feature. This
indicates that the up-stream sequence of PAS in mRNA sequence may also contain T-rich seg-
ments. However, when we apply this model built for mRNA sequences using amino acid patterns
to predict PASes in DNA sequences, we can not get as good results as that achieved in the pre-
vious experiment. This indicates that the down-stream elements are indeed important for PAS
prediction in DNA sequences.
7.4 Chapter Summary
In this chapter, we proposed a machine learning methodology to identify functional site in biolog-
ical sequences. Our method comprises three sequential steps: (1) generating candidate features
using k-gram nucleotide acid patterns or amino acid patterns and then transforming original se-
quences respect to the new generated feature space; (2) selecting relevant features using certain
feature selection algorithm; and (3) building classification model to recognize the functional
site by applying classification techniques to the selected features. Our idea is different from
traditional methodologies because it generates new features and also transforms the original nu-
cleotide sequence data to k-gram frequency vectors. The feature selection step does not only
greatly shorten the running time of classification program, but also help to obtain explicit impor-
tant features around the functional site and lead to a more accurate prediction.
We applied our idea to predict translation initiation site (TIS) and polyadenylation signal
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(PAS) in DNA and mRNA sequences. For each application, both public data sets and our own
extracted sequences were used to test the effectiveness and robustness of the method. The ex-
perimental results achieved are better than those reported previously using the same data sets (if
available). The important features captured are highly consistent with those reported in the lit-
erature. Most importantly, we not only conducted the cross validation within the individual data
sets separately, but also established the validation across the different data sets. The success of
such a validation indicates that there are predictable patterns around TIS or PAS.
In addition, a web-based toolbox to recognize TIS and PAS from DNA sequences has been
implemented based on the techniques presented in this chapter. This toolbox is named as DNAF-





This thesis is about how to effectively apply data mining technologies to biological and clinical
data. Some problems arising from gene expression profilings and DNA sequence data are stud-
ied in depth using data mining techniques of feature generation, feature selection, and feature
integration with learning algorithms.
In order to identify genes associated with disease phenotype classification or patient sur-
vival prediction from gene expression data, a new feature selection strategy, ERCOF (Entropy-
based Rank sum test and COrrelation Filtering), is worked out by combining entropy measure,
Wilcoxon rank sum test and Pearson correlation coefficient test. ERCOF conducts three-phase
feature filtering aiming to find a subset of sharply discriminating genes with little redundancy. In
the first phase, it selects genes using an entropy-based method that generally keeps only 10% of
the features. In the second phase, a non-parametric statistics called the Wilcoxon rank sum test
is applied to the features kept by the first phase to further filter out some genes and divide the
remaining ones into two groups — one group consists of genes that are highly expressed in one
type of samples (such as cancer) while another group consists of genes that are highly expressed
in another type of samples (such as non-cancer). In the third phase, correlated genes in each
group are determined by Pearson correlation coefficient test and only some representatives of
them are chosen to form the final set of selected genes.
In Chapter 5, ERCOF is applied to six published gene expression profiling data sets and
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one proteomic data set to identify genes for phenotype classification. For comparison purpose,
several other entropy-based feature selection methods are also run. The classification algorithms
used include four ensemble of decision trees approaches, support vector machines (SVM) and
k-nearest neighbour (k-NN). The four decision tree methods are the newly implemented CS4
(cascading-and-sharing for decision trees) and state-of-the-art Bagging [19], Boosting, and Ran-
dom forests. More than one thousand tests are conducted and a variety of comparisons among
different feature selection methods and different classification algorithms are addressed. For each
data set, some identified discriminating features are also reported and related to the literature and
the disease. To demonstrate the advantage of the decision trees over the other classification algo-
rithms, some simple, explicit and comprehensible trees/rules induced from the data sets are also
presented and analysed.
In the study of patient survival prediction described in Chapter 6, we present a new idea of
selecting informative training samples by defining long-term and short-term survivors. ERCOF
is then applied to these samples to identify genes associated with survival status. A regression
function built on the selected samples and genes by linear kernel SVM is implemented to assign
a risk score to each patient. Kaplan-Meier plots for different risk groups formed on the risk
scores are then drawn to show the effectiveness of the model. Two case studies, one on survival
prediction for patients after chemotherapy for diffuse large-B-cell lymphoma and one on lung
adenocarcinomas, are conducted.
In Chapter 7, data mining methodologies are applied to identify functional sites in DNA
sequences. Feature generation is emphasized in this application since sequence data generally
contain no explicit features. We first construct feature space using k-gram nucleotide acid or
amino acid patterns and then transform original sequences under the new constructed feature
space. Feature selection is then conducted to find signal patterns that can distinguish true func-
tional sites from those false ones. In the third step, classification and prediction models are
built on the training data sets with the selected features. Our methodology is used to recognize
translation initiation sites and polyadenylation signals in DNA and mRNA sequences. For each
application, experimental results across different data sets (including both public ones and own
extracted ones) are collected to demonstrate the effectiveness and robustness of our method.
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8.2 Conclusions
In this thesis, we successfully make use of data mining technologies to solve some problems
arising from biological and clinical data. We have articulated explicitly the 3-step frame work of
feature generation, feature selection and feature integration with learning algorithms and demon-
strated its effectiveness when dealing with phenotype classification and patient survival predic-
tion from gene expression data, and functional sites recognition in DNA sequences.
From large amount of experiments conducted on some high-dimensional gene expression
data sets, we clearly observe the improvements on performances of all the classification algo-
rithms under the proposed feature selection scenarios. Among these gene identification methods,
we claim ERCOF is an effective approach.
In the aspect of classification algorithms, no single algorithm is absolutely superior to all
others, though SVM achieves fairly good results in most of tests. Compared with SVM, decision
tree methods can provide simple, comprehensive rules and are not very sensitive to feature selec-
tions. Among the decision tree methods, the newly implemented CS4 achieves good prediction
performance and provides many interesting rules.
Feature generation is important for some kinds of biological data. We illustrate this point
by properly constructing new feature space for functional sites recognition in DNA sequences.
Some of the signal patterns identified from the generated feature space are highly consistent with
related literature or biological knowledge. The rest might be useful for biologists to conduct
further analysis.
8.3 Future Work
There are many ongoing and future explorations regarding to the works presented in this thesis.
Currently, our proposed gene selection method ERCOF is not a non-parametric measure
since the expression values are used in the third phase filtering when evaluating the correlations
between genes. To avoid this, other metrics and clustering algorithms to measure the relationships
of genes are under development.
With more and more high quality gene expression profiles being published, we expect to
further test the effectiveness of our proposed frame work and the robustness of various gene
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selection and classification algorithms on many other data sets. For some particular diseases, we
will further extract biological meanings of the genes identified to be most associated with the
phenotypes or patient survival status.
Future works in identifying translation initiation sites and poly(A) signals from DNA se-
quences are planned as follows. (1) We are considering to include patterns containing “dont care”
symbols into feature space. Here, a “dont care” symbol (?) stands for any symbol of amino acid
or nucleotide acid. Thus, more general signal patterns might be found around functional sites. (2)
Some parameters used in constructing feature space and extracting sequences around a candidate
functional site will be adjusted so that their impacts on the classification performance will be
known. These parameters include the k value of k-gram patterns used as features, the up-stream
window size and the down-stream window size of the sequence segment extracted for each can-
didate, and so on. (3) The classification models built will be tested on more EST (Expressed
Sequence Tags) and genomic sequences. (4) Meanwhile, we are expecting the 3-step frame work
of feature manipulations will achieve good results on the recognition of other functional sites,
such as splice site and etc.
In the aspect of using classification methods to solve biological problems, we will try to
provide insight and limitations of different algorithms. In addition to the good performance, how
easy it is for users to understand the learning process, to interpret the output classification models,
and to incorporate domain knowledge are also important factors in measuring the classification
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Appendix A
Lists of Genes Identified in Chapter 5
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Table A.1: 54 common genes selected by each fold of ERCOF in 10-fold cross validation test for
prostate cancer data set.
Probe Accession Gene name
name number
40435 at J03592 Human ADP/ATP translocase mRNA, 3’end, clone pHAT8
40419 at X85116 H.sapiens epb72 gene exon 1
31444 s at M62895 Human lipocortin (LIP) 2 pseudogene mRNA, complete cds-like region
37720 at M22382 Human mitochondrial matrix protein P1 (nuclear encoded) mRNA, complete cds
32634 s at U38260 Human islet cell autoantigen ICAp69 mRNA, complete cds
34608 at M24194 Human MHC protein homologous to chicken B complex protein mRNA, complete cds
33137 at Y13622 Homo sapiens mRNA for latent transforming growth factor-beta binding protein-4
40436 g at J03592 Human ADP/ATP translocase mRNA, 3’end, clone pHAT8
34784 at Z83844 Human DNA sequence from clone 37E16 on chromosome 22 Contains a novel gene,
a gene similar to SH3-binding protein, LGALS1 (14 kDa beta-galactoside-binding lectin)
gene, part of a gene similar to mouse p116Rip, ESTs, STSs, GSSs and two CpG islands
1676 s at M55409 Homo sapiens pancreatic tumor-related protein mRNA, partial cds
36587 at Z11692 H.sapiens mRNA for elongation factor 2
33614 at X80822 H.sapiens mRNA for ORF
38814 at AF038954 Homo sapiens vacuolar H(+)-ATPase subunit mRNA, complete cds
33668 at AF037643 Homo sapiens 60S ribosomal protein L12 (RPL12) pseudogene, partial sequence
40024 at D86640 Homo sapiens mRNA for stac, complete cds
39756 g at Z93930 Human DNA sequence from clone 292E10 on chromosome 22q11-12. Contains the XBP1
gene for X-box binding protein 1 (TREB5), ESTs, STSs, GSSs and a putative CpG island
34853 at AB007865 Homo sapiens KIAA0405 mRNA, complete cds
33820 g at X13794 H.sapiens lactate dehydrogenase B gene exon 1 and 2
40856 at U29953 Human pigment epithelium-derived factor gene, complete cds
31538 at M17885 Human acidic ribosomal phosphoprotein P0 mRNA, complete cds
36601 at M33308 Human vinculin mRNA, complete cds
33134 at AB011083 Homo sapiens mRNA for KIAA0511 protein, partial cds
32076 at D83407 ZAKI-4 mRNA in human skin fibroblast, complete cds
31545 at AL031228 dJ1033B10.4 (40S ribosomal protein S18 (RPS18, KE-3))
33328 at W28612 49b3 Homo sapiens cDNA
39416 at U90913 Human clone 23665 mRNA sequence
40607 at U97105 Homo sapiens N2A3 mRNA, complete cds
769 s at D00017 Homo sapiens mRNA for lipocortin II, complete cds
32412 at M13934 Human ribosomal protein S14 gene, complete cds
37819 at AF007130 Homo sapiens clone 23750 unknown mRNA, partial cds
1521 at X17620 Human mRNA for Nm23 protein, involved in developmental regulation
(homolog. to Drosophila Awd protein)
1513 at Antigen, Prostate Specific, Alt. Splice Form 3
39939 at D21337 Human mRNA for collagen
35776 at AF064243 Homo sapiens intersectin short form mRNA, complete cds
31527 at X17206 Human mRNA for LLRep3
33408 at AB023151 Homo sapiens mRNA for KIAA0934 protein, partial cds
34840 at AI700633 we38g03.x1 Homo sapiens cDNA, 3’end
39315 at D13628 Human mRNA for KIAA0003 gene, complete cds
35119 at X56932 H.sapiens mRNA for 23 kD highly basic protein
575 s at M93036 Human (clone 21726) carcinoma-associated antigen GA733-2 (GA733-2) mRNA,
exon 9 and complete cds
262 at M21154 Human S-adenosylmethionine decarboxylase mRNA, complete cds
37639 at X07732 Human hepatoma mRNA for serine protease hepsin
32243 g at AL038340 DKFZp566K192 s1 Homo sapiens cDNA, 3’end
36864 at AJ001625 Homo sapiens mRNA for Pex3 protein
38044 at AF035283 Homo sapiens clone 23916 mRNA sequence
38098 at D80010 Human mRNA for KIAA0188 gene, partial cds
39366 at N36638 yx88f05.r1 Homo sapiens cDNA, 5’end
168
Table A.2: 54 common genes selected by each fold of ERCOF in 10-fold cross validation test for
prostate cancer data set (continued 1).
Probe Accession Gene name
name number
32206 at AB007920 Homo sapiens mRNA for KIAA0451 protein, complete
39550 at AB011156 Homo sapiens mRNA for KIAA0584 protein, partial
34304 s at AL050290 Homo sapiens mRNA; cDNA DKFZp586G1923 (from clone DKFZp586G1923)
37730 at U22055 Human 100 kDa coactivator mRNA, complete cds
41288 at AL036744 DKFZp564I1663 r1 Homo sapiens cDNA, 5’end
31583 at X67247 H.sapiens rpS8 gene for ribosomal protein S8
172 at U57650 Human SH2-containing inositol 5-phosphatase (hSHIP) mRNA, complete cds
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Table A.3: 39 common m/z identities among top 50 entropy measure selected features in 10-fold
cross validation on ovarian cancer proteomic profiling. Their corresponding Wilcoxon test
p-values are derived from paper [118].









































Table A.4: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41].
Probe Gene name
X95735 at Zyxin
M55150 at FAH Fumarylacetoacetate
M31166 at PTX3 Pentaxin-related gene, rapidly induced by IL-1 beta
M27891 at CST3 Cystatin C (amyloid angiopathy and cerebral hemorrhage)
U46499 at GLUTATHIONE S-TRANSFERASE, MICROSOMAL
L09209 s at APLP2 Amyloid beta (A4) precursor-like protein 2
X70297 at CHRNA7 Cholinergic receptor, nicotinic, alpha polypeptide 7
M77142 at NUCLEOLYSIN TIA-1
J03930 at ALKALINE PHOSPHATASE, INTESTINAL PRECURSOR
M92287 at CCND3 Cyclin D3
U22376 cds2 s at C-myb gene extracted from Human (c-myb) gene, complete primary cds,
and five complete alternatively spliced cds
M27783 s at ELA2 Elastatse 2, neutrophil
D14874 at ADM Adrenomedullin
M16038 at LYN V-yes-1 Yamaguchi sarcoma viral related oncogene homolog
U50136 rna1 at Leukotriene C4 synthase (LTC4S) gene
M98399 s at CD36 CD36 antigen (collagen type I receptor, thrombospondin receptor)
M21551 rna1 at Neuromedin B mRNA
Y12670 at LEPR Leptin receptor
M83652 s at PFC Properdin P factor, complement
M23197 at CD33 CD33 antigen (differentiation antigen)
U46751 at Phosphotyrosine independent ligand p62 for the Lck SH2 domain mRNA
D88422 at CYSTATIN A
M54995 at PPBP Connective tissue activation peptide III
U02020 at Pre-B cell enhancing factor (PBEF) mRNA
M31523 at TCF3 Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
X04085 rna1 at Catalase (EC 1.11.1.6) 5’flank and exon 1 mapping to chromosome 11,
band p13 (and joined CDS)
M81933 at CDC25A Cell division cycle 25A
U12471 cds1 at Thrombospondin-p50 gene extracted from Human thrombospondin-1 gene, partial cds
M91432 at ACADM Acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain
X59417 at PROTEASOME IOTA CHAIN
M12959 s at TCRA T cell receptor alpha-chain
X74262 at RETINOBLASTOMA BINDING PROTEIN P48
L27584 s at CAB3b mRNA for calcium channel beta3 subunit
HG4316-HT4586 at Transketolase-Like Protein
J05243 at SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)
M31303 rna1 at Oncoprotein 18 (Op18) gene
X62654 rna1 at ME491 gene extracted from H.sapiens gene for Me491/CD63 antigen
X90858 at Uridine phosphorylase
M84526 at DF D component of complement (adipsin)
J04615 at SNRPN Small nuclear ribonucleoprotein polypeptide N
D26308 at NADPH-flavin reductase
L08177 at CMKBR7 Chemokine (C-C) receptor 7
X14008 rna1 f at Lysozyme gene (EC 3.2.1.17)
X87613 at Skeletal muscle abundant protein
M80254 at PEPTIDYL-PROLYL CIS-TRANS ISOMERASE, MITOCHONDRIAL PRECURSOR
M96326 rna1 at Azurocidin gene
J04990 at CATHEPSIN G PRECURSOR
U62136 at Putative enterocyte differentiation promoting factor mRNA, partial cds
D10495 at PRKCD Protein kinase C, delta
X52142 at CTPS CTP synthetase
U73737 at GTBP DNA GT mismatch-binding protein
X74801 at T-COMPLEX PROTEIN 1, GAMMA SUBUNIT
U32944 at Cytoplasmic dynein light chain 1 (hdlc1) mRNA
X15949 at IRF2 Interferon regulatory factor 2
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Table A.5: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41] (continued 1).
Probe Gene name
M31158 at PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta
M15780 at GB DEF = DNA/endogenous human papillomavirus type 16 (HPV) DNA,
right flank and viral host junction
X62320 at GRN Granulin
D49950 at Liver mRNA for interferon-gamma inducing factor(IGIF)
U37055 rna1 s at Hepatocyte growth factor-like protein gene
D88378 at Proteasome inhibitor hPI31 subunit
X61587 at ARHG Ras homolog gene family, member G (rho G)
X07743 at PLECKSTRIN
AFFX-HUMTFRR/M11507 3 at AFFX-HUMTFRR/M11507 3 at (endogenous control)
L42572 at Motor protein
Z69881 at Adenosine triphosphatase, calcium
M63138 at CTSD Cathepsin D (lysosomal aspartyl protease)
M28170 at CD19 CD19 antigen
L41870 at RB1 Retinoblastoma 1 (including osteosarcoma)
D26156 s at Transcriptional activator hSNF2b
M11722 at Terminal transferase mRNA
U09087 s at Thymopoietin beta mRNA
M29540 at CARCINOEMBRYONIC ANTIGEN PRECURSOR
L47738 at Inducible protein mRNA
D38073 at MCM3 Minichromosome maintenance deficient (S. cerevisiae) 3
HG4321-HT4591 at Ahnak-Related Sequence
U41813 at HOXA9 Homeo box A9
X85116 rna1 s at Epb72 gene exon 1
X58431 rna2 s at HOX 2.2 gene extracted from Human Hox2.2 gene for a homeobox protein
M28130 rna1 s at Interleukin 8 (IL8) gene
Y00787 s at INTERLEUKIN-8 PRECURSOR
U82759 at GB DEF = Homeodomain protein HoxA9 mRNA
U16954 at (AF1q) mRNA
Z48501 s at GB DEF = Polyadenylate binding protein II
M62762 at ATP6C Vacuolar H+ ATPase proton channel subunit
M22960 at PPGB Protective protein for beta-galactosidase (galactosialidosis)
M28209 at RAS-RELATED PROTEIN RAB-1A
U85767 at Myeloid progenitor inhibitory factor-1 MPIF-1 mRNA
M13792 at ADA Adenosine deaminase
L05148 at Protein tyrosine kinase related mRNA sequence
L08246 at INDUCED MYELOID LEUKEMIA CELL DIFFERENTIATION PROTEIN MCL1
M19045 f at LYZ Lysozyme
M20203 s at GB DEF = Neutrophil elastase gene, exon 5
U67963 at Lysophospholipase homolog (HU-K5) mRNA
J03801 f at LYZ Lysozyme
X51521 at VIL2 Villin 2 (ezrin)
M13452 s at LMNA Lamin A
D87076 at KIAA0239 gene, partial cds
L07648 at MXI1 mRNA
HG2810-HT2921 at Homeotic Protein Pl2
L38608 at ALCAM Activated leucocyte cell adhesion molecule
L28821 at MANA2 Alpha mannosidase II isozyme
U73960 at ADP-ribosylation factor-like protein 4 mRNA
M94633 at GB DEF = Recombination acitivating protein (RAG2) gene, last exon
S50223 at HKR-T1
Z15115 at TOP2B Topoisomerase (DNA) II beta (180kD)
U84487 at CX3C chemokine precursor, mRNA, alternatively spliced
U65928 at JUN V-jun avian sarcoma virus 17 oncogene homolog
U53468 at NADH:ubiquinone oxidoreductase subunit B13 (B13) mRNA
U72936 s at X-LINKED HELICASE II
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Table A.6: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41] (continued 2).
Probe Gene name
X66401 cds1 at LMP2 gene extracted from H.sapiens genes TAP1, TAP2, LMP2, LMP7 and DOB
X66533 at GUANYLATE CYCLASE SOLUBLE, BETA-1 CHAIN
AF009426 at Clone 22 mRNA, alternative splice variant alpha-1
U90546 at Butyrophilin (BTF4) mRNA
U28833 at Down syndrome critical region protein (DSCR1) mRNA
M63488 at RPA1 Replication protein A1 (70kD)
U02493 at 54 kDa protein mRNA
D86479 at Non-lens beta gamma-crystallin like protein (AIM1) mRNA, partial cds
M31211 s at MYL1 Myosin light chain (alkali)
U26266 s at DHPS Deoxyhypusine synthase
U05259 rna1 at MB-1 gene
M58297 at ZNF42 Zinc finger protein 42 (myeloid-specific retinoic acid-responsive)
D63880 at KIAA0159 gene
U38846 at Stimulator of TAR RNA binding (SRB) mRNA
M81695 s at ITGAX Integrin, alpha X (antigen CD11C (p150), alpha polypeptide)
D14664 at KIAA0022 gene
X16546 at RNS2 Ribonuclease 2 (eosinophil-derived neurotoxin; EDN)
HG627-HT5097 s at Rhesus (Rh) Blood Group System Ce-Antigen, Alt. Splice 2, Rhvi
M22324 at ANPEP Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M,
microsomal aminopeptidase, CD13)
HG2981-HT3127 s at Epican, Alt. Splice 11
Z49194 at OBF-1 mRNA for octamer binding factor 1
HG1612-HT1612 at Macmarcks
X77533 at Activin type II receptor
U20998 at SRP9 Signal recognition particle 9 kD protein
X17042 at PRG1 Proteoglycan 1, secretory granule
HG2788-HT2896 at Calcyclin
HG2855-HT2995 at Heat Shock Protein, 70 Kda (Gb:Y00371)
U29175 at Transcriptional activator hSNF2b
J03589 at UBIQUITIN-LIKE PROTEIN GDX
U41767 s at Metargidin precursor mRNA
X06182 s at KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
M57731 s at GRO2 GRO2 oncogene
M24400 at CTRB1 Chymotrypsinogen B1
M69043 at MAJOR HISTOCOMPATIBILITY COMPLEX ENHANCER-BINDING PROTEIN MAD3
D43950 at T-COMPLEX PROTEIN 1, EPSILON SUBUNIT
M19507 at MPO Myeloperoxidase
M59820 at CSF3R Colony stimulating factor 3 receptor (granulocyte)
D83785 at KIAA0200 gene
U50733 at Dynamitin mRNA
D80001 at KIAA0179 gene, partial cds
M29696 at IL7R Interleukin 7 receptor
U72621 at LOT1 mRNA
M63438 s at GLUL Glutamate-ammonia ligase (glutamine synthase)
X62535 at DAGK1 Diacylglycerol kinase, alpha (80kD)
M84371 rna1 s at CD19 gene
L13278 at CRYZ Crystallin zeta (quinone reductase)
X14850 at HISTONE H2A.X
J03473 at ADPRT ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)
U79274 at Clone 23733 mRNA
D86983 at KIAA0230 gene, partial cds
X63469 at GTF2E2 General transcription factor TFIIE beta subunit, 34 kD
D88270 at GB DEF = (lambda) DNA for immunoglobin light chain
X59350 at CD22 CD22 antigen
U35451 at Heterochromatin protein p25 mRNA
X61970 at PROTEASOME ZETA CHAIN
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Table A.7: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41] (continued 3).
Probe Gene name
U66838 at Cyclin A1 mRNA
U94836 at ERPROT 213-21 mRNA
X54326 at MULTIFUNCTIONAL AMINOACYL-TRNA SYNTHETASE
D55654 at MDH1 Malate dehydrogenase 1, NAD (soluble)
U31556 at E2F5 E2F transcription factor 5, p130-binding
X83490 s at GB DEF = Fas/Apo-1 (clone pCRTM11-Fasdelta(3,4))
M83667 rna1 s at NF-IL6-beta protein mRNA
D38522 at KIAA0080 gene, partial cds
Z68747 at GB DEF = Imogen 38
X64072 s at SELL Leukocyte adhesion protein beta subunit
M65214 s at TCF3 Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
M29194 at LIPC Lipase, hepatic
M86406 at ACTN2 Actinin alpha 2
U16307 at Glioma pathogenesis-related protein (GliPR) mRNA
U26173 s at BZIP protein NF-IL3A (IL3BP1) mRNA
L11669 at Tetracycline transporter-like protein mRNA
X15573 at PFKL Phosphofructokinase (liver type)
X56411 rna1 at ADH4 gene for class II alcohol dehydrogenase (pi subunit), exon 1
X96752 at L-3-hydroxyacyl-CoA dehydrogenase
U90552 at Butyrophilin (BTF5) mRNA
HG4582-HT4987 at Glucocorticoid Receptor, Beta
AF005043 at Poly(ADP-ribose) glycohydrolase (hPARG) mRNA
U47077 at DNA-dependent protein kinase catalytic subunit (DNA-PKcs) mRNA
M83233 at TCF12 Transcription factor 12 (HTF4, helix-loop-helix transcription factors 4)
X16832 at CTSH Cathepsin H
D00763 at GAPD Glyceraldehyde-3-phosphate dehydrogenase
U27460 at Uridine diphosphoglucose pyrophosphorylase mRNA
X63753 at SON SON DNA binding protein
Z21507 at EEF1D Eukaryotic translation elongation factor 1 delta
(guanine nucleotide exchange protein)
U57721 at L-kynurenine hydrolase mRNA
S68134 s at GB DEF = CREM=cyclic AMP-responsive element modulator beta isoform
[human, mRNA, 1030 nt]
U81556 at Hypothetical protein A4 mRNA
X97335 at Kinase A anchor protein
D86967 at KIAA0212 gene
X66899 at EWSR1 Ewing sarcoma breakpoint region 1
M37435 at CSF1 Colony-stimulating factor 1 (M-CSF)
J03798 at SMALL NUCLEAR RIBONUCLEOPROTEIN SM D1
U30521 at FRAP FK506 binding protein 12-rapamycin associated protein
U50939 at Amyloid precursor protein-binding protein 1 mRNA
U83410 at CUL-2 (cul-2) mRNA
X59543 at RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE M1 CHAIN
S71043 rna1 s at Ig alpha 2=immunoglobulin A heavy chain allotype 2 constant region, germ line
[human, peripheral blood neutrophils, Genomic, 1799 nt]
L49229 f at GB DEF = Retinoblastoma susceptibility protein (RB1) gene, with a 3 bp deletion in
exon 22 (L11910 bases 161855-162161)
M95678 at PLCB2 Phospholipase C, beta 2
U49020 cds2 s at MEF2A gene (myocyte-specific enhancer factor 2A, C9 form) extracted from
Human myocyte-specific enhancer factor 2A (MEF2A) gene, first coding
U00802 s at Drebrin E
M93056 at LEUKOCYTE ELASTASE INHIBITOR
M95178 at ALPHA-ACTININ 1, CYTOSKELETAL ISOFORM
L25931 s at LBR Lamin B receptor
M32304 s at TIMP2 Tissue inhibitor of metalloproteinase 2
D38128 at PTGIR Prostaglandin I2 (prostacyclin) receptor (IP)
174
Table A.8: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41] (continued 4).
Probe Gene name
D87742 at KIAA0268 gene, partial cds
M63379 at CLU Clusterin (complement lysis inhibitor; testosterone-repressed prostate
message 2; apolipoprotein J)
X80907 at GB DEF = P85 beta subunit of phosphatidyl-inositol-3-kinase
AF012024 s at Integrin cytoplasmic domain associated protein (Icap-1a) mRNA
J04621 at SDC2 Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)
M80899 at AHNAK AHNAK nucleoprotein (desmoyokin)
U97105 at Dihydropyrimidinase related protein-2
M30703 s at Amphiregulin (AR) gene
U43292 at MDS1B (MDS1) mRNA
U05572 s at MANB Mannosidase alpha-B (lysosomal)
D31887 at KIAA0062 gene, partial cds
X97748 s at GB DEF = PTX3 gene promotor region
Y00339 s at CA2 Carbonic anhydrase II
X52056 at SPI1 Spleen focus forming virus (SFFV) proviral integration oncogene spi1
M92357 at B94 PROTEIN
AFFX-HUMTFRR/M11507 M at AFFX-HUMTFRR/M11507 M at (endogenous control)
X66610 at ALPHA ENOLASE, LUNG SPECIFIC
U07139 at CAB3b mRNA for calcium channel beta3 subunit
HG4535-HT4940 s at Dematin
X64364 at BSG Basigin
HG3162-HT3339 at Transcription Factor Iia
X51420 at TYRP1 Tyrosinase-related protein 1
D50918 at KIAA0128 gene, partial cds
AJ000480 at GB DEF = C8FW phosphoprotein
J04027 at Adenosine triphosphatase mRNA
S76638 at NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
U28042 at DEAD box RNA helicase-like protein mRNA
M11147 at FTL Ferritin, light polypeptide
HG4755-HT5203 s at Spinal Muscular Atrophy 4
X65644 at IMMUNODEFICIENCY VIRUS TYPE I ENHANCER-BINDING PROTEIN 2
D26579 at Transmembrane protein
U88964 at HEM45 mRNA
U07132 at Orphan receptor mRNA, partial cds
L20941 at FTH1 Ferritin heavy chain
M83221 at TRANSCRIPTION FACTOR RELB
L09235 at ATP6A1 ATPase, H+ transporting, lysosomal (vacuolar proton pump),
alpha polypeptide, 70kD, isoform 1
Z32765 at GB DEF = CD36 gene exon 15
M57710 at LGALS3 Lectin, galactoside-binding, soluble, 3 (galectin 3)
L22075 at Guanine nucleotide regulatory protein (G13) mRNA
K03195 at (HepG2) glucose transporter gene mRNA
M21119 s at LYZ Lysozyme
U61836 at Putative cyclin G1 interacting protein mRNA, partial sequence
U77396 at No cluster in current Unigene and no Genbank entry for U77396 (qualifier U77396 at)
L41067 at Transcription factor NFATx mRNA
L33930 s at CD24 signal transducer mRNA and 3’ region
M22898 at TP53 Tumor protein p53 (Li-Fraumeni syndrome)
M92439 at 130 KD LEUCINE-RICH PROTEIN
M61853 at CYP2C18 Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
polypeptide 18
X66171 at CMRF35 mRNA
AF015913 at GB DEF = SKB1Hs mRNA
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Table A.9: 280 genes identified by ERCOF from training samples on ALL-AML leukaemia data
set. Probes with bold font were also reported in [41] (continued 5).
Probe Gene name
U50928 at PKD2 Autosomal dominant polycystic kidney disease type II
D63874 at HMG1 High-mobility group (nonhistone chromosomal) protein 1
X82240 rna1 at TCL1 gene (T cell leukemia) extracted from H.sapiens mRNA for
Tcell leukemia/lymphoma 1
U79285 at GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE
U21858 at HISTONE H3.3
L76702 at Protein phosphatase 2A 74 kDa regulatory subunit (delta or B”” subunit)
M19888 at SPRR1B Small proline-rich protein 1B (cornifin)
U31814 at Transcriptional regulator homolog RPD3 mRNA
X77307 at 5-HYDROXYTRYPTAMINE 2B RECEPTOR
U49844 at Protein kinase ATR mRNA
U65410 at Mitotic feedback control protein Madp2 homolog mRNA
D14658 at KIAA0102 gene
Y07604 at Nucleoside-diphosphate kinase
M60527 at DCK Deoxycytidine kinase
X58072 at GATA3 GATA-binding protein 3
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Table A.10: Thirty-seven genes selected by ERCOF on training samples and reported in [140] to
separate TEL-AML1 from other subtypes of ALL cases in pediatric ALL study. All these genes
are relatively highly expressed (above the mean value aross all the samples) in TEL-AML1
samples.
Probe Accession No. Description
34481 at AF030227 vav proto-oncogene, exon 27
36239 at Z49194 H.sapiens mRNA for oct-binding factor
37470 at AF013249 Homo sapiens leukocyte-associated Ig-like receptor-1 (LAIR-1) mRNA
38203 at U69883 Human calcium-activated potassium channel hSK1 (SK) mRNA
38570 at X03066 Human mRNA for HLA-D class II antigen DO beta chain
38578 at M63928 Homo sapiens T cell activation antigen (CD27) mRNA
38906 at M61877 Human erythroid alpha-spectrin (SPTA1) mRNA
40745 at L13939 Homo sapiens beta adaptin (BAM22) mRNA
41381 at AB002306 Human mRNA for KIAA0308 gene
41442 at AB010419 Homo sapiens mRNA for MTG8-related protein MTG16a
31898 at D86967 Human mRNA for KIAA0212 gene
32660 at AB002340 Human mRNA for KIAA0342 gene
34194 at AL049313 Homo sapiens mRNA; cDNA DKFZp564B076 (from clone DKFZp564B076)
35614 at AB012124 Homo sapiens TCFL5 mRNA for transcription factor-like 5
35665 at Z46973 H.sapiens mRNA for phosphatidylinositol 3-kinase
36524 at AB029035 Homo sapiens mRNA for KIAA1112 protein
36537 at AB011093 Homo sapiens mRNA for KIAA0521 protein
37280 at U59912 Human chromosome 4 Mad homolog Smad1 mRNA
41200 at Z22555 H.sapiens encoding CLA-1 mRNA
32224 at AB018312 Homo sapiens mRNA for KIAA0769 protein
36985 at X17025 Human homolog of yeast IPP isomerase
38124 at X55110 Human mRNA for neurite outgrowth-promoting protein
40570 at AF032885 Homo sapiens forkhead protein (FKHR) mRNA
41498 at AB020718 Homo sapiens mRNA for KIAA0911 protein
41814 at M29877 Human alpha-L-fucosidase
32579 at U29175 Human transcriptional activator (BRG1) mRNA
33162 at X02160 Human mRNA for insulin receptor precursor
1779 s at M16750 Human pim-1 oncogene mRNA
1488 at L77886 Human protein tyrosine phosphatase mRNA
1336 s at X06318 Human mRNA for protein kinase C (PKC) type beta I
1299 at X93512 H.sapiens mRNA for telomeric DNA binding protein (orf2)
1217 g at X07109 Human mRNA for protein kinase C (PKC) type beta II
932 i at L11672 Human Kruppel related zinc finger protein (HTF10) mRNA
880 at M34539 Human FK506-binding protein (FKBP) mRNA
755 at D26070 Human mRNA for type 1 inositol 1,4,5-trisphosphate receptor
577 at M94250 Human retinoic acid inducible factor (MK) gene exons 1-5
160029 at X07109 protein kinase C beta 1
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Table A.11: Top 20 genes selected by entropy measure on training samples to separate MLL
from other subtypes of ALL cases in pediatric ALL study. The last column indicates the sample
class in which the gene is highly expressed (above the mean value aross all the samples).
Probe Accession No. Description HighlyExp
34306 at AB007888 Homo sapiens KIAA0428 mRNA MLL
36777 at AJ001687 Homo sapiens NKG2D gene, exons 2-5 and MLL
joined mRNA and CDS
33412 at AI535946 vicpro2.D07.r Homo sapiens cDNA, 5’ end MLL
657 at L11373 Human protocadherin 43 mRNA, MLL
complete cds for abbreviated PC43
32207 at M64925 Human palmitoylated erythrocyte membrane OTHERS
protein (MPP1) mRNA
33847 s at AI304854 Homo sapiens cDNA, 3’ end MLL
34337 s at AJ010014 Homo sapiens mRNA for M96A protein OTHERS
1389 at J03779 Human common acute lymphoblastic OTHERS
leukemia antigen (CALLA) mRNA
34861 at D63997 Homo sapiens mRNA for GCP170 OTHERS
40518 at Y00062 Human mRNA for T200 leukocyte common antigen MLL
(CD45, LC-A)
40913 at W28589 Homo sapiens cDNA OTHERS
31898 at D86967 Human mRNA for KIAA0212 gene OTHERS
38413 at D15057 Human mRNA for DAD-1 MLL
2062 at L19182 Human MAC25 mRNA MLL
794 at X62055 H.sapiens PTP1C mRNA for protein-tyrosine phosphatase 1C MLL
40519 at Y00638 Human mRNA for leukocyte common antigen (T200) MLL
41747 s at U49020 Human myocyte-specific enhancer factor 2A (MEF2A) gene MLL
38160 at AF011333 Homo sapiens DEC-205 mRNA MLL
37692 at AI557240 Homo sapiens cDNA, 3’ end MLL
40797 at AF009615 Homo sapiens ADAM10 (ADAM10) mRNA MLL
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Table A.12: Twenty-four genes selected by ERCOF on training samples and reported in [140]
to separate MLL from other subtypes of ALL cases in pediatric ALL study. All these genes
are relatively highly expressed (above the mean value aross all the samples) in MLL samples
except U70321 (accession number). Genes with bold font are among top 20 features selected by
entropy measure and can be found in Table A.11 as well.
Probe Accession No. Description
36777 at AJ001687 Homo sapiens NKG2D gene, exons 2-5 and joined mRNA and CDS
39424 at U70321 Human herpesvirus entry mediator mRNA
40076 at AF004430 Homo sapiens hD54+ins2 isoform (hD54) mRNA
40493 at L05424 Human hyaluronate receptor (CD44) gene
40506 s at U75686 Homo sapiens polyadenylate binding protein mRNA
40763 at U85707 Human leukemogenic homolog protein (MEIS1) mRNA
40797 at AF009615 Homo sapiens ADAM10 (ADAM10) mRNA
40798 s at Z48579 H.sapiens mRNA for disintegrin-metalloprotease (partial)
41747 s at U49020 Human myocyte-specific enhancer factor 2A (MEF2A) gene, first coding
32193 at AF030339 Homo sapiens receptor for viral semaphorin protein (VESPR) mRNA
32215 i at AB020685 Homo sapiens mRNA for KIAA0878 protein
33412 at AI535946 Homo sapiens cDNA, 5’ end
34306 at AB007888 Homo sapiens KIAA0428 mRNA
34785 at AB028948 Homo sapiens mRNA for KIAA1025 protein
35298 at U54558 Homo sapiens translation initiation factor eIF3 p66 subunit mRNA
37675 at X60036 H.sapiens mRNA for mitochondrial phosphate carrier protein
38391 at M94345 Homo sapiens macrophage capping protein mRNA
38413 at D15057 Human mRNA for DAD-1
2062 at L19182 Human MAC25 mRNA
2036 s at M59040 Human cell adhesion molecule (CD44) mRNA
1914 at U66838 Human cyclin A1 mRNA
1126 s at L05424 Human cell surface glycoprotein CD44 (CD44) gene,
3’ end of long tailed isoform
1102 s at M10901 Human glucocorticoid receptor alpha mRNA
657 at L11373 Human protocadherin 43 mRNA, complete cds for abbreviated PC43
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Table A.13: Nineteen genes selected by ERCOF on training samples and reported in [140] to
separate Hyperdip>50 from other subtypes of ALL cases in pediatric ALL study. All these genes
are relatively highly expressed (above the mean value aross all the samples) in Hyperdip>50
samples.
Probe Accession No. Description
38518 at Y18004 Homo sapiens mRNA for SCML2 protein
39628 at AI671547 Homo sapiens cDNA, 3’ end
31863 at D80001 Human mRNA for KIAA0179 gene
37543 at D25304 Human mRNA for KIAA0006 gene
38968 at AB005047 Homo sapiens mRNA for SH3 binding protein
39039 s at AI557497 Homo sapiens cDNA, 3’ end
39329 at X15804 Human mRNA for alpha-actinin
39389 at M38690 Human CD9 antigen mRNA
32207 at M64925 Human palmitoylated erythrocyte membrane protein (MPP1) mRNA
32236 at AF032456 Homo sapiens ubiquitin conjugating enzyme G2 (UBE2G2) mRNA
32251 at AA149307 Homo sapiens cDNA, 3’ end
36620 at X02317 Human mRNA for Cu/Zn superoxide dismutase (SOD)
36937 s at U90878 Homo sapiens carboxyl terminal LIM domain protein (CLIM1) mRNA
37350 at AL031177 26S Proteasome subunit p28 (Ankyrin repeat protein)) (isoform 1)
38738 at X99584 H.sapiens mRNA for SMT3A protein
39168 at AB018328 Homo sapiens mRNA for KIAA0785 protein
40903 at AL049929 Homo sapiens mRNA; cDNA DKFZp547O0510
(from clone DKFZp547O0510)
32572 at X98296 H.sapiens mRNA for ubiquitin hydrolase




B.1 Kent Ridge Biomedical Data Set Repository
All the gene expression profiles and proteomic data described in Chapter 5, and some DNA
sequences used in Chapter 7 can be found in the Kent Ridge Biomedical Data Set Repository at
http://sdmc.i2r.a-star.edu.sg/rp/. In this data repository, we have collected gene
expression data, protein profiling data and genomic sequence data that are related to classification
and are published recently in Science, Nature and other prestigious journals. As the file formats
of these original raw data are different from common ones used in most of machine learning
softwares, we have transformed these data sets into the standard .data and .names format and
stored them in this repository. Besides, we also provide data in .arff format which is used by
Weka, a machine learning software package developed at University of Waikato in New Zealand.
Detailed information of Weka can be found at http://www.cs.waikato.ac.nz/˜ml/
weka/.
B.2 DNAFSMiner
The DNAFSMiner (DNA Functional Site Miner) is a web-based toolbox for recognition of func-
tional sites in DNA sequences. It was built on the technologies presented in Chapter 7 and written
in Java and Perl languages. It can be accessed via http://sdmc.i2r.a-star.edu.sg/
DNAFSMiner/. Currently, it can be used to identify translation initiation site (TISMiner) in ver-
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tebrate mRNA, cDNA, and DNA sequences and polyadenylation signal (Poly(A) Signal Miner)
in human sequences.
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